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Abstract  
 
Advances in next generation sequencing technologies have brought a paradigm 
shift in how medical researchers investigate human disorders. Whole exome 
sequencing (WES) allows to comprehensively study, in a single experiment, coding 
variations of a human genome.  
My PhD thesis focuses on the use of WES to dissect genetic aetiologies of 
neurodegenerative diseases. First, I present a pilot study where I prove the 
feasibility of this technology and I test the methods used in the following projects. I 
then describe the use of WES in rare Mendelian disorders: i) in patients with 
Kohlschütter-Tönz Syndrome, where WES has failed to identify the disease gene, 
because the mutation is in a non-coding region; ii) in a family with Charcot-Marie-
Tooth type 6, where coupled with linkage data, WES rapidly identified the mutation 
causing the disease. Last, I present two projects where next generation sequencing 
plays an important role in elucidating the role of variants present in two loci 
(PARK16 and EIF4G1) in Parkinson’s Disease. 
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1 INTRODUCTION 
 
 
1.1 NEURODEGENERATIVE DISEASES: IMPORTANCE OF GENETIC 
ANALYSIS 
Neurodegenerative diseases represent the major medical and social problem in the 
ageing population and have drawn a lot of attention due to their irreversibility, lack 
of effective treatment, and accompanied social and economical burdens. In our 
aging societies they afflict about 2% of the population at any time and the current 
demographic trends point to a likely increase their prevalence. Neurodegenerative 
diseases are characterized by a chronic progressive clinical course and irreversible 
neuronal loss in the central nervous system, leading to distinct clinical phenotypes. 
Although the majority of neurodegenerative diseases are sporadic, Mendelian 
forms have been well documented. For several inherited disorders, most of what is 
known about the biological mechanisms underlying the disease comes from the 
knowledge of the protein affected by the mutations that causes it. Interestingly, the 
clinical presentations and neuropathological findings of Mendelian forms of the 
disease are often indistinguishable from the sporadic disease, raising the possibility 
that common pathophysiologic mechanisms underlie both forms of disease. The 
study of genetics of neurodegenerative diseases is important as the identification of 
causative genes accelerates studies on the pathophysiologic mechanism of disease, 
and thus offers target pathways for therapy. It also leads to the development of 
animal models of the disease that can be used to develop ideas about pathogenesis 
and to test therapies. Lastly, but not less importantly, the identification of a 
mutation in a family, has a potential clinical impact on that family in terms of 
diagnosis and presymptomatic and prenatal testing. 
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For example, the identification of genetic variants causing Parkinson’s Disease (PD) 
allows the identification of individuals at risk for disease prior to the onset of motor 
symptoms, since symptoms normally appear when a high percentage of neurons in 
the substantia nigra have already degenerated. 
This thesis focuses on the use the recently developed whole exome sequencing 
technology (WES), to dissect the genetic aetiology of neurodegenerative diseases. 
 
1.2 GENETIC RESEARCH OVERVIEW 
The fundamental aim of genetics is to connect genotype with phenotype. However 
determining the DNA sequence that causes a specific trait can be particularly 
difficult in humans, for which experimental interventions (such as mutagenesis, 
crosses and selection) are unavailable and the phenotype of interest may be very 
subtle.  
Traditionally, the search for a disease gene in a Mendelian trait starts with linkage 
analysis. In this approach, the aim is to find out the rough location of the gene by 
taking advantage of the meiotic process of recombination as manifest in families 
segregating for the disease. Markers (such as microsatellites) in the disease gene 
region show the strongest correlation with disease patterns in families; the tracking 
of recombination events can narrow the region harbouring a disease gene to 
between 100 and several thousand kilobases. This provides information regarding 
the location of the causative gene, after which sequencing of candidate genes is 
performed to pinpoint the actual mutation.   
Gene discovery in Mendelian disorders advanced after the 1980s, following the 
discovery of restriction fragment length polymorphisms (RFLPs) first (Botstein et al., 
1980) and then of the abundant highly polymorphic microsatellite (short tandemly 
repetitive DNA) loci (Weber and May, 1989), (Litt and Luty, 1989). Linkage analysis 
using RFLPs and microsatellite was established as a general method for connecting 
simple Mendelian diseases with the DNA sequence.  In the following decades this 
method successfully identified over a 1000 genes causing to Mendelian diseases 
(Botstein and Risch, 2003). With respect to neurodegenerative diseases such as PD, 
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to date, 15 PD-associated loci have been identified in familial forms of the disease 
(also knows as PARK-, OMIM #168600) (Table 3).  
This success reflects the power of linkage analysis when applied to Mendelian 
phenotypes, characterized by a (near) one-to-one correspondence between 
genotypes at a single locus and the observed phenotype. Of note, linkage analysis 
has been very successful in monogenic diseases presenting in families with the 
following features: 1) clinically well-characterized disorders, where the misdiagnosis 
is unlikely; 2) families with juvenile/young onset form of disease, where disease 
appears early in life and is unlikely to be missed; 3) families with adequate pedigree 
size, where sufficient number of affected individuals can be collected and 4) with 
sufficient locus homogeneity. This approach has led to the identification of genetic 
variants (mainly coding) that are usually rare but confer high risk toward disease, 
owing to the clear inheritance patterns they display.  
 
The genetics of common disorders have proven much more challenging to study by 
linkage analysis, owing to the weak linkage signals (mainly due to locus 
heterogeneity) and the concomitant requirement for large sample cohorts. Indeed, 
complex disorders are thought to be caused by a combined effect of many different 
susceptibility DNA variants of low penetrance (Weeks and Lathrop, 1995). Linkage 
analysis was shown to have low power when a trait locus contributes only a small 
fraction to the disease (Risch, 2000).  Moreover the mapping of human 
susceptibility loci for such diseases can be complicated by incomplete penetrance, 
phenocopies and possible epistasis (a combined effect of one or more loci). As a 
consequence, linkage approaches to complex diseases without Mendelian 
inheritance had very limited success (Altmüller et al., 2001).  
A popular hypothesis about genetic variation and risk of complex diseases is the 
‘common disease – common variant’ hypothesis, which suggests that common 
modest‐risk alleles confer susceptibility to common disease (CDCV hypothesis). To 
dissect the genetic background of sporadic diseases the attention turned to 
association studies, in which a difference in allele frequency is sought between 
affected individuals and unrelated unaffected controls.  
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Efforts to catalogue the human genome sequence and common genetic variants 
were required to test whether a common genetic variant (eg. a Single Nucleotide 
Polymorphism, SNP) increases risk of disease by comparing allele frequencies in 
affected and unaffected cases. 
The completion of the Human Genome Project in early 2000 laid the foundation for 
the development of the International Haplotype Map (HapMap) project in 2002. 
The HapMap project aimed at determining common patterns in DNA sequence 
variation in the human genome, by characterising sequence variants and their 
frequencies from populations with ancestry from Africa, Asia and Europe. 
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1.2.1 Genetic analysis using high throughput SNP genotyping 
The development of the HapMap project coupled with the technological advances 
in ultra-high-throughput genotyping made genome-wide – SNP (GW-SNP) testing 
possible. The HapMap project produced a minimal set of informative SNPs to tag 
variation throughout the human genome (McVean et al., 2005).  In parallel with the 
HapMap project an effort was undertaken to produce cost-effective methods to 
perform high throughput genotyping accurately and reproducibly. These 
developments provided the basis for a new era of genetic analysis such as genome 
wide association studies (GWAS) in complex diseases, and autozygosity mapping in 
consanguineous families.  
Homozygosity mapping in diseases 
The concept of homozygosity mapping was first proposed in 1987 by Lander and 
Botstein (Lander and Botstein, 1987) to map genes that cause recessive traits in 
consanguineous marriages. In a consanguineous marriage, both parents share some 
of their ancestors and may have each inherited a copy of the same ancestral allele 
at a locus. Their child may then be homozygous by descent (or autozygous) for that 
allele. If a child from consanguineous marriage is homozygous for a particular allele, 
this could be because of autozygosity (they are identical by descent, IBD) or it could 
be because a second, independent example of the same allele has entered the 
family at some stage (these alleles can be described as identical by state, IBS). The 
rarer the allele is in the population, the greater is the likelihood that homozygosity 
represents autozygosity. Autozygosity mapping involves the detection of the 
disease locus by taking advantage of the fact that adjacent region (haplotype) will 
be preferentially homozygous by descent in inbred children. By defining the regions 
of homozygosity in an affected individual from an inbred family, the disease locus 
can be refined, thus facilitating the eventual identification of the gene. As in 
traditional linkage analysis, the identification of homozygous regions is followed by 
candidate gene sequencing in the region to pinpoint the causal mutation, which is 
the rate-limiting step for the entire procedure.  
GW-SNP assays offer many advantages over microsatellite/RFLP methods to define 
recessive loci. In families with an apparently recessive disease, particularly one 
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where parental consanguinity is suspected, this approach can be used to map 
regions of extended homozygosity with high resolution (and essentially complete 
genomic coverage), and in a short amount of time. Moreover the data lends itself 
to immediate visualization of large homozygous tracts (Figure 1). Because all tracts 
of disease segregating homozygosity are identified and all heterozygous 
regions/nonsegregating homozygous tracts excluded, one can be confident that the 
region harboring the genetic lesion underlying disease has been identified - if the 
model is correct (i.e., the disease must be caused by a homozygous change 
inherited from a relatively recent common ancestor). Furthermore, this technique 
allows the direct visualization of structural genetic variations, such as genomic 
deletions or duplications  (Figure 16 for an example). 
This approach has been successfully applied to various neurodegenerative diseases, 
for example it allowed the identification of mutations in phospholipase A2, group VI 
(PLA2G6) in early onset parkinsonism dystonia (Paisan-Ruiz et al., 2009). 
The main limitation of autozygosity mapping in gene identification for recessive 
traits is the size of the candidate fragments identified. Candidate gene sequencing 
by traditional Sanger sequencing can be time-consuming and expensive (Table 1). 
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Figure 1. Homozygous region identified using GW-SNP genotyping 
 
Example of a disease-segregating homozygous region identified by homozygosity mapping 
using GW-SNP genotyping in families with dystonia-parkinsonism (genotyping performed 
using Illumina Infinium II HumanHap317 BeadChips). In the upper panel, B allele frequency 
(BAF) metrics across chromosome 2 from four affected individuals. BAF can be calculated 
as the proportion of the total allele signal (A + B) explained by a single allele (A). Stretches 
of homozygosity are denoted by a contiguous stretch of calls with BAF is equal to 1 
(corresponding to A/A genotyping calls) or to 0 (corresponding to B/B) and by a lack of 
genotypes calls with BAF 0.5 (corresponding to A/B). Bounded in red is the primary 
candidate interval identical by state between all affected. The lower portion of the figure 
shows an ideogram of chromosome 2 and the genes in this primary critical interval.  
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Genome-Wide association studies 
This concept was first proposed by Neil Risch and Kathleen Merikangas as a 
mechanism to discover common disease‐associated variants in complex disorders 
(Risch and Merikangas, 1996). GWAS involve scanning large case-control cohorts, 
using hundreds of thousands of SNP markers located throughout the human 
genome. Algorithms are applied that compare the frequencies of SNPs (alleles or 
genotypes) between disease and control cohorts. This analysis identifies loci with 
statistically significant differences in allele or genotype frequencies between cases 
and controls. The identification of susceptibility genes or variants depends on the 
existence of an association between the causal variants and surrounding SNPs 
nearby.  Indeed, SNP markers used in GWAS are tagging-SNPs that cover common 
variation across the genome, targeting minor allele frequency (MAF) greater than 1-
5%. The tagging SNP is a representative SNP in a region of the genome with high 
linkage disequilibrium (LD) (the non-random association of alleles at two or more 
loci). Therefore, the tagging SNP is representative of the alleles of nearby SNPs (i.e. 
in LD with it). 
GWAS using SNPs test the hypothesis that common diseases are attributable to 
allelic variants present in more than 1–5% of the population. For these reasons 
large case-control cohort are needed: the number of required cases and controls is 
determined by the expected effect size of a genetic variant underlying the specific 
trait and by the minor allele frequency MAF of this variant (Figure 2). 
GWAS have been shown to have a higher power than linkage studies to detect 
common variants with low effect size (Risch and Merikangas, 1996). In the last few 
years, several GWAS have been conducted in neurodegenerative diseases, leading 
to the identification of statistical association between many loci across the genome 
and the trait studied (see paragraph 1.4.1 for literature review). 
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Figure 2. Power Calculation for GWAS 
 
This graph shows the relationship between power and sample size. For this simulation a 
minor allele frequency of 0.1 and a p value of 1 x 10‐7, based on the Bonferroni corrected 
significance threshold for testing 500,000 SNP markers, were chosen under an additive 
model. As for the sample size, an equally matched case‐control cohort was assumed. For 
example, this plot shows that a GWA study with a sample size of 5,000 subjects (2,500 
cases and 2,500 controls), testing 500,000 SNP markers in each individual, has an 80% 
power to detect variants with an odds ratio of 1.3.  
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Limitations of GWAS 
The results of GWAS have increased the understanding of molecular pathways 
underlying specific diseases, however they have some limitations and challenges. 
First, there is great difficulty finding the biological basis of the link between the 
locus and the complex trait. The statistical association of the GWAS is held by a tag-
SNP, and does not pinpoint to the precise variant in the bin that have a causal role 
in the disease. A way of pinpointing the causal variant is to identify variants that are 
in LD with a tagging SNP and that are located in exons that truncate or alter the 
gene product. However, the causative variants underlying GWAS can be regulatory. 
For these reasons, many studies are being conducted with the aim to map genetic 
factors underlying differences in expression levels by assessing simultaneously 
global gene expression and genome wide variation (Cookson et al., 2009).  
Second, SNP associations identified in one population frequently are not 
transferable to other populations. This is due to allele frequency differences 
between populations (Myles et al., 2008). For instance the MAPT H2 haplotype, 
reported to be almost exclusively of Caucasian origins, is rare in most other 
populations. This can explain the different association signal at GWAS (as discussed 
in paragraph 1.4.1) (Satake et al., 2009), (Simón-Sánchez et al., 2009). Different 
genetic markers should be used when investigating different populations because 
some may not be relevant to all populations.  
Third, the bulk of the heritable fraction of complex traits has not been accounted 
for in recent GWAS. For example, despite the discovery of common low-risk 
susceptibility variants associated with sporadic PD, only a proportion of estimated 
heritability has been found (Hindorff et al., 2009). Common low risk loci identified 
in PD by GWAS such as SNCA, MAPT and HLA explain about 10% of risk each 
(Simón-Sánchez et al., 2009), (Hamza et al., 2010).  Many factors have been 
suggested to explain the ‘missing heritability’. Genetic risk factors identified by 
GWAS are common, low risk variants. Rarer variants (possibly with larger effects) 
poorly captured by existing arrays (which focus mainly on variants whose MAF >5%) 
and that do not carry sufficiently large effect-size are yet to be found. When MAF is 
< 0.5% detection of association becomes unlikely, unless effect sizes are very large 
as in monogenic conditions. 
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Another hypothesis on the genetic cause of complex disorders is the multiple rare 
variant hypothesis (Pritchard, 2001), where multiple rare high risk variants 
contribute to complex diseases. Unlike common variants, low-frequency alleles are 
not fixed in the population, and thus, there has been little selective pressure to 
limit the effect size of such variants (Figure 3). Rare, alleles with large effect can be 
hard to detect by GWAS employing common SNPs.  This is well documented by the 
glucocerebrosidase (GBA) risk variants in PD. Heterozygous mutations in GBA are 
the strongest genetic risk factor for PD, yet the GBA locus is not detected by any 
GWAS, presumably because its risk variants are rare and hard to detect by using 
arrays representing common SNPs. So far multiple rare GBA variants could only be 
identified through comprehensive resequencing of the gene. These data show that 
resequencing strategies can be very powerful in identifying rarer variants.  
 
Figure 3. Schematic genetic architecture of disease  
 
 
 
This figure has been published elsewhere (Manolio et al., 2009). The genetic bases of 
disease in modern humans reflect the architecture and evolution of the human genome. 
The common variants implicated in diseases, such as those identified in GWAS, are likely to 
exert little negative selective pressure, either because they have quite small biological 
effect, or because the variants are associated with post-reproductive diseases. In contrast, 
low-frequency alleles are not fixed in the population, and thus, there has been little 
opportunity for selective pressure to limit the effect size of such variants. 
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1.3 WHOLE EXOME SEQUENCING 
1.3.1 Overview: next generation sequencing technologies 
Detailed study of all human genetic variants is required to elucidate the complete 
genetic architecture of human disease (Figure 3). This is achievable only by direct 
DNA sequencing. Until recently, sequencing was limited by cost and time (Table 1). 
In the last few years several approaches have been developed to DNA sequencing: 
the so called Next Generation Sequencing (NGS) technologies, making it feasible to 
sequence large amount of DNA in a fast and accurate way. NGS increase sequencing 
and reduce cost by processing in parallel hundreds of millions of DNA templates. 
NGS technologies provide enormous increases in speed and quantity of generated 
data, free of cloning biases and arduous sample preparation.  
 
The hallmark of this technology is parallel sequencing, with determination of DNA 
sequence by iterative cycles of nucleotide extensions done in parallel on massive 
numbers of clonally amplified template molecules. Three platforms for next-
generation DNA sequencing read production are most commonly used: the 
Roche/454 FLX (Margulies et al., 2005), the Illumina Genome Analyzer (GA) or HiSeq 
(Bentley et al., 2008), and Applied Biosystem SOLiD Platform (Shendure et al., 2005). 
They all use a reaction chamber (eg. the flow cell for Illumina GA) where the 
sequencing happens, but the specifics of template preparation, sequencing 
chemistry and the reaction chamber configuration differ among the platforms.  
Given the variety of NGS features, some platforms tend to have clear advantages 
for a particular application over the others. The Illumina technology has been 
widely used in human genetics and is the one we have used (chapter 2). 
 
The development of methods for coupling targeted capture and massively parallel 
DNA sequencing, has made possible to determine all coding variation present in an 
individual genome in a single experiment, a process called ‘whole exome 
sequencing’ (WES).  This technology has already become widely used in human 
genetics for the identification of genes that underlie Mendelian disorders.  
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Table 1. Comparison of sequencing features: Sanger sequencing versus NGS 
Sequencing 
 
Sanger Sequencing 
(ABI 3730) 
Next Generation Sequencing 
(Illumina GAIIx) 
 
Processing method 
 
 
Individual reactions 
 
 
Cloned single-molecule array (custers) 
 
Throughput 
 
.0001 Gb / run 
 
50-95 Gb / run 
 
Read Length 
 
1000 base 
100-150 base paired ends 
 
Run time 
 
1-2 hours 
10 days 
 
Cost 
 
$100,000 / Gb 
 
$500 / Gb 
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1.3.2 Whole exome sequencing: premises 
The exome consists of all the protein coding parts of the genome. Several 
considerations motivated implementation of robust approaches to sequencing the 
whole exome. First, the exome harbours the coding variation, which is responsible 
for most Mendelian diseases. This is based on the observation that mutations that 
cause Mendelian diseases occur primarily in genes 
(http://www.hgmd.cf.ac.uk/ac/index.php); less than 1% of Mendelian disease 
mutations have been found in regulatory regions (Stenson et al., 2009). Second, 
mutations that cause amino acid substitutions (including changes to nonsense 
codons) are the most frequent type of disease causing mutation (Botstein and Risch, 
2003). WES provides researchers with a powerful tool for gene discovery in an 
accurate and fast way.  
Firstly because potentially all causal variants are identified, WES can be applied to 
Mendelian disorders where linkage analysis has failed (for instance in pedigrees 
that are too small to provide meaningful information using linkage) effectively 
allowing small families and even single probands to be analyzed jointly (Ng et al., 
2010), or in consanguineous families with very large regions of homozygosity, 
where  Sanger sequencing is a costly, time consuming process. 
Secondly, WES has particular potential in diseases caused by germline or de-novo 
mutations, that were particularly resistant to previous methods for gene 
localization and identification. The identification of these kind of mutations could 
be achieved with complementary approaches: one is to sequence a cohort of cases 
suspected to have disease-causing de novo or non-inherited mutations and look for 
a gene that is commonly mutated; the other is to sequence trios (parents-affected 
child) to establish the variant(s) that occur only in the affected child.  
Thirdly, WES can be used in complex diseases to identify variability in protein 
coding regions that alters risk for disease, such as GBA or LRRK2 in Parkinson’s 
disease (Tan, 2006), (Sidransky et al., 2009). WES enables researchers to identify 
rare high-risk alleles, with suitable statistical power and study design. This approach 
centers on an analytical design that involves assessment of the collective burden of 
multiple risk alleles at a locus. 
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1.3.3 The technology 
The basic steps required for WES are: 1) DNA library preparation, 2) cluster 
generation, 3) sequencing and 4) data analysis.  
1) DNA library preparation. The first step is to prepare a “library” comprising DNA 
fragments corresponding to exons ligated at both ends to universal oligonucleotide 
adapters (Figure 4a). Key performance parameters include the degree of 
enrichment, the uniformity with which targets are captured and the molecular 
complexity of the enriched library. Currently, there are three commercial exome 
capture platforms: NimbleGen SeqCap EZ, Agilent’ s SureSelect and Illumina TruSeq.  
Each platform uses biotinylated oligonucleotide baits complementary to the exome 
targets to hybridize sequencing libraries prepared from fragmented genomic DNA. 
These bound libraries are enriched for targeted regions by pull-down with magnetic 
streptavidin beads. The capture technologies differ in their target choice, bait 
lengths, bait density and molecule used for capture (DNA for Nimblegen and 
Illumina, and RNA for Agilent). As for the target region, each platform targets 
particular exonic segments based on combinations of the available databases that 
catalogue mRNA coding sequences [for example based on Refseq (Pruitt et al., 
2012), UCSC KnownGenes (Hsu et al., 2006)]. A large number of bases (29.45 Mb) 
are targeted by all three platforms (represented mainly by mRNA coding exons in 
both RefSeq and CCDS). The major difference is that Illumina Truseq captures also 
untranslated regions (UTRs). 
2) Cluster generation. The DNA fragments (templates) are immobilized to the 
surface of the flow cell. This allows billions of sequencing reactions to be performed 
simultaneously. The template is amplified (“bridge amplification”), because the 
imaging system during sequencing cannot detect single fluorescent events (Figure 
4b).  
3) Sequencing. The Illumina machine works on the principle of ‘sequencing by 
synthesis’ to produce sequence reads of 75-100 bp from billions of clusters 
simultaneously (Figure 5). At the end of the sequencing run, the sequence of each 
cluster is subjected to quality filtering to eliminate low-quality reads. 
 32 
4) Bioinformatic analysis. Preliminary analysis includes tools to convert intensity 
data into sequence reads and quality scores. Details of the process are discussed in 
the chapter 2. 
Ultimately the bioinformatic analysis produces a list of all allelic variants present in 
the exome sequenced. 
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Figure 4. WES technology 
 
 
This figure shows the basic steps required for WES. 
(A) Library preparation. Genomic DNA is randomly fragmented, and terminal overhangs are 
repaired. Then universal oligonucleotide adapters are ligated at both ends of DNA 
fragments.  This DNA library is amplified using primers  complimentary to adapters. Then, 
the library is enriched for fragments corresponding to the exons by hybridization capture in 
an aqueous-phase: the DNA fragments are hybridized to biotinylated DNA or RNA baits.  
(B) Cluster generation. In a specific machine (the microfluidic cluster station) the DNA 
fragments are immobilized at one end on the flow cell surface. The interior surfaces of the 
flow cell have covalently attached oligos complementary to the universal adapters. Then 
they are incubated with reagents and a polymerase resulting in the amplification of the 
fragments in a discrete area or ‘cluster’ on the flow cell surfaces. This process (also called 
“bridge amplification”) creates millions of clusters on the flow cell surface, each containing 
about 1000 copies of the same template. Bridge amplification produces millions clonally 
amplified clusters, providing free ends to which a universal sequencing primer can be 
hybridized to initiate the NGS sequencing. 
Parts of this figure have been kindly made available by Dr. Harold Swerdlow, during the 
Wellcome Trust advanced Course “Next Generation Sequencing”, July 2010.  
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Figure 5. WES Sequencing process 
 
 
 
 
 
(A) Sequencing by synthesis. The flow cell is placed into the sequencer, in which each 
cluster is supplied with polymerase and four differentially labeled fluorescent nucleotides 
that have their 3’-OH chemically inactivated, to ensure that only a single base is 
incorporated per cycle. Each base incorporation cycle is followed by an imaging step to 
identify the incorporated nucleotide at each cluster and by a chemical step that removes 
the fluorescent group and deblocks the 3’ end for the next base incorporation cycle. This 
series of steps continues for n cycles, which permits a discrete read length of n bp 
(maximum 150bp for the current Illumina technology) or 100 bp. 
(B) Imagine and base calling. The first cycle of sequencing consists first of the incorporation 
of a single fluorescent nucleotide, followed by high resolution imaging of the flow cell. This 
image represents the data collected for the first base. Any signal above background 
identifies the physical location of a cluster, and the fluorescent emission identifies which of 
the four bases was incorporated at that position. 
This cycle is repeated, one base at a time, generating a series of images each representing a 
single base extension at a specific cluster. Base calls are derived with an algorithm that 
identifies the emission color over time. At this time reports of useful Illumina reads range 
from 75-100 bases. 
Parts of this figure have been kindly made available by Dr. Harold Swerdlow, during the 
Wellcome Trust advanced Course “Next Generation Sequencing”, July 2010.   
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1.3.4 How to identify the causal variants in Mendelian disorders 
Exome sequencing of a DNA sample from a single individual reveals on average 
24,000 single nucleotide variants (SNV) in African American samples and ~20,000 in 
European American samples (Bamshad et al., 2011). ~10,000 variants are non-
synonymous (lead to differences in protein sequence) and ~11,000 are synonymous. 
A number of variants are likely to have greater functional impact: 80-100 nonsense 
variants (premature stop codons), 40-50 splice site and 200 inframe indels. Of note, 
it is estimated that each genome is heterozygous for 50-100 variants classified by 
the Human Gene Mutation Database (HGMD) as causing inherited disorders 
(Durbin et al., 2010).  
A key challenge of using WES in human genetics is how to identify disease-related 
alleles among the background of benign variants and sequencing errors. The 1000 
Genomes Project has provided a comprehensive resource on human genetic 
variation by sequencing the genomes of about 2500 individuals (Via et al., 2010) 
and has tremendously helped defining the pattern of genetic variation in human 
population for rare variants (<5% MAF).  
When WES is used for gene discovery in Mendelian disorders, fundamentally two 
assumptions are made: 1) that the mutation is rare or novel, 2) that it is protein 
changing (such as nonsense, splice or missense).  
Different approaches are applied for identifying causal variants in exome 
sequencing data: discrete filtering, stratifying variants on the bases of their 
functional impact and the use of pedigree information. 
Discrete filtering. A common step, when looking for extremely rare mutations, 
involves filtering for novelty, i.e. against variants present in the general population 
(as these variants are unlikely to cause disease). The most used reference panel is 
the data derived from the 1000 Genomes Project. This approach is very powerful, 
as only about 2% of the variants identified in an individual are novel (i.e. not 
previously reported). Thus sequencing only a modest number of affected 
individuals, then applying this discrete filtering to the data, can be very powerful for 
identifying new genes for Mendelian disorders. Nonetheless this approach can be 
problematic, as it assumes that the filter set does not contain alleles from 
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individuals with the phenotype being studied. This needs to be accounted for future 
projects, as more sequence data will accumulate in the public domain, but with this 
the likelihood of erroneously filtering out a disease-causing mutation increases. This 
error is less likely in very young-onset severe diseases, but probably quite likely in 
later-onset diseases (who are too young to express disease), diseases with benign 
phenotypes, or those with mutations that have a low penetrance (mutation carriers 
who do not show symptoms). Furthermore, most reference data do not include 
very detailed phenotypic data, so patients with, or who will get, common diseases 
are likely to be included but not identified. 
A more reliable approach to filtering is to do it based on MAF reported in the 1000 
Genomes project. For recessive disorders, filtering for variants with a maximum 
MAF of 1% is still a well-powered approach. A lower MAF cutoff of 0.1% can be 
used for dominant disorders, as the estimated prevalence of the disorder provides 
an upper boundary on the MAF (Bamshad et al., 2011). 
A very useful panel is the National Heart, Lung, and Blood Institute (NHLBI) exome 
sequencing project (ESP, (Exome Variant Server, NHLBI Exome Sequencing Project 
(ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) [January 2011], which 
includes exome data for 3,500 American individuals of European descent and 1,850 
African American. Simply by looking at allele frequencies in this dataset can 
dramatically help distinguish between benign variants, sequencing artifacts (e.g. 
usually those occur at very high frequency privately to this dataset) or true highly 
penetrant, pathogenic variants. Both in chapter 4 and chapter 6 I used this data to 
define the role of variants we were interested in. 
 
Deleterious nature of variants. Candidate variants can be further stratified on the 
basis of their predicted impact or deleteriousness on protein structure and function. 
Alleles can be stratified by their functional class by giving greater weight to stop 
codons, frameshifts and disruptions of canonical splice sites than to missense 
variants. However, this is an oversimplification that is insensitive to causal alleles 
that do not directly alter protein-coding sequences or canonical splice sites. 
Additionally, candidate alleles can be stratified by existing biological or functional 
information about a gene: for example, its predicted role (or roles) in a biological 
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pathway or its interactions with genes or proteins that are known to cause a similar 
phenotype. 
 
Use of pedigree information and mode of inheritance 
For Mendelian disorders, the use of pedigree information can substantially narrow 
the list of candidate causal alleles. When mapping data is available, the best 
strategy is to sequence a pair of individuals whose overlapping haplotype produces 
the smallest genomic region. In consanguineous pedigrees where a recessive mode 
of inheritance is suspected, sequencing the individual with the smallest region(s) of 
homozygosity, as determined by the genome-wide genotyping data, can be 
sufficient (Walsh et al., 2010). In the absence of mapping data, sequencing the two 
most distantly related affected individuals can substantially restrict the genomic 
search space.  
WES can also be highly effective for identifying de novo coding mutations by 
sequencing parent-child trios, as multiple de novo events occurring within a specific 
gene (or within a gene family or pathway) is an extremely unlikely event (Xu et al., 
2011).  
The approach to reducing the size of a candidate list of variants to define the causal 
variants has proven successful in many diseases, as in the identification of 
mutations that cause Parkinson’s disease [VPS35 for example   (Vilariño-Güell et al., 
2011), (Zimprich et al., 2011)] . 
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Table 2. Mean number of coding variants per exome 
 
Variant type 
 
Mean number of variants 
In African Americans 
Mean number of variants 
In European American 
TOTAL VARIANTS 24,049 20,283 
Missense 11,131 9,511 
Nonsense 103 93 
Splice 38 34 
Synonymous 12,776 10,645 
NOVEL VARIANTS (TOTAL) (520) (307) 
Missense 303 192 
Nonsense 5 2 
Splice 2 2 
Synonymous 209 109 
KNOWN VARIANTS (TOTAL) (23,529) (19,976) 
Missense 10,828 9,319 
Nonsense 98 89 
Splice 36 32 
Synonymous 12,567 10,536 
 
 
 
Parts of this table have been published elsewhere (Bamshad et al., 2011). The table lists the 
mean number of coding single nucleotide variants from 100 sampled African Americans 
and 100 European Americans. 
  
 39 
1.3.5 How is WES changing neurogenetics 
WES has already proven in few years its worth in neurogenetics for different 
applications: 1) genetic diagnosis and screening; 2) further defining and expanding 
the phenotypes associated with mutations; 3) gene identification in Mendelian 
disorders; 4) identification of de novo mutations. I will briefly discuss each 
application. 
1. Genetic diagnosis and screening. Many neurological diseases, such as 
neuropathies and ataxia, are genetically heterogeneous. Current screenings are 
often designed to catch only the most common mutations or alterations in the 
most frequently mutated genes. The identification of mutations by WES is cheaper 
and quicker than it is by traditional sequencing approaches. Recently, two papers 
have shown the power of WES in this situation both in neuropathy and ataxia 
(Montenegro et al., 2011), (Sailer et al., 2012). Montenegro and colleagues studied 
a family with inherited neuropathy. Instead of screening the all the genes known to 
cause this disease (35 genes), the investigators used WES in two affected family 
members and identified a GJB1 mutation, previously associated to X-linked 
neuropathy. This case also shows the power of WES in genetic diagnosis as the GJB1 
mutation would have been ruled out for screening because of a reported male-to 
male inheritance, incompatible with the transmission of a mutation that lies on 
chromosome X. Sailer and colleagues also used WES in a family a large, 5-
generational British kindred with progressive cerebellar ataxia where conventional 
genetic testing had not revealed a causal aetiology. By sequencing one affected 
member they identified a novel p.Arg26Gly change in the PRKCG gene, known to 
cause spinocerebellar ataxia 14. In this case WES data enabled the identification of 
a novel mutation in a gene known to cause the phenotype and to provided a 
genetic diagnosis in a fast and cheap way. 
2. Expanding the phenotype associated with mutations. WES has provided 
researchers with a powerful tool to identify mutations in genes previously 
associated to different disease phenotype or pathology.  
For example mutations in the VCP gene, previously linked to Paget’s disease, 
inclusion body myopathy and frontotemporal dementia have been shown also to 
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cause amyotrophic lateral sclerosis (ALS) in one of the first study involving WES in 
neurodegenerative diseases (Johnson et al., 2010). Of note, this group showed that 
VCP mutations substantially contribute to the cause of familial ALS, being 
responsible for about 2% of cases. This finding broadened the clinical and 
pathological phenotype of VCP mutations to include ALS. 
Recently, another group was able to identify mutations in ATP13A2, a gene known 
to cause a form of dystonia-parkinsonism (Kufor-Rakeb syndrome, KRS), in a family 
with neuronal ceroid lipofuscinosis (NCL). NCL is part of a heterogeneous group of 
inherited progressive degenerative diseases of the brain and sometimes the retina, 
that are characterized by lysosomal accumulation of auto fluorescent lipopigment. 
The relationship between the diseases was not obvious, as the clinical features do 
not appear to overlap significantly. KRS typically presents with rigidity, bradykinesia, 
spasticity, supranuclear upgaze paresis and dementia. NCL disease varies according 
to the underlying gene defect and severity of the mutation, but typically includes 
seizures, a progressive intellectual and motor deterioration, and in children but 
usually not adult onset cases, visual failure.  
These results indicate that broadening the phenotype associated with mutations 
provides information on the aetiological basis of disorders by uniting what is known 
about the biological underpinnings of apparently unrelated disorders into a single 
model. The work of Bras and colleagues also shows that KRS is indeed linked to the 
lysosomal pathway, a feature that was already hypothesized for a variety of 
parkinsonian phenotypes, but was not previously shown for KRS. 
3. Gene identification in Mendelian disorders. Despite still being a new technology 
WES has already led to the identification of novel genes that cause rare, familial 
forms of neurodegenerative disease. Thanks to the comprehensive discovery of 
protein-coding variants throughout the genome, DNA samples collected from small 
families and isolated affected individuals, can be used to discover mutations that 
cause disease. Two independent studies utilized WES in a Swiss and an Austrian 
kindred to identify the same p.D620N (c.1858G>A) mutation in the vacuolar protein 
sorting 35 homolog (VPS35) gene as the cause of autosomal dominant Parkinson 
disease in these families (Zimprich et al., 2011), (Vilariño-Güell et al., 2011). This 
mutation was subsequently found in several additional families and is a rare cause 
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of Parkinson disease, with a frequency lower than 0.1%. The p.D620N mutation co-
segregates with a phenotype indistinguishable from idiopathic Parkinson disease 
and has incomplete, age-associated penetrance. 
WES has also been used to identify novel mutations in heterogeneous neurological 
diseases, such as trans-2,3-enoyl-CoA reductase (TECR) mutations in nonsyndromic 
mental retardation (Çalışkan et al., 2011), WD repeat domain 62 (WDR62) 
mutations in severe brain development malformations (Bilgüvar et al., 2010), TGM6 
transglutaminase 6 (TGM6) mutations in ataxia, and a Werner syndrome, RecQ 
helicase-like (WRN) mutation in atypical Werner’s syndrome (Raffan et al., 2011). 
4. De novo mutations. In three different studies, researchers used WES to show 
that de novo mutations are associated with risk of autism (Sanders et al., 2012), 
(O’Roak et al., 2012) and (Neale et al., 2012). In the first study, Sanders et al. 
performed WES of 238 families from a group of families in which one child has a 
non-inherited autism spectrum disorder (ASD) and compared the exomes of the 
affected patients to that of their unaffected siblings. They found the rate of de novo 
SNVs expressed in brain to be higher in individuals with ASD. 
O'Roak et al. performed WES of 189 trios (parents and their child with autism) and 
found 248 de novo autism-associated mutations, 120 of which were designated as 
severe (that is, the mutation affected protein function). Of interest, 39% of the 
most disruptive genes were part of one highly interconnected protein network, 
related to β-catenin and chromatin remodeling. 
In the third study, Neale et al. sequenced whole exomes of 175 children with ASD 
and their parents, and found the rate of de novo mutations in patients with autism 
to be slightly higher than in unaffected controls. In agreement with the findings of 
O'Roak et al., proteins that were affected by structural mutations seemed to be 
more connected with one another in terms of function than would be expected by 
chance.  
Most of the autism-related de novo mutations identified in the three studies were 
found in independent genes, indicating the genetic heterogeneity of ASDs.  
These studies confirmed the potential of WES to identify 1) de novo mutations, that 
were particularly resistant to previous efforts aimed at gene localization and 2) 
mutations in genetically heterogeneous disorders.  
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5. Complex diseases. In Alzheimer’s Disease (AD), two groups have recently 
identified a rare variant in the TREM2 gene associated with susceptibility to the 
disease, with a odds ratio of ~3 (Guerreiro et al., 2013). Researchers first 
nominated TREM2 as a candidate gene, following the discovery of homozygous 
TREM2 mutations as a cause of Nasu-Hakola disease, a rare recessive form of 
dementia with leukoencephalopathy and bone cysts. They generated exome 
sequence data sets and identified the R47H variant, which associated with the 
disease in cohorts from North America and Europe. This work was confirmed by 
researchers at deCODE Genetics, who separately identified the R47H variant in a 
GWAS using the Icelandic population and replicated the association with AD in 
North American and European cohorts. TREM2 is an immune phagocytic receptor 
expressed in brain microglia. These studies suggest that reduced function of TREM2 
causes reduced phagocytic clearance of amyloid proteins or cellular debris and thus 
impairs a protective mechanism in the brain, assuming that the risk variants impair 
TREM2 function. 
 
1.3.6 Limitations and challenges 
Despite the great success of WES human genetics, there are still significant 
limitations associated with this technology. WES can fail to identify variants for 
many reasons, mainly due to design and technical reasons or analytical pitfalls.  
Some genes may not be in the target definition or there is a failure in the design. Of 
note the exome is defined by CCDS, a collaborative effort to identify a core set of 
protein coding regions that are consistently annotated and of high quality 
(http://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi). WES using CCDS can result in 
true coding variation being missed; a more comprehensive annotation such as 
GENCODE (Harrow et al., 2006) provides an alternative that some companies are 
adopting. Nonetheless both CCDS and GENCODE exclude non-coding regions, some 
of which are known to contribute to disease mechanism. For example, an intronic 
hexanucleotide repeat in chromosome 9 open reading frame 72 (C9orf72) was 
recently identified as the cause of ALS and frontotemporal dementia (DeJesus-
Hernandez et al., 2011), (Renton et al., 2011). On the other hand, a gene may be in 
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the target region but not adequately captured or sequenced (for example because 
it is too GC rich, which can cause difficulty during sample preparation) (chapter 3 as 
an example). 
Analytical limitations can be attributed to misalignment or inadequate variant 
calling algorithm. For example, repetitive regions and homologous sequences may 
mismap to the reference genome, generating false variants. This is the case of the 
glucosidase, beta, acid gene (GBA), that has a pseudogene with  ~ 96% homology in 
the same genomic region. The existence of this similarity complicates the 
determination of the source of DNA sequenced fragments during alignment. 
Similarly, polyglutamine-type diseases are difficult to study by WES as the 
underlying defect is a repetitive sequence.  
As for inadequate variant calling algorithms, WES does not currently accurately calls 
large indels. For example, WES failed to identify the genetic defect of a simple 
Mendelian disorder (medullary cystic kidney disease type 1), since it is caused by a 
repeat unit comprising the extremely long (~1.5-5 kb), GC-rich (>80%) coding 
variable-number tandem repeat sequence in the MUC1 gene encoding mucin 1 
(Kirby et al., 2013). 
Improvements in the technology and wider target will overcome some of these 
limitations. 
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1.4 GENETICS OF SELECTED NEURODEGENERATIVE DISEASES 
In the following paragraphs I will discuss about the genetic background of some 
neurodegenerative diseases that are relevant to this thesis.  
1.4.1 Genetics of Parkinson’s Disease 
Parkinson’s Disease (PD, OMIM #168600) was first documented in 1817 in An Essay 
on the Shaking Palsy by James Parkinson. This publication contained the details of 
tremors occurring in elderly people and gave a description of the shaking palsy as a 
mixture of tremor, bradikynesia and gait disturbance. The term "Parkinson's 
disease" was coined later in the 1850s by Jean-Martin Charcot, who also added 
rigidity to the signs identified by Parkinson. Because those typical PD clinical 
features have subsequently been found to associate with other neurological 
disorders, the term “parkinsonism” was introduced to describe the syndrome 
characterized by akinesia accompanied by tremor or rigidity or postural/gait 
disturbance. To date many causes of parkinsonism have been identified (Dick et al., 
2007). All these disorders are believed to manifest parkinsonian motor features 
because of a disruption of the nigrostriatal dopaminergic pathway. 
PD is by far the most common form of parkinsonism, constituting about 75% of 
cases seen in large movement disorders centers (Colcher and Simuni, 1999) and is 
the second most common neurodegenerative disease after Alzheimer Disease with 
a prevalence of about 1% over 60 years of age (de Lau and Breteler, 2006). The 
main clinical features of PD are bradykinesia, resting tremor, rigor, postural 
instability and marked response to levo‐dopa (L-DOPA). Pathologically, PD is 
characterized by two key events: the loss of pigmented neurons in the substantia 
nigra (SN) and presence of intracytoplasmatic, ubiquitin-positive inclusions that 
contain α synuclein in surviving neurons (also referred to as Lewy Bodies) (Braak 
and Del Tredici, 2008).  
PD is a complex disorder whose etiology is still largely unknown. Age is the main 
risk factor for PD. There has been a considerable debate about the contribution of 
environmental versus genetic risk factors. Environmental risk factors, including 
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exposure to pesticides and metals, drugs (1‐methyl 4‐phenyl 1,2,3,6‐
tetrahydropyridine [MPTP]), viruses, rural living and farming have been investigated 
in different epidemiological studies. Those studies have shown a tenuous link 
between environmental factors and PD (Lees et al., 2009)  and true single causes 
are probably restricted to a small number of poisonings. The genetic contribution to 
the pathogenesis has been investigated through twin studies –where discordancy 
between twins was interpreted as evidence against a genetic etiology of disease. 
Several twins studies showed low concordance rates in monozygotic and dizygotic 
twins (Ward et al., 1983), (Duvoisin et al., 1981). These results were controversial, 
since they were cross‐sectional studies that did not exclude the possibility of a later 
disease onset in unaffected siblings. This obstacle has been partly overcome by 
functional imaging of the brain (positron emission tomography studies [PET]), which 
is sufficiently sensitive to identify decreased function in the nigrostriatal 
dopaminergic system.  Based on PET scan data, the concordance rate becomes 
significantly higher for monozygotic twins compared to dizygotic twins (55% versus 
18%), suggesting a substantial genetic contribution to the PD pathogenesis (Piccini 
et al., 1999).  
Of note, discordance has been seen even in twins with LRRK2 mutations 
(Xiromerisiou et al., 2012), [known to be the most common Mendelian cause of PD 
(Zimprich et al., 2004)], suggesting considerable variance in the penetrance of this 
gene.  
The role of heredity in the etiology of PD is supported by the discovery of rare, 
Mendelian forms of disease. The mode of inheritance can be recessive or dominant, 
often with incomplete penetrance. In the last two decades, important advances 
have been made in the understanding of genetic contribution to PD owing to the 
identification of genes responsible for monogenic PD (Table 3). Although at the 
beginning the difference in clinical presentation and pathology were emphasized, it 
is becoming clear that genes firstly implicated in the Mendelian forms of disease 
also play a role in the sporadic disorder (Ahn et al., 2008), (Simón-Sánchez et al., 
2011a). 
Familial forms of PD related to PARK loci are characterized by the presence of 
parkinsonism (Table 3). Typical, late-onset Parkinson's disease is linked to 
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heterozygous mutations in three genes: SNCA (encoding α-synuclein) 
(Polymeropoulos et al., 1997), LRRK2 (encoding leucine-rich repeat kinase 2) (Kitada 
et al., 1998) and VPS35 (Vilariño-Güell et al., 2011). Recently, linkage and candidate 
gene analysis reported a mutation (the p.R1205H) in EIF4G1, encoding a 
component of the eIF4F translation initiation complex that regulates cell survival in 
response to stressor, in a large French family with typical late-onset PD and 7 
smaller families of various origin, probably resulting from a founder effect 
(Chartier-Harlin et al., 2011). Screening additional patients with parkinsonism 
identified one less frequent putatively disease-causing mutations, p.A502V, absent 
from approximately 4000 controls. However, their involvement in disease 
pathogenesis remains inconclusive, in the absence of segregation.  I will describe 
the first genetic analysis carried out to clarify the role of this gene in PD in chapter 6. 
Mutations linked to early-onset Parkinson's disease are found in affected 
individuals with disease onset under the age of 45 years. They are recessive 
mutations in the genes encoding PARK2 (Kitada et al., 1998), PINK1 (Valente et al., 
2004) and DJ-1 (Bonifati et al., 2003). Some families have more complex 
phenotypes (atypical forms of parkinsonism) and show Lewy body pathology (eg. 
PARK14) (Paisan-Ruiz et al., 2009).  They might therefore share with PD common 
pathophysiological mechanisms. Mutations in PARK9 (ATP13A2 gene), PARK14 
(PLA2G6) and PARK15 (FBX07) have been described in this kind of parkinsonism. 
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Table 3. Monogenic loci for Parkinson’s disease 
Locus 
Gene 
symbol 
Gene product 
Mode of 
inheritance 
Features References 
PARK1/PARK4 SNCA α-synuclein AD Parkinsonism, dementia, autonomic dysfunction 
(Polymeropoulos et 
al., 1997) 
PARK2 PARK2 Parkin AR 
Juvenile- or young-onset parkinsonism, often with foot 
dystonia, slow progression, good response to L-dopa 
(Kitada et al., 1998) 
PARK6 PINK1 Pten-induced kinase 1 AR 
early‐ onset parkinsonism, hyperreflexia, dystonia, slow 
progression 
(Valente et al., 2004) 
PARK7 PARK7 DJ1 AR 
early‐ onset parkinsonism, psychiatric features, slow 
progression 
(Bonifati et al., 
2003) 
PARK8 LRRK2 
Leucine-rich repeat 
kinase 2 
AD mid-late onset parkinsonism, good response to L-dopa 
(Paisán-Ruíz et al., 
2004), (Zimprich et 
al., 2004) 
PARK9 ATP13A2 ATPase type 13A2 AR 
Causes Kufor-Rakeb syndrome; juvenile‐ onset parkinsonism, 
spasticity, hallucinations, dementia, supranuclear gaze paresis 
(Ramirez et al., 
2006) 
PARK14 PLA2G6 
Phospholipase A2, 
group VI 
AR L‐DOPA responsive dystonia-parkinsonism 
(Paisan-Ruiz et al., 
2009) 
PARK15 FBX07 F-box protein 7 AR Early-onset parkinsonian-pyramidal syndrome 
(Di Fonzo et al., 
2009) 
PARK17 VPS35 
Vacuolar protein 
sorting 35 homolog 
AD Typical, late onset-PD 
(Zimprich et al., 
2011), (Vilariño-
Güell et al., 2011) 
 
AD = autosomal dominant; AR = autosomal  recessive
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Genetic risk in PD 
In the last few years several GWAS have been conducted for PD in multiple 
populations (Maraganore et al., 2005), (Simón-Sánchez et al., 2009), (Edwards et al., 
2010), (Hamza et al., 2010), (Spencer et al., 2011), (Saad et al., 2011), (Simón-
Sánchez et al., 2011a), (Do et al., 2011), (Satake et al., 2009). These studies have 
identified a number of risk loci associated with PD that have been independently 
confirmed in follow-up studies. 
The first GWAS published using GW-SNP genotyping were performed in 2009 by 
Simón-Sánchez (Caucasian population) and Satake (Japanese population). In the 
Caucasian study initial GWAS was performed in 1,820 patients with PD and 4,047 
controls, and follow-up was conducted in an independent series comprising 3,452 
patients with PD and 4,756 controls. Two loci, one located on chromosome 4q22 
(where SNCA lies) and the other within a region encompassing the MAPT gene on 
chromosome 17q21.3, reached genome-wide significance.  
The study conducted by Satake et al., consisting solely of Japanese participants 
identified several SNPs significantly associated with PD on 4q22, 12q12, 1q32 and 
4p15.  Chromosome 12q12 was tagged at loci proximal to the LRRK2 gene, 
previously implicated to Mendelian PD (Table 3). The locus on chromosome 4q22 
where the SNCA gene is located also reached genome-wide significance. By contrast, 
no association was observed between MAPT and PD, even though MAPT H1 
variability contributes to PD risk in European samples H2, which is inversely 
associated with disease, does not occur in the Japanese population. This study also 
reported two novel genome-wide significant loci, one located on chromosome 1q32 
(designed as PARK16), and the other on chromosome 4p15 (in the BST1 locus). 
Replication of the PARK16 findings was obtained in the European study, but only a 
1% difference was observed in the PARK16 minor allele frequency between cases 
and controls. By contrast Simón-Sánchez and colleagues did not find an association 
between the locus on 4p15 and PD risk. Subsequent genome-wide association 
studies in the Caucasian population have shown repeatedly that common variation 
in the loci encompassing the SNCA region and MAPT region are associated with PD 
(Hamza et al., 2010), (Spencer et al., 2011), (Simón-Sánchez et al., 2011b). 
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Additionally novel loci not previously implicated in PD have also been identified: 
6p21.3, containing the HLA (human leukocyte antigen) region (Hamza et al., 2010), 
4p16.3, containing the GAK locus (cyclin G associated kinase) (Latourelle et al., 
2009) (Spencer et al., 2011) and 4p15.32, where BST1 (bone marrow stromal cell 
antigen 1) is located (Saad et al., 2011) ), confirming the initial Japanese study. 
GWAS results have provided evidence that common genetic variation does play a 
role in the cause of Parkinson’s disease, confirming the CDCV hypothesis. Moreover 
they highlight the commonality between monogenic Parkinson's disease and the 
late-onset sporadic Parkinson's disease both in terms of genetic basis and likely 
common pathogenic pathways. Highly penetrant mutations in SNCA, MAPT and 
LRRK2 have been associated to autosomal dominant forms of parkinsonism.  The 
strongly associated SNPs at the SNCA locus lie at the 3’ end of SNCA gene, 
suggesting they may act on regulating expression, RNA stability or splicing. The 
signal observed in the LRRK2 region, initially only found to be associated to PD in 
the Japanese population, might account for several LRRK2-associated coding 
polymorphisms, which have been recognized as contributors to PD susceptibility in 
the Asian population (Funayama et al., 2007). Further work suggests that in 
addition to protein-coding risk variants, there are low-risk, noncoding variants 
immediately 5′ of LRRK2 (Nalls et al., 2011). 
The MAPT H1 haplotype has been reported to be associated with several 
neurodegenerative disorders named tauopathies (Pittman et al., 2006), and tau is 
known to be an aggregating protein in several neurodegenerative diseases, 
including Alzheimer's disease (Small and Duff, 2008). An association between tau 
and Parkinson's disease suggests that there may be cross talk between pathways 
that involve different aggregating proteins. Prior to GWAS findings, the importance 
of studying tau pathways in sporadic Parkinson's disease was not appreciate
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Table 4. Risk loci associated to PD 
 
 
Locus 
 
Gene(s)  Map Position Risk variants Approx odds ratio References 
PARK1/PARK4 SNCA 4q21 
REP1 repeat 
polymorphism, multiple 
SNPs in 3’ half of gene 
1.2-1.4 
(Satake et al., 2009), 
(Simón-Sánchez et al., 
2009), (Spencer et al., 
2011), (Edwards et al., 
2010) 
PARK8 LRRK2 12q12 G2385R, R1628P  2.0-2.2 
(Tan et al., 2010) 
(Mata et al., 2005) 
Not assigned MAPT 17q21.1 H1 haplotype 1.4 
(Simón-Sánchez et al., 
2009), (Spencer et al., 
2011),(Edwards et al., 
2010) 
Not assigned GBA 1q21 
>300 mutations including 
N370S and L444P 
5.4 
(Sidransky et al., 2009) 
PARK16 unknown 1q32 
Multiple SNPs from 
GWASs 
1.3 
(Satake et al., 2009)(Nalls 
et al., 2011) 
PARK17 GAK, DGKQ 4p16 
Multiple SNPs from 
GWASs 
1.5 
(Pankratz et al., 2009),(Lill 
et al., 2012) 
PARK18 HLA-DRA 6p21.3 
Multiple SNPs from 
GWASs 
1.3 
(Hamza et al., 2010) 
Not assigned BST1 4p15 
Multiple SNPs from 
GWASs 
 1.2 
(Satake et al., 2009), (Saad 
et al., 2011) 
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1.4.2 Genetics of Kohlschütter-Tönz syndrome  
Kohlschütter-Tönz syndrome (KTS, OMIM #226750), first described in 1974 by 
Kohlschütter (Kohlschütter et al., 1974) is a rare hereditary disorder characterized 
by seizures, spasticity, psychomotor delay or regression and the most distinctive 
feature of amelogenesis imperfecta. Onset of epilepsy is usually very early in life 
and seizures may be refractory to treatment; amelogenesis imperfecta affects both 
primary and secondary dentition: the enamel is thin and rough, and the teeth are 
yellow and prone to crumble. Developmental delay and spasticity occur usually in 
early childhood. Ataxia is also frequently reported. Cerebellum hypoplasia is 
frequent, and enlargement of lateral ventricles were seen in most of the affected 
subjects. The pregnancies are usually uneventful. Other minor symptoms include 
broad toes and thumbs, skull deformities, and muscle cramps. Because this 
syndrome is quite rare, the epidemiology remains largely unknown and the 
differential diagnosis is quite limited.  
After the first report (Kohlschütter et al., 1974),  KTS was established as a clinical 
entity and to date only 20 pedigrees with a total of 52 affected members have been 
reported in the literature, presenting with the typical combination of enamel defect 
tooth and neurological involvement (Christodoulou et al., 1988), (Donnai et al., 
2005), (Guazzi et al., 1994), (Haberlandt et al., 2006), (Kohlschütter et al., 1974), 
(Musumeci et al., 1995), (Petermöller et al., 2008), (Schossig et al., 2012a), (Wygold 
et al., 1996), (Zlotogora et al., 1993), (Mory et al., 2012).   
In the following section I will describe all the clinical features of KTS reported so far 
in literature. Chapter 3 describes the genetic analysis performed on KTS cases, 
including some of those that have previously reported. 
Kohlsch tter described this syndrome on 5 affected brothers in a farming family 
from a small valley in central Switzerland (Kohlschütter et al., 1974). The seizures 
onset in these 5 brothers was between 11 months and 4 years of age. Their teeth 
were yellowish with hypoplasia of the enamel. Significant mental deterioration was 
noticed as they grew older and none of them survived into their teens possibly 
because they were severely handicapped and prone to complications, and 
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adequate nursing was not available. In the following years, Kohlsch tter observed 
another 2 Swiss families with similar clinical presentations. The seizure onset was 
between 11 month and 4 years of age in these 2 pedigrees. The neurological 
developmental milestones were normal before the seizure onset, but cognitive 
deterioration and spasticity gradually developed after the onset of intractable 
seizures. No female patients were reported in the three pedigrees Kohlsch tter 
reported.  
Later on, Christodoulou (Christodoulou et al. 1988) documented a Sicilian family 
comprising 4 male and 2 female affected with early onset seizures, spasticity, 
mental retardation or deterioration after onset of intractable seizures with 
amelogenesis imperfecta. The clinical presentations were similar to the kindred 
described by Kohlsch tter. Besides the affected individuals, there were another 4 
maternal female relatives who had mental retardation of unknown cause.  
Zlotogora (Zlotogora et al. 1993) reported a Druze family with two affected 
individuals with intractable febrile seizures, spastic gait, increased deep tendon 
reflex, amelogenesis imperfecta with yellow teeth (amelogenesis imperfecta), and 
intellectual learning disability. The seizures onset was between 12 months and 3 
years old. In this pedigree, the parents were unaffected and they had 4 children, 
only 2 younger children were affected. The parents were said to be first cousins.  
A German pedigree with similar clinical presentation was reported by Petermöller 
(Petermöller et al. 1993). In this pedigree, there were two affected individuals. 
Their clinical presentations were similar to the kindred reported before and 
included febrile seizures and later afebrile seizures with jerks mainly on the left side, 
psychomotor deterioration, and amelogenesis imperfecta with yellow teeth. The 
parents were unaffected unrelated healthy individuals.  
A variant of Kohlsch tter-Tönz syndrome was reported by Guazzi in a Sicilian family 
(Guazzi et al. 1994). In this family, the clinical presentations were different from the 
pedigrees described above. The neurological deficit occurred in the second decade, 
and seizure onset was not in early infancy or childhood, and in some individuals the 
seizures were well controlled. Muscle cramps and pain were the first symptoms in 
one of the affected individual which started at the age of 10, with gradual 
psychomotor deterioration. Other symptoms in this individual were ataxia, yellow 
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teeth, hyperactive deep tendon reflexes, and degenerative muscular change of the 
calves in the lower limbs. This pedigree was quite complicated as there were 4 
different phenotypes and the parents were first cousins. Some of the individuals in 
this pedigree had amelogenesis imperfecta only, some of them had abnormal 
neurological symptoms only, such as delay of psychomotor development or 
seizures only without amelogenesis imperfecta, and some of them had both but 
without signs of mental retardation. Although Guazzi concluded that the 
inheritance pattern of this pedigree was autosomal dominant, it could also be an 
autosomal recessive pattern depending on the phenotype defined.  
Another variant of Kohlsch tter-Tönz syndrome was described by Musumeci in 
another Sicilian family (Musumeci et al. 1995). In this pedigree, in addition to 
seizures, abnormal enamel, and mental retardation which are frequently reported, 
these individuals also had broad thumbs, toes and enlargement of the lateral 
ventricles, cerebellum malformation. Similar to the pedigree reported by Guazzi, 
they also had ataxia and spasticity. There was consanguinity in this pedigree.  
More recently, a family with the diagnosis of Kohlsch tter-Tönz Syndromes was 
documented by Donnai (Donnai et al. 2005). As better medical care became 
available, the cases reported by Donnai were able to live into their teens but with 
severe handicap. Besides seizures, mental retardation, and amelogenesis 
imperfecta, abnormal crystal sediments were found in the urine of these cases. The 
parents were healthy unrelated individuals.  
The latest case report was documented by Haberlandt and appeared to be another 
form of Kohlsch tter-Tönz Syndrome (Haberlandt E et al. 2006). The neurological 
deficits in his case were milder than the previous cases reported, and the seizures 
in this case showed good response to medical treatment. His seizures onset was at 
8 months and developmental delay was noted at the same time. There was no 
consanguinity reported in this pedigree. However, the parents were from 
neighboring villages, and inbreeding was possible. Only one child in this pedigree 
was affected. MRI showed moderate ventricle enlargement and cerebellum 
hypoplasia.  
 
Genetic analysis of Ko lsc  tter-Tönz Syndrome 
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In Kohlsch tter’s report, he noticed that geographical isolation could accidentally 
contribute to the development of Kohlsch tter-Tönz Syndrome, although no 
consanguinity was found. The other phenomenon he noticed was there were no 
female cases. He concluded that the inheritance mode could either be autosomal 
recessive or X-linked. As more families were reported, it appeared that the 
inheritance mode was likely to be autosomal recessive as consanguinity and 
geographical isolation existed in most of the affected families, except the one 
reported by Guazzi, which was complicated by several different phenotypes.  
The genetic defect had not been identified due to lack of large genetically 
informative families. This is a typical scenario where WES had been shown to be a 
powerful tool for gene identification.  
Linkage analysis was carried out in our department on five families (including 
families from Christodoulou et al., Musumeci et al., Petermöller et al., Donnai et al.  
and Guazzi et al.) by using whole genome microsatellite markers as a part of a PhD 
thesis (Lo, C.-N., 2009). Maximum LOD score obtained was 3.05, at θ =0 at D16S423 
(chromosome 16) in parametric linkage analysis for the combined families, with 
mode of inheritance set as autosomal recessive with full penetrance (Table 5). 
Haplotype analysis further suggested a disease locus between 16p13.3-13.2 present 
in the families reported by Christodoulou, Musumeci and Petermöller. 
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Table 5. LOD scores on chromosome 16. 
                  
θ 
Marker    
0.0 0.01 0.05 0.1 0.2 0.3 0.4 
D16S521 -infini -5.59 -2.35 -1.17 -0.31 -0.04 0.02 
D16S3065 -infini -0.57 0.56 0.82 0.75 0.47 0.18 
D16S423 3.05 2.97 2.64 2.23 1.44 0.74 0.22 
D16S418 -infini -0.58 0.57 0.85 0.81 0.53 0.23 
D16S3062 -infini -3.92 -1.40 -0.54 0.00 0.09 0.06 
Obtained by Merlin, table published elsewhere (Lo, C.-N., 2009). 
 
While we were analyzing genetic data from some KTS families, loss of function 
mutations in ROGDI were identified in different pedigrees with typical features of 
KTS (Schossig et al., 2012a), (Mory et al., 2012): the original family reported by 
Kohlschütter in 1974, the Austrian family reported by Haberlandt, a novel 
Moroccan family and a cohort of five Israeli families, likely to be all related. 
Schossig et al performed linkage analysis and autozygosity mapping in the 
Moroccan consanguineous family (two affected and two unaffected siblings): they 
identified 4 possible linked regions, comprising a total of 15.83Mb and containing 
326 genes. Considering the large number of genes in the regions they did WES in 
one affected individual. After alignment and SNP calling (identification of about 
21000 variants) they applied the auto_annovar functionality to filter variants (here 
described in chapter 2). After filtering, they considered only the homozygous 
variants in the linked region and only ROGDI remained, with novel frameshift 
deletion (c.229_230del: p.Leu77Alafs*64) predicted to disrupt aminoacid structure 
and cause a premature stop codon. The mutation was confirmed by Sanger 
sequencing and shown to segregate with disease. They also screened this gene in 
additional KTS families and found three novel mutations: two splice site mutations 
(c.531+5G.C and c.532-2A>T in intron 7) present in a compound heterozygous state 
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in one family and a novel homozygous nonsense mutation (c.286C>T in exon 5) in a 
different family. 
Mory et al described 14 new KTS cases pertaining to 5 families (three closely 
related) from a small Druze village in northern Israeli. Homozygosity mapping on 
ten affected individuals, one unaffected sibling and one obligate carrier parent with 
6000 SNP array identified a 2Mb candidate segment on chromosome 16p13.3. 
Haplotype analysis with microsatellite markers further confirmed a 500,000 base 
pairs segment shared by all affected individuals, with a LOD score of 6.4 under a 
recessive model of full penetrance. Traditional Sanger sequencing of the gene 
identified a nonsense mutation in ROGDI (c.469C>T: p.Arg157*) homozygous in all 
affected individuals, heterozygous in 10 unaffected relatives and absent from Druze 
controls. 
ROGDI is the human homolog of Drosophila ROGDI and encodes for a protein of 
unknown function. ROGDI is widely expressed with higher levels in the adult brain, 
spinal cord, peripheral blood, bone marrow and heart. Genome wide expression 
studies show that the protein is expressed more in hippocampus than in other 
tissues in both human and mice (Kapushesky et al., 2012). At a cellular level, RODGI 
has been shown to localize in the nuclear envelope (Mory et al., 2012). Protein 
prediction methods (Rost et al., 2004) indicate that ROGDI is a globular protein and 
the secondary structure consists of 45% helix motifs, 37 percent loop structures and 
17 percent loop strands. The identification of ROGDI mutations in KTS has provided 
information on the clinical effects of the loss of ROGDI function in humans. The 
studies described above identify loss of function ROGDI mutations in patients 
presenting with the typical core features of KTS. Future work is needed to elucidate 
the function of ROGDI in neurogenesis and amelogenesis.  
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1.4.3 Genetics of complex neuropathies 
Inherited neuropathies are the most common genetic neurological disorders, and 
affect ∼1 in 2,500 people. Charcot Marie Tooth (CMT) includes a group of 
hereditary disorders in which motor and sensory neuropathy is the sole or primary 
part of the disease.  CMT is traditionally classified into two types based on 
electrophysiological and neuropathological criteria, with CMT1 defined as 
‘demyelinating’ and CMT2 as ‘axonal’ (Shy et al., 2000). Symptoms of CMT include 
slowly progressing distal weakness, atrophy and sensory loss, which spread 
proximally as the disease progresses.  CMT can be also associated with a variety of 
additional symptoms, such as spastic paraparesis, optic atrophy, cranial nerve 
involvement and glaucoma (Shy et al., 2000).   
The search for a genetic cause in CMT started in late 1980s, and currently 
mutations in over 30 genes have been identified (Reilly et al., 2011). CMT1 is 
predominantly (70-80% of the cases) caused by the duplication of a large region on 
the short arm of chromosome 17, that includes the gene peripheral myelin protein 
(PMP22). The most frequent cause of CMT 2 are mutations in the mitofusin 2 gene 
(MFN2)  (accounting for about 20% of CMT2 cases) (Lawson et al., 2005). Notably, 
CMT2 caused by mutations in the MFN2 can be phenotypically heterogeneous, 
presenting as classical CMT2, CMT2 with pyramidal signs (Ajroud-Driss et al., 2009), 
CMT2 with optic atrophy (Züchner et al., 2006), and a severe early-onset (<10 
years) or a mild late-onset (>10 years) phenotype (Chung et al., 2006). 
Despite genetic and clinical heterogeneity, a classification was proposed in 1975 
dividing the hereditary motor and sensory neuropathies into seven types (Dyck PJ, 
1975). Types I through IV represent known genetic entities. Types V to VII represent 
CMT with additional features such as spastic paraparesis (type V), optic atrophy (VI) 
or retinitis pigmentosa (VII).  
1.4.3.1 Hereditary motor and sensory neuropathy type 6 (HMSN VI) 
The association of axonal neuropathy with optic atrophy is known as CMT 6 or 
hereditary motor and sensory neuropathy VI (OMIM #601152).  This clinical entity 
was first report by Vizioli in 1879 (Vizioli F., 1889). Subsequently, further studies 
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have reported the association of axonal neuropathy and optic atrophy in different 
families, comprising at least 42 cases. The clinical manifestations of CMT6 consist of 
distal muscle weakness and wasting starting in the lower limb with reduced reflexes 
and glove and stocking sensory loss. There is progressive visual acuity loss due to 
optic atrophy, eventually leading to blindness. The age at onset is usually in 
childhood (first decade) for the neuropathy and in the second decade for the optic 
atrophy.  
Vizioli (Vizioli F., 1889) described a kinship in which a father and sons were found to 
have amaurosis with optic atrophy in association with CMT. The father became ill 
with neuropathy at age 59 and the two sons at age 26 and at age 6 respectively. 
The father and the older son lost visual acuity and eventually became blind. Muscle 
weakness started in the lower limb and later affected the arm and hand. 
Schneider and Abeles (Abeles M., 1937) reported two brothers aged 41 and 26 
affected by primary optic atrophy with progressive peroneal atrophy. The disease 
manifested gradually in childhood and progressed slowly. The affected brothers 
had four healthy siblings and the parents were first cousins.  
Milhorat (Milhorat A.T., 1943) described two brothers, who developed nystagmus 
at age 9 years, distal muscular atrophy at age 15, and decreased visual acuity in 
their 20s. The brothers were born from first-cousin parents.  
Barreira (Herrera  RF, 1990) reported a slowly progressing decrease of visual acuity 
and peroneal weakness in 12 years old boy and his 10 years old sister. The siblings 
were born from consanguineous parents.  
Chalmers (Chalmers et al., 1997) described three siblings (two females and a male) 
with childhood onset of motor and sensory neuropathy and adult onset optic 
atrophy. Neither their parents nor four other siblings had any neurological or 
ophthalmological condition. 
Ippel (Ippel et al., 1995) reported a father and two affected offspring (a boy and a 
girl) with polyneuropathy and optic atrophy. The distal muscle atrophy/weakness 
manifested early in childhood and the reduction of visual acuity started in late 
childhood/adolescence.  
In another report, Chalmers described a three generations family (comprising four 
affected) with optic atrophy and asymptomatic neuropathy.  Impaired vision 
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developed in early childhood and although none of the affected members had 
symptoms related to neuropathy, they had diminished tendon reflexes and 
impairment of sensation. Moreover, nerve conduction studies confirmed the 
presence of axonal sensory-motor neuropathy (Chalmers et al., 1996). 
Voo (Voo et al., 2003) described a large family in which 58 members were affected 
by peripheral neuropathy and optic atrophy. Twelve members were affected by 
both neuropathy and optic atrophy; three other family members had either 
neuropathy or optic atrophy. Although the clinical syndrome was variable, most 
had childhood onset of progressive visual loss and abnormal gait, distal sensory 
impairment, and hyporeflexia. Other clinical features included hearing loss, tinnitus, 
and anosmia. 
Züchner reported 6 unrelated families, comprising 10 affected individuals with 
axonal neuropathy and optic atrophy. Onset of axonal peripheral neuropathy was in 
childhood, ranging from 1 to 10 years. The symptoms showed severe progression, 
with almost all patients becoming wheelchair-bound. Onset of optic atrophy was 
between 5 and 50 years of age (mean age 19 years). Remarkably, 60% of the 
patients experienced significant recovery of their visual acuity after several years. 
Incomplete penetrance was observed in 1 family (Züchner et al., 2006). 
 
Genetics of CMT6 
CMT 6 is genetically heterogeneous, as both autosomal dominant and recessive 
inheritance has been suggested. The first reports are consistent with autosomal 
recessive inheritance, where the affected offspring is born to consanguineous 
parents (Abeles M., 1937), (Milhorat A.T., 1943), (Herrera  RF, 1990) or the diseases 
manifest in siblings with normal parents (Chalmers et al., 1997).   
Clear autosomal dominant inheritance is first described Voo in a large one multi-
generation family comprising a total 97 members, with 12 members having CMT6. 
The disease shows great clinical variability (age at onset, severity of disability) and 
the penetrance is incomplete.  
Züchner (Züchner et al., 2006) clarified the genetic basis of the dominant forms of 
CMT6 by performing genetic analysis of  the mitofusin 2 (MFN2) gene in six families 
and  identified a unique MFN2 mutation in each pedigree. 
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MFN2 encodes a mitochondrial membrane protein that participates in 
mitochondrial fusion and contributes to the maintenance and operation of the 
mitochondrial network (events that are essential for mitochondrial morphology and 
function).  
The causes of the the recessive forms of CMT2 with optic atrophy has remained 
elusive due to the small number of reported recessive multigenerational families, 
and a genome wide linkage scan have never been attempted for this form of 
disease. We describe the first genetic defect in a recessive form of CMT 6 in chapter 
4. 
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2 WHOLE EXOME SEQUENCING PILOT 
PROJECT 
 
2.1 STATEMENT OF CONTRIBUTION TO THIS RESEARCH 
I was involved in the experimental design of this study (choice of the sample 
preparation kit, sequencing machine and sequencing method). I did all the wet lab 
work for samples preparation (DNA library). I performed most of the data analysis, 
from quality control to alignment and variant calling.  
 
2.2 BACKGROUND 
WES was first commercially available in 2009 and had never been used in our 
Institute. We conducted a pilot project to test and validate the technology by 
preparing DNA libraries and sequencing from small number of samples. We 
generated the first sequencing data in the department, and set up an analysis 
pipeline which would be used for all following WES projects. 
I am using the pilot data in this chapter to explain the methods that I used in the 
other chapters. 
 
2.3 MATERIALS AND METHODS 
2.4 DNA samples selection 
We selected autopsy confirmed progressive supranuclear palsy (PSP) samples of 
self-reported European ancestry. Genomic DNA was extracted from brain by 
standard procedures. A total of four samples were selected on the basis of DNA 
quality (spectrophotometer) and quantity (about 10 μg). 
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2.4.1 Library preparation 
Adapter-enriched DNA sample libraries were captured using the Illumina protocol 
for preparing samples for paired-end sequencing (part #1005063, June 2008) and 
NimbleGen SeqCap EZ Exome (v1.0, 29/10/2009) following the manufacturer’s 
protocol.  
The Illumina protocol prepares DNA for paired-end analysis on the Illumina Cluster 
Station and Genome Analyzer by adding adapter sequences to the ends of DNA 
fragments. The adapters contain sequences that correspond to the surface-bound 
amplification primers on the flow cell; this allow the DNA molecules to hybridize to 
the surface of the flow cell. 
The NimbleGen SeqCap EZ Exome captures specified regions of the human genome 
from genomic DNA prepared with Illumina Paired-End Genomic DNA Sample 
Preparation Kit. The NimbleGen EZ Exome system uses variable length DNA probes 
(biotinylated oligonucleotide baits) complementary to the targets to hybridize 
sequencing libraries prepared from fragmented genomic DNA. These libraries are 
enriched for targeted regions by pull-down with magnetic streptavidin beads and 
then sequenced. The NimbleGen kit targets 174,984 Consensus Coding Sequence 
(CCDS) (http://www.ncbi.nlm.nih.gov/CCDS) exons of 16,008 high confidence 
protein coding genes (build 36.2), and 528 human miRNA genes obtained from 
miRBase (release 10). In sum, the coding and miRNA target covered approximately 
26.2 Mb of the human genome.  
2.4.1.1 Samples preparation for Paired-End sequencing 
Briefly genomic DNA was fragmented using COVARIS E210 water bath sonicator, 
which shears DNA to fragment sizes of about 100-500 base pairs. 3 μg of genomic 
DNA was brought to a total volume of 100 μl with 1xTE Buffer. Sonication 
conditions were as in Appendix A (Duty Cycle: 10%, Intensity: 5, Cycles per Burst: 
200, Time: 180 s, Temp:  4°C as suggested by the NimbleGen tech support). Then 
each fragmented sample was cleaned with a Qiagen QIAquick PCR Purification 
column (following the manufacturer’s directions: MinElute Handbook PCR 
purification, March 2008), and finally elute with 30μl of buffer EB. Each sample was 
loaded on an Agilent DNA 1000 chip for confirmation of size distribution. Then, the 
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overhangs resulting from fragmentation were converted into blunt ends using 
Klenow enzyme and T4 DNA polymerase (the exonuclease activity removes the 3’ 
overhangs, and polymerase activity fills the 5’ overhangs). The sonicated DNA was 
incubated for 30 minutes at 20°C in a 100 µl reaction volume containing T4 DNA 
ligase buffer with 10mM ATP (10 µl), 10 mM dNTP mix, 10 mM dNTP mix (4 µl), T4 
DNA polymerase (5µl), Klenow enzyme (1 µl), T4 PNK (5 µl), Water (45 µl), DNA (30 
µl). Samples were then cleaned with QIAquick PCR Purification Kit on one QIAquick 
column, eluting in 32 μl of EB. 
Then an ‘A’ base was added to the 3’ end of blunt phosphorylated DNA fragments 
using the polymerase activity of Klenow fragment: each DNA sample was incubated 
for 30 minutes at 37°C with the Adenylation mastermix, containing Klenow buffer 
(5 µl), 1 mM dATP (10 µl), Klenow exo (3’ to 5’ exo minus) (3 µl), DNA sample (3 µl). 
Samples were cleaned using QIAquick MinElute columns, eluting in 10 μl of EB.  
The adapters, that have a single ‘T’ overhang, were ligated to DNA fragments using 
a DNA ligase: DNA samples were incubated thermal cycler for 15 minutes at 20°C 
with the Adapter ligation mastermix, containing DNA ligase buffer, 2X (25 µl), PE 
adapter oligo mix (10 µl), DNA ligase (5 µl), DNA sample (10 µl). Samples were 
purified with QIAquick PCR Purification Kit on QIAquick columns, eluting in 30 μl of 
EB. The ligation products were then size-selected at approximately 300 base pairs 
on a gel to remove all unligated adapters and adapters that may have ligated to one 
another. Briefly, a 2% agarose gel was prepared with 150 ml distilled water and TAE 
(Certified low-range Ultra Agarose BIO-RAD, part # 161-3106) and 60 μg EtBr. All 
samples and one ladder (Hyperladder IV from Bioline) were loaded and run at 120 V 
for 120 minutes. After that, a gel slice containing the fragment of interest was then 
excised and DNA extracted (using the QIAquick Gel Extraction Kit on QIAquick 
columns), eluting in 30 ml of EB. Then the adapter ligated DNA fragments were 
enriched by PCR using two primers that anneal to the end of the adapters. This step 
was also required to amplify the amount of DNA in the library. The reaction, 
containing Phusion DNA polymerase (25 µl), PCR primer PE 1.0 (1 µl), PCR primer PE 
2.0 (1 µl), DNA sample (10 µl) was incubated at the following conditions: 30 seconds 
at 98°C, 10 cycles of: 10 seconds at 98°C, 30 seconds at 65°C, 30 seconds at 72°C, 5 
minutes at 72°C, then hold at 4°C. PCR products were purified across four QIAquick 
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columns (Qiagen) and all the elutants pooled (elution in 10μl of EB as suggested by 
the NimbleGen protocol). The quality of the purified and amplified DNA library was 
assessed on an Agilent DNA 1000 chip. 
2.4.1.2 Exome capture 
Adapter-enriched DNA sample libraries were captured using NimbleGen SeqCap EZ 
Exome following the manufacturer’s protocol. DNA libraries were first amplified by 
ligation PCR (using primers complementary to sequencing adaptors) in 50 µl 
reaction volume containing PE-PRE1 Oligo (1µl), PE-PRE2 Oligo (1µl), Phusion High 
fidelity PCR Master mix (271µl), DNA library (1µl) at the following conditions:  30 
seconds at 98°C, 11 cycles of 10 seconds at 98°C - 30 seconds at 65°C - 30 seconds 
at 72°C, 5 minutes at 72°C, hold at 4°C.  Amplified DNA sample libraries were then 
hybridized to the Exome Library. They were first prepared with COT DNA (100 µl of 
1mg/ml), PE-H1 and PE-H2 (1000 µM) and dried in a SpeedVac at high heat (60°C). 
Then SC Hybridization Buffer (7.5 µl) and Hybridization Component A (3µl) were 
added to the dried amplified sample library; this cocktail was placed in a 95°C heat 
block for 10 minutes to denature DNA.  The amplified sample library/COT DNA/PE-
HE Oligos/Hybridization cocktail was transferred to an aliquot (4.5 µl) SeqCap EZ 
Exome library and the resulting mixture was incubated at 42°C for 72 hours. The 
captured DNA was then washed: SC Wash Buffers and Stringent Wash Buffer were 
first diluted to 1x working solution, then Stringent Wash Buffer (20 µl) and SC Wash 
Buffer I (5 µl) were heated to 47°C in a water bath. Streptavidin Dynabead Binding 
and wash buffer were prepared with Trizma Hydrochloride 1M (25 µl), ETDA 0.5M 
(5 µl), NaCl 5M (1000 µl) and PCR grade water (1470 µl) and 100 µl of beads were 
aliquoted in one single 1.5 ml tube and placed in a DynaMag-2 device. All clear 
liquid was removed with 3 wash steps. The beads were resuspended in 100 µl 
Streptavidin Dynabead and Wash Buffer; the hybridization sample was finally 
transferred to this mix. The tube containing the beads and the hybridized sample 
library was placed in a thermo cycler at 47°C for 45 minutes to allow the binding of 
captured sample to the beads. Then the Streptavidin Dynabeads plus bound DNA 
were washed to remove fragment not bound to beads. First, 100 µl of SC Wash 
buffer I (at a temperature of 47°C) was added to the tube containing DNA bound to 
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beads. The tube was then placed in a DynaMag-2 device to bind the beads and the 
liquid was discarded. Then 200 µl of Stringent Wash Buffer (at a T of 47°C) was 
added to the mix and incubated at 47°C for 5 minutes.   A total of two washes were 
performed with Stringent Wash Buffer as described earlier. Subsequent washes 
with 200 µl SC Wash Buffer I, 200 µl SC Wash Buffer II, 200 µl SC Wash Buffer III 
were performed and for each wash the tube was placed in a DynaMag-2 device and 
clear liquid was discarded. After the last wash, 50 µl of PCR grade water were 
added to each tube of bead-bound captured sample. Last, the bead bound DNA was 
amplified by ligation PCR in a 50 µl reaction volume containing PE-POST1 Oligo 1µl, 
PE-POST2 Oligo 1µl, Phusion High fidelity PCR Master mix 271µl, DNA library 1µl at 
following conditions:  30 seconds at 98°C, 11 cycles of 10 seconds at 98°C - 30 
seconds at 60°C - 30 seconds at 72°C, 5 minutes at 72°C, hold at 4°C.  Each amplified 
captured library was purified with QIAquick columns (Qiagen) and analyzed on an 
Aglient 1000 DNA chip. 
2.4.1.3 Measurement of enrichment 
A standardized set of qPCR SYBR Green assays were used to estimate relative fold-
enrichment by measuring the relative abundance of control targets in amplified 
sample library and amplified captured DNA. For each amplified samples library 
(n=4), we used a standard set of 4 NimbleGen Sequence Capture control locus qPCR 
assay (table S1), and each assay was performed in triplicate. For each assay, we also 
included one negative control (PCR grade water) and one positive control template 
(control genomic DNA). Briefly, each amplified sample library and captured library 
was diluted to 5ng/µl in PCR grade water, for use as templates. For each assay we 
added: 5,9µl of PCR grade water, 0.3µl of NimbleGen Sequence Capture assay 
forward primer (2µM), 0.3µl of NimbleGen Sequence Capture assay reverse primer 
(2µM), 7,5 µl of SYBR Green Master (2X), 1µl of templates. The reactions were run 
on a thermocycler using the following conditions: 10 minutes at 95°C, 40 cycles of 
10 seconds at 95°C and 1 minute at 60°C (Quantification), followed by Melting 
Curve analysis. A total of 192 assays were run: 48 assay per library (each of the 4 
qPCR assay was run in triplicates for each DNA sample analyzed: 12 per amplified 
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sample library, 12 per captured sample library, 12 per negative control and 12 per 
positive control). 
Following data collection, analysis was performed with Absolute Quantification 
Analysis Module within the LightCycler® 480 Software, where the raw Cp values 
were used to perform relative quantification comparing amplified sample library 
and captured DNA. Cp values were exported to a spreadsheet: the average Cp value 
from all replicate reaction was calculated. For each different sample and NSC assay 
combination, we calculated the delta-Cp by subtracting the average Cp value 
measured for the amplified captured DNA template from the average Cp value 
measured for the corresponding amplified sample library template. We also 
calculated the fold-enrichment for all NSC loci by raising the PCR Efficiency for that 
assay to the power of the delta-Cp measured for the corresponding control locus. 
2.4.2 Sequencing 
Sequencing was performed by UCL Genomics on the Illumina Genome Analyzer IIx. 
Sequencing was carried out as paired end 76base pairs reads, following the 
manufacturer’s instructions and using the standard sequencing primer. Image 
analysis and base calling was performed by the Genome Analyzer Pipeline version 
v1.6.  Data were handed in two separate files for each read (read_1 and read_2) for 
each sample. 
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2.4.3 Bioinformatics 
A schematic representation of data analysis is represented in Figure 6. 
1.QUALITY CONTROL 
The sequencing data generated by the Genome Analyzer is stored in a FASTQ file, a 
text-based format for storing nucleotide sequence and its corresponding quality 
scores. The certainty of each base call is recorded as a ‘Phred’ quality score, which 
measures the probability that a base is called incorrectly. The quality score of a 
given base, Q, is defined by the equation: 
Q = -10log10(e) 
where ‘e’ is the estimated probability of the base call being wrong. Thus, a higher 
quality score indicates a smaller probability of error. A quality score of 20 
represents an error rate of 1 in 100, with a corresponding call accuracy of 99% 
(Table 6).  
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Table 6. Phred quality scores 
 
Quality Score Probability of Incorrect Base Call Inferred Base Call Accuracy 
10 (Q10) 1 in 10 90% 
20 (Q20) 1 in 100 99% 
30 (Q30) 1 in 1000 99.9% 
Phred quality scores are logarithmically linked to error probabilities 
 
 
In the Illumina technology the per-base quality score is determined by background 
noise during imaging (Nielsen et al., 2011). Practically Phred scores over 40 are 
uncommon, and a cut-off Phred score of 20 is commonly used (Metzker, 2010). 
We analyzed raw reads with the FastQC program 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  FastQC runs a 
series of tests on a fastq file to generate a comprehensive quality control report. 
FastQC assess data quality by evaluating: read length, per base quality score, per 
sequence quality scores, GC content, nucleotide content, sequence duplication and 
overrepresented sequences.            
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Figure 6. Analysis pipeline for WES 
 
 
 
 
 
Left panel: Program used for each step. Middle: analysis steps. Right panel: data 
formats. 
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2.MAPPING 
Mapping (or alignment) is the process of aligning reads to the reference genome. 
Illumina Genome Analyzer generates millions of 76 base pairs (comprising tens of 
Gb) and corresponding quality scores for each base call.  Because of the large 
volume of reads and the huge size of the whole reference genome, alignment 
algorithms have been optimized for speed and memory usage. Furthermore, since 
the sequencing genome is usually different from the reference genome, alignment 
algorithms have been designed to be robust enough to sequencing errors, but do 
not miss true genomic polymorphism. Therefore different alignment tools are 
designed with different approaches to trading off speed and accuracy to optimize 
detection of different types of variations in donor genomes. Alignment algorithms 
usually follow a multistep procedure to map a sequence. First they quickly identify 
a small set of places in the reference sequence where the sequence is most likely to 
accurately align to. Then slower and more accurate alignment algorithms are run on 
the limited subset of possible mapping location identified in the first step.  To speed 
up the process most alignment algorithms construct auxiliary data structures, called 
indices, for the reference sequence and/or read sequences.  
We performed our analysis with Novoalign (www.novocraft.com), an aligner 
designed for single and paired-end reads from the Illumina Genome Analyzer.  First, 
a reference assembly (downloaded from UCSC: 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/) was indexed; then the 
paired-end reads were aligned to the indexed set of reference sequence: 
 
novoindex  hg19.nix  hg19.fasta 
novoalign -o SAM -F ILMFQ -f input_1 input_2 -d hg19.nix 
> outputSAM 
 
the options indicate: 
-o = output report in the SAM format (see paragraph 3) 
-F = Specifies the format of the read sequence file. In this case ILMFQ (Fastq with Illumina 
coding of quality values) 
-f = specifies the files containing the read sequences to be aligned 
-d = indicated the full pathname of indexed reference sequence 
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Novoalign finds global optimum alignments using an index called fast-hashing 
Needleman-Wunsch algorithm, and uses affine gap penalties to allow consecutive 
run of spaces in a single string of a given alignment. Novoalign allows gaps up to 
7bp on single end reads, even longer on paired end reads.  Novoalign also supports 
paired-end mapping: it first finds the positions of all the good hits, sorts them 
according to the chromosomal coordinates and then does a scan through all the 
potential hits to pair the two ends. The expected size distribution for these 
sequencing runs were on average 300 base pairs as determined in the library 
preparation. Importantly, Novoalign calculates a mapping quality score, which is 
Phred-scaled probability of the alignment for the whole read being incorrect. This 
probability depends on the length of alignment, on the number of mismatches and 
gaps and on the uniqueness of the aligned region on to the genome. It is important 
in the downstream analysis to distinguish the real SNPs from the mismatches 
between, for instance repeated homologous genomic regions. 
 
3. PCR DUPLICATE REMOVAL: SAMTOOLS AND PICARD 
Samtools (http://samtools.sourceforge.net/) is a suite of tools designed primarily to 
manipulate SAM files, and the binary transformed BAM files, in preparation for 
downstream analysis. The SAM format was created in 2009 (Li et al., 2009) to 
define a generic nucleotide alignment format that described the alignment of large 
nucleotide sequences to a reference sequence. SAM files are tab-delimitated text 
files that contain a header section, which carries information on the project and the 
genome, and an alignment section, that contains alignment information such as 
mapping position and information on mismatches. This information is used for 
downstream analysis.  
Samtools was used for converting SAM and BAM files, for sorting (arranging the file 
according to left-most coordinates) and indexing (generating a complementary file 
‘.bai’ which aids fast access to the BAM file) the alignment files generated by 
Novoalign. Samtools was also used for calling SNPs and short indel variants (see 
paragraph on SNP calling). Below are the commands used. 
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To make a BAM file: 
samtools view -bS -t ${fasta}i -o inputBAM outputSAM   
 
To sort the BAM file: 
samtools sort inputBAM output_sortedBAM 
 
To build the index: 
samtools index output_sortedBAM 
  
 
One technical artifact of capture-sequencing procedures is the generation of 
duplicate DNA sequencing reads (defined as reads with the same start point and 
direction) that are due to PCR-induced duplication. They share the same sequence 
and have the same alignment position and could cause trouble during SNP calling as 
some allele could be overrepresented due to amplification biases.  We removed 
PCR artifacts with Picard (http://sourceforge.net/projects/picard/), which 
comprises Java-based command-line utilities that manipulate SAM or BAM files. 
Picard removes all read pairs with identical coordinates, only retaining the pair with 
the highest mapping quality. Picard examines aligned records in the supplied SAM 
file to locate duplicate molecules and generates a SAM output file that includes all 
aligned reads, without the duplicate records. Picard also generates a file that 
contains information on the percentage of PCR duplicates found in the original 
aligned file. 
 
 
java –Xmx2g -jar MarkDuplicates.jar ASSUME_SORTED=true 
REMOVE_DUPLICATES=TRUE INPUT=output_sortedBAM  
OUTPUT=output_sorted_uniqueBAM 
METRICS_FILE=output_picard_metrics.out 
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Picard can also create a summary of alignment metrics about the alignment of 
reads within a SAM file. For instance, given the target intervals Picard calculates 
useful information on the quality of the alignment (eg. percentage of reads aligned, 
coverage) that can be useful to know for downstream analysis (Table 9). 
 
 
java –Xmx2g -jar CalculateHsMetrics.jar 
BAIT_INTERVALS=Nimblegen_tiled_regions.hg19.bed 
TARGET_INTERVALS=CCDS_hg19  
INPUT=output_sorted_uniqueBAM  
OUTPUT=output.hybridMetrics 
 
 
4.SNP CALLING 
Once an alignment is generated, SNP calling can be performed by comparing the 
aligned SAM/BAM file to the reference genome. The end result of a SNP calling 
analysis is a collection of SNPs, each associated to a Phred-like quality score that 
takes into account base calling as well as mapping scores. A standard file has been 
created to hold these SNPs and related information, the Variant Call Format (VCF). 
BCF is the binary version of VCF: it keeps the same information in VCF, while much 
more efficient to process especially for many samples.  
We performed SNP calling with Samtools and VCFtools (Danecek et al., 2011), a 
software suite that implements various utilities for processing VCF files, including 
validation, merging, comparing. 
 
 
samtools mpileup -q 20 -L 400 -d 400 -ugf 
indexed_hum_ref output_sorted_uniqueBAM  | bcftools view 
-bvcg - > output_rawVar.bcf | bcftools view 
output_rawVar.bcf  > output_Var.vcf 
 
where the options indicate: 
SNP and INDEL CALLING PARAMETERS: 
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q = 20. Minimum mapping quality for an alignment to be used 
L = Skip the INDEL calling if the average depth is above 400 
d = 400. Maximal read depth at a position 
OUTPUT PARAMETERS:  
u = output is uncompressed BCF  
g = Compute genotype likelihoods and output them in the binary call format (BCF) 
f = snp calling is based on the indexed reference file in the FASTA format  
BCFTOOLS VIEW OPTIONS: 
b = tells to output to BCF format (rather than VCF) 
c = tells to do SNP calling  
v = tells it to only output potential variant sites (i.e., exclude monomorphic ones) 
g = tells to call genotypes for each sample in addition to just calling SNPs 
 
 
Samtools collects summary information in the input BAMs, such as the number of 
different reads that share a mis-match from the reference, the cloning process 
artifacts (e.g. PCR induced mutations), the error rate associated with the sequence 
reads (eg. the Phred score associated to every base in the read), the error rate 
associated with the mapping (mapping quality) and computes the likelihood of data 
given each possible genotype; then it stores the likelihoods in the BCF format. 
Bcftools does the actual SNP calling.  
Then the .bcf was converted to .vcf, and only the SNPs on the set of exons targeted 
by Nimblegen (i.e., CCDS) were included.  Lastly, the varFilter script was used to rule 
out error-prone variant calls caused by factors not considered in the statistical 
model: 
 
 
 
vcftools --vcf output_Var.vcf --bed CCDS --recode --out 
output_Var_target 
 
 
vcfutils.pl varFilter output_Var.vcf | awk '{if ( (\$6 
>= 18) || ( \$1 ~ /^#/) ) print}' > 
output_Var.vcf_filtered 
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5.INDELS CALLING 
To call indels we used Dindel (Albers et al., 2011), a program specifically designed 
for calling small indels from next-generation sequence data by realigning reads to 
candidate haplotypes. Dindel considers all candidate indels in a BAM file, and tests 
whether each of these is a real indel, a sequencing error or mapping error. In stage 
I) Dindel extracts all indels from the read-alignments in the BAM file. These indels 
are the candidate indels around which the reads will be realigned in stage III). In 
this stage, Dindel also infers the library insert size distributions. These will be used 
in stage III) for paired-end reads. In stage II) the candidate indels obtained in stage 
I) are grouped into windows of ∼ 120 bp, into a realign-window-file. In stage III) for 
every window, Dindel generates candidate haplotypes from the candidate indels it 
detects in the BAM file, and realigns the reads to these candidate haplotypes. 
Realignment is the computationally most intensive step. In stage IV) indel calls and 
qualities are produced in the VCF4 format. This step integrates the results from all 
windows into a single VCF4 file. 
 
 
STAGE I) 
dindel --analysis getCIGARindels --bamFile  
output_sorted_uniqueBAM --outputFile 
output.dindel_output --ref fasta 
 
STAGE II) 
makeWindows.py --inputVarFile 
output.dindel_output.variants.txt --windowFilePrefix 
sample.realign_windows --numWindowsPerFile 1000 
 
STAGE III) 
for realign in /*.txt; do 
  mbcode=\`basename \$realign\` 
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dindel --analysis indels --doDiploid --bamFile 
output_sorted_uniqueBAM --ref fasta --varFile realign --
libFile output.dindel_output.libraries.txt --outputFile 
\${mbcode}.output 
 
echo \${mbcode}.output.glf.txt  >> 
output.dindelfilenames 
 
 
STAGE IV) 
mergeOutputDiploid.py --inputFiles 
output.dindelfilenames --outputFile output_dindel.vcf --
ref ${fasta} 
 
Then, a one line awk script line was used to extract only the indels that passed the 
filters and write them in a vcf file (output_dindel_filtered.vcf): 
 
awk '{if ( ( \$1 ~ /^#/) || (\$7 == \"PASS\") ) print}' 
output_dindel.vcf > output_dindel_filtered.vcf  
 
 
 
6.ANNOTATION 
The ANNOVAR tool (Wang et al., 2010) is a program that utilizes information to 
functionally annotate genetic variants detected by SNP and indel calling, such as 
examining their functional consequence on genes, infer cytogenetic bands, report 
functional importance scores, find variants in conserved regions, or identify variants 
reported in the 1000 Genomes Project and dbSNP. 
 
 
annovar/convert2annovar.pl -format vcf4  
output_Var.vcf_filtered -outfile 
output_annovar/annovar_${code}_temp 
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summarize_annovar_DK_23steps.pl –genetype refgene -
buildver hg19 ${output}_annovar/annovar_${code} 
${annoDB} 
 
 
 
A program called auto_annovar.pl is also provided to automate the procedure to 
identify a small subset of most likely causal variants, from a large list of variants in 
Mendelian disorders. This has been used for instance to identify ROGDI mutations 
in Kohlschütter-Tönz (Schossig et al., 2012a). This script first identifies a list of 
variants that are more likely to cause a Mendelian disease by identifying: splicing 
and exonic variants, variants located in genomic regions that are annotated as Most 
Conserved Elements (more likely to be functional), variants that are not located in 
segmental duplications regions (less likely to be affected by genotype calling issues), 
and by  removing variants observed in the 1000 Genomes Project and dbSNP130  
(CEU, YRI, JPT, CHB, respectively) as these variants are less likely to be causing 
Mendelian diseases.  
 
2.5 RESULTS 
2.5.1 Coupling NimbleGen SeqCap EZ to Illumina sequencing 
Two commercial platforms were available for exome capture, which conducted the 
capture either on a solid-phase substrate (i.e. a glass microarray, NimbleGen 2.1M 
Human Exome Array, Roche-NimbleGen) or in solution (NimbleGen SeqCap EZ 
Exome). Both capture kits tiled the same oligonucleotides from approximately 
180,000 exons of 18,673 protein-coding genes and 551 micro-RNAs and comprise 
34.0Mb of genomic sequence. We adopted the solution-based captured kit as it 
required smaller amounts of input DNA (3 μg versus 10 μg required for array), had 
lower reagents cost and it did not require an investment in array-processing 
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equipment or careful training of personnel on array handling. Moreover it was 
shown to have to have high reproducibility and scalability because it could be 
conducted entirely in small laboratory tubes. In terms of performance, the two 
methods were shown to have similar levels of specificity (Bainbridge et al., 2010).  
As for sequencing, two platforms for next-generation DNA sequencing reads 
production were available: the Roche/454 FLX (Margulies et al., 2005), the 
Illumina/Solexa Genome Analyzer (Bentley et al., 2008) (Table 7). The GA appeared 
better suited for WES because sequencing by synthesis used by the Illumina 
technology had better accuracy in base calling (more accurate for variant calling), 
and also because it had higher throughput at lower cost. Moreover the GA 
technology used paired end (PE) sequencing, where reads are generated from both 
ends of a captured DNA fragment. With PE sequencing, because the approximate 
size of the fragment is known  (DNA shearing during library preparation to a 
fragment size of about 300 base pairs), this information is used to constrain the 
alignment of both reads to the human genome. PE sequencing was shown to 
provide more accurate read alignment and therefore better accuracy and coverage 
of target sequences and SNP calling (Bentley et al., 2008).  
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Table 7. Summary of the Genome Analyzer and Roche 454 main features 
 
 Illumina (GA IIx) Roche 454 
 
Sequencing 
chemistry 
 
Sequencing by 
synthesis 
 
Pyrosequencing 
 
 
Amplification 
approach 
 
Bridge 
Amplification 
 
Emulsion PCR 
 
Paired end/ 
Separation 
 
yes/ 200bp 
 
yes/ 3kb 
 
Gb/run 
 
37-45 Gb 
 
0.5–1 Gb  
 
Read length 
 
100 bp 
 
500-700 bp 
 
Cost per Gb 
 
$500 per Gb 
 
$20,000 per Gb 
 
Pros 
 
High accuracy in 
base calling 
 
 
Longer reads  (better mapping in 
repetitive regions and de novo 
assembly) 
 
Cons 
 
Low multiplexing 
capacity 
 
High error rate in homopolymer repeats. 
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All the samples were run on the GA. The GA produced ~20 Gb data per run; each 
run sequenced 8 lanes on the flowcell. Each sample was run on a single lane of the 
flow cell, as we were aiming to obtain each targeted base sequenced 30 times (i.e., 
coverage 30x). We decided to aim at a coverage of 30x because SNP discovery 
sensitivity was shown to increase by depth of coverage by several studies (Bentley 
et al., 2008), (Brockman et al., 2008), (Choi et al., 2009): essentially all homozygous 
positions could be  detected at depth of coverage of 15, whereas heterozygous 
positions accumulate more gradually to 33× coverage.  
2.5.1.1 Library preparation  
Library preparation was successful as showed by the quality control performed 
after each step of the library preparation process (Figure 7). DNA library is 
represented by the peak at 200-400 base pairs (which reflects the DNA fragment 
size) present in all samples. The peak is very low in PSP 1 in the precapture check. 
At the end of library preparation measure of enrichment showed good enrichment 
(Figure 8) across samples, indicating that the exome target (as defined by 
Nimblegen) was successfully captured. 
2.5.1.2 Sequencing 
Three PSP samples (PSP 1, 3 and 4) were run on the same flow cell. PSP sample 5 
was sequenced on a different run (two months later).  Data were handed together 
with a sequencing report describing the amount and the quality of data generated 
by each run (Table 8). The sequencing reports showed that the lane yield (i.e. the 
amount of data generated for each lane, in terms of sequenced bases) almost 
doubled for PSP sample 5, compared PSP sample 1, 3 and 4. I believe this largely 
depends on the quality of the sequencing for the following reasons: i) standard 
amount of DNA library was sequenced in each run; ii) DNA libraries were prepared 
with the same protocol and showed roughly the same amount of captured 
library/quality or quantity (Figure 7 and Figure 8); iii) Data on a standard control 
sample library showed more clusters in the second run (283533 +/- 16410 versus  
176749 +/- 9376) (Table 8). 
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Figure 7. DNA library preparation: quality control 
 
 
  
 
 
Left panel: Bioanalyser track shows quality of the amplified paired-end library prepared using 
the Illumina protocol. Right panel: Bioanalyser track shows quality of the captured amplified 
sample library prepared using the Nimblgen exome capture protocol. 
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Figure 8. Measure of enrichment 
 
A) Dissociation analysis of the qPCR assays. Four different qPCR locus assays were performed 
on the DNA library pre and post capture to measure the enrichment of standardized control 
loci. These assays act as a proxy for estimating the enrichment of the capture targets. 
B) Example of sequence capture qPCR data for 2 assays. In the successful experiment the Cp 
value form qPCR of amplified captured DNA templates are significantly lower than Cp values 
form amplified sample library templates. CAP = post captured; NON = pre capture
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Table 8. Sequencing report 
   
READ 1 READ2 
Lane Customer Name Sample ID Lane Yield (kbases)  Clusters (raw)  % PF Clusters  Lane Yield (kbases)  Clusters (raw)  % PF Clusters  
1 Arianna Tucci 1 PSP 1568868 262450 +/- 4409 65.53 +/- 3.61 1568868 262450 +/- 4409 65.53 +/- 3.61 
2 Arianna Tucci 3 PSP 1611049 258034 +/- 2973 68.47 +/- 1.87 1611049 258034 +/- 2973 68.47 +/- 1.87 
3 Arianna Tucci 4 PSP 1641785 239310 +/- 5045 75.24 +/- 1.69 1641785 239310 +/- 5045 75.24 +/- 1.69 
4 CONTROL LANE  PhiX 1398539 176749 +/- 9376 86.80 +/- 1.08 1398539 176749 +/- 9376 86.80 +/- 1.08 
         
         
Lane Customer Name Sample ID Lane Yield (Kbases)  Clusters (raw)  % PF Clusters  Lane Yield (Kbases)  Clusters (raw)  % PF Clusters  
3 Arianna Tucci 5 PSP 3537000 387877 +/- 10250  76.47 +/- 1.67  3537000 387877 +/- 10250  76.47 +/- 1.67  
4 CONTROL LANE PhiX 2586000 283533 +/- 16410  89.56 +/- 0.95  2586000 283533 +/- 16410  89.56 +/- 0.95  
 
 
Upper panel: sequencing report for PSP sample 1, 3 and 4. Lower panel: sequencing report for PSP sample 5. Clusters (raw):  The number of clusters per tile 
detected by the image analysis module of the Pipeline. % PF Clusters:  The percentage of clusters passing filters. Note that there are 120 tiles per lane on 
the GAIIx system
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Figure 9. FastQC graphs 
 
 
 
 
The per-base sequence quality graphs show an overview of the range of quality values 
across all bases at each position in the FastQ files. The y-axis shows the quality scores, the 
x-axis shows the position in the read. For each position a box whisker type plot is drawn. 
The elements of the plot are: the central red line is the median value; the yellow box 
represents the inter-quartile range (25-75%); the upper and lower whiskers represent the 
10% and 90% points; the blue line represents the mean quality. The dotted line represents 
the quality score threshold of 20. 
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2.5.2 Data analysis 
Quality check on all samples from the first run (PSP 1, 3 and 4) showed very poor 
quality scores of base calling towards the end of our reads (Figure 9). Considering a 
threshold of 20 for quality score, two thirds of the reads could not be reliably used 
for alignment or SNP calling. Conversely, the quality was good for PSP sample 5 (the 
mean quality score never falls below 20).  
Further analysis confirmed the bad sequencing quality of PSP samples 1, 3 and 4, 
having only about 40 millions sequencing reads each (as shown by the low lane 
yield in Table 8). Of note PSP sample 1 was particularly poor in terms of PCR 
duplicates that had to be removed from the alignment, leaving only about 20% of 
reads for alignment and a resulting coverage on target of only 5x.  Consequently, 
only 8848 variants could be called from this sample (Table 9). The small number of 
reads from PSP sample 3 and 4 resulted in a coverage of 15,2x and 19,6x 
respectively. A total number of variants of 1338 and 13787 were called for each 
sample (Table 9). 
On the other hand, PSP sample 5 had higher coverage (32,7) and 17087 variants 
were called (Table 9,Table 10). Although current studies report 20,000 cSNVs per 
individual (Choi et al., 2009), the number of variants we called for PSP sample 5 was 
consistent with other studies at that time (Ng et al., 2009).  
For PSP sample 5, about 751 variants had not been previously reported, and were 
classified as novel. Of all the cSNVs called, there were 7914 missense variants (316 
novel), 77 premature termination codons (16 novel), 85 canonical splice site 
variants (22 novel) and 8760 synonymous variants (181 novel) (Table 10). 
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Table 9. Alignment and SNP/INDEL calling summary 
 
 PSP 1 PSP 3 PSP 4 PSP 5 
total number 
of reads  
41286030 42396038 43204888 93090718 
non-
duplicated 
reads 
21% 45% 52% 37,4% 
reads aligned 
to target  
24% 34% 36% 37% 
target bases 
10x 
7,7% 55% 60% 73% 
mean target 
coverage  
5,1 15,2 19,6 32,7 
Tot num of 
variants  
8848 13338 13787 17087 
 
 
 
total number of reads = total number of reads  
non duplicated reads = reads that have not been removed by Picard after PCR  
reads aligned to target = aligned, on-target bases out of the bases available 
target bases 10x = target bases sequenced at a coverage of 10x or more 
mean target coverage = mean coverage of targets that received at least coverage depth = 2 
at one base. 
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Table 10. Summary of variants in PSP 5 
 
VARIANT TYPE NUMBER OF VARIANTS 
Total variants 17087 
Missense 7914 
Nonsense 77 
Splice 85 
Synonymous 8760 
NOVEL VARIANTS  
Total 751 
Missense 316 
Nonsense 16 
Splice 22 
Synonymous 181 
KNOWN VARIANTS  
Total 15707 
Missense 7227 
Nonsense 53 
Splice 60 
Synonymous 8355 
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Although this was a pilot project performed mainly with the aim of validating the 
methods for WES, we looked at the variants present in the samples in a search for 
clinically relevant variants. We started by analyzing the most easily identifiable 
damaging (loss of function) mutations: nonsense, splice site or frameshift changes. 
134 novel LOF variants (i.e.) were present in PSP sample 5  (table S6).  
None of these were known to be linked in OMIM to PSP or forms of 
dementia/parkinsonism. Conversely, a number of these were in genes that had 
previously been associated with neurological disorders. Although the probability of 
two or more of the sequenced PSP samples sharing a genetic cause was extremely 
low, given the sporadic nature of these cases, we looked for the LOF variants 
present in two or more samples (Table 11), since this would have been an 
appropriate method with the availability of a much larger cohort.  
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Table 11. Variants shared by two or more PSP exomes 
Gene chr.  mut  PSP_1 PSP_2 PSP_3 PSP_5 
MLL3 chr7:151945072 stop gain v v v v 
NIPA2 chr15:23006219 frameshift del   v v v 
SIGLEC12 chr19:52004794 frameshift ins v v v   
PRAMEF1 chr1:12854090 stopgain     v v 
OR5K3 chr3:98110413 frameshift ins     v v 
C11orf40 chr11:4592710 frameshift ins     v v 
 
  
Surprisingly we found a LOF mutation shared by all samples in the 
myeloid/lymphoid or mixed-lineage leukaemia 3 gene. MLL3 is part of the  
myeloid/lymphoid or mixed-lineage leukemia (MLL) family. The change occurring in 
all samples, a one bp insertion (uc003wla.2: c.2447_2448insA:p.Y816_I817delinsX) 
maps also to a duplicated region on chromosome 21 (Figure 10). To investigate this 
further, we compared the sequence containing the DNA change to the human 
genome database using blast tool (http://genome.ucsc.edu/cgi-
bin/hgBlat?command=start). This showed that the sequence containing the 
insertion perfectly matches to a region on chromosome 21, which contains the 
same change in the same position, and is also known to be a SNP (rs 71292114). 
This means that the read containing that sequence aligned to the wrong position in 
the reference genome. This is due to the high sequences homology and shows the 
difficulty of aligning short sequence reads. Similarly, other variants shared by two 
or more samples, mapped to highly homologous/duplicated sequences (variants in 
the PRAMEF1, OR5K3 and SIGLEC12 genes for example). Conversely, the variant in 
the NIPA2 gene, turned out to be a SNP later described in the 1000 Genomes 
Project.  
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Figure 10. The MLL3 mutation is a SNP on a different chromosome 
 
 
The sequence containing the MLL3 stopain novel variants (here showns as a horizontal 
black bar: “Your sequence from blat search”) maps to chromosome 21 (region shown here). 
An in-depth analysis of the sequence shows the variant initially annotated as a novel 
nonsense variant is a SNP (rs7129114).   
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2.6 CONCLUSIONS 
The promise that WES brought to genetic research in 2009 was enormous, but the 
hurdles to make this technique functional in the laboratory were many. The 
importance and usefulness of this pilot project were in understanding both 
technical and analytical obstacles to overcome. 
On the technical point of view, a) I acquired familiarity with the cumbersome 
procedure of library preparation and observed the bias in results (PSP 1) that can 
derive from the amplification steps of the procedure. Indeed Illumina and 
Nimblegen later modified and optimized these steps; b) I learned how to evaluate 
the quality of a sequencing run based on the lane yield which directly influences the 
coverage. These points are particularly important as most of the WES projects in 
our lab are outsourced and it is crucial to understand when an exome is bad quality 
and where it is not worth carrying additional analysis.  
This pilot project provided me with two areas of knowledge: the technological 
aspects for WES  as well as a first feeling of human coding variation. 
On the analytical point of view, the striking number of LOF variants poses major 
challenges when interpreting such variants:  
a) The proportion of annotation error might be high due to the complexity of the 
genome (duplications and homology regions) and the short length of the 
sequencing reads.  
b) Some of these variants can be true rare variants that have not been described 
(frequency <0.1) but that are benign. Indeed with the growing number of publicly 
available WES resources (ESP for instance), many of these variants are being 
described. 
c) Clinical interpretation of LOF variants: determining which of the variants is 
actually responsible for causing disease remains a hurdle. In Mendelian diseases we 
can reduce the number of LOF by looking at segregation (i.e. filter for variants 
present only in affected family members). In complex diseases very large cohorts 
are needed.  
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3 KOHLSCHÜTTER-TÖNZ SYNDROME: 
ROGDI MUTATIONS AND GENETIC 
HETEROGENEITY 
 
3.1 STATEMENT OF CONTRIBUTION TO THIS RESEARCH 
I performed WES data analysis of patients with Kohlschütter-Tönz syndrome (KTS). I 
supervised the laboratory based sequencing and fragment analysis experiments. I 
collected all the clinical data of KTS patients seen elsewhere.  
I wrote the original manuscript that has been published in the journal “Human 
Mutation”. 
 
3.2 BACKGROUND 
Ten families with KTS were identified with the core features of epilepsy, 
psychomotor delay or regression and abnormal amelogenic teeth. We performed 
clinical and genetic investigations leading to the identification of ROGDI mutations 
in five of them, all presenting with a typical KTS phenotype.  The other families, 
mostly presenting with additional atypical features, were negative for ROGDI 
mutations, suggesting genetic heterogeneity of atypical forms of KTS. 
 
3.3 MATERIALS AND METHODS 
3.3.1 Samples 
The recruitment of subjects from the Kohlschütter-Tönz pedigrees was made by 
Prof. Henry Houlden, who contacted the family or researcher working on the family 
and obtained their permission to use DNA for genetic studies. DNA samples were 
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collected for a total of 22 samples, comprising 13 affected and 9 unaffected 
individuals. 
3.3.1.1 Clinical details  
A total of ten families were identified. Written informed consent was obtained 
before sample collection and institutional ethics approval was also obtained (Figure 
11). 
 
Family A 
This family was reported in 1988 (Christodoulou et al., 1988). The parents originate 
from a small isolated town in Sicily. The affected individuals (6 siblings) had all a 
similar phenotype characterized by delayed neuromotor development, epilepsy 
(onset between 7 and 22 months), and amelogenesis imperfecta of the hypoplastic 
rough type affecting primary dentition.  
 
Family B 
This is a new case of KTS. The affected boy was the first child of healthy non-
consanguineous parents. He was born after an uneventful pregnancy and his 
development was normal during the first half year of life. Then it slowed down and 
at age 7 month the boy presented with treatment resistant seizures followed by 
severe delay of motor and cognitive development. The primary dentition showed 
severe enamel defects with yellow teeth. At age 28 months the boy had  
microcephaly (48cm/ -2,3 SDS) and small stature (83,4 cm/-2,2SDS).  
 
Family C 
This family was reported in 1995 (Musumeci et al., 1995). Briefly, it consists of two 
affected siblings (male and female) born from first-degree cousins parents of 
Sicilian origin. They had their first seizures between the age of two and 10 months, 
developed psychomotor regression starting age of two and had very thin 
hypoplastic enamel with yellow teeth. Presence of broad thumbs and toes is 
reported. 
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Family D 
This family was reported by Petermöller (Petermöller et al., 2008). Briefly, this 
family consists of two affected siblings, offspring from healthy unrelated parents. 
They both had the first epileptic seizures at the age of 8 months, yellow teeth with 
amelogenesis imperfecta and psychomotor regression starting at the age of two. 
One of the children died at the age of 21 years. 
 
Family E  
This family was reported (Schossig et al., 2012b). The affected individual was born 
from healthy, unrelated parents of German origin and has two healthy sisters. The 
boy was born at term after an uneventful pregnancy, and had normal development 
until he had his first seizures at age of 11 months. After that he showed delay of 
psychomotor development and partial regression of motor skills. The epilepsy was 
difficult to treat. His teeth had a brownish discoloration.  
 
Family F 
This family has not been previously reported.  The child presented at 8 months with 
seizures and was found to have infantile spasms. MRI of the brain was normal.  He 
went on to have profound developmental handicaps, developed spasticity in all 
extremities and had intractable mixed focal onset and generalized myoclonic/tonic 
epilepsy. He was noted to have amelogenesis imperfecta when his teeth erupted 
and they were yellow.   Spasticity was treated with baclofen and he required 
bilateral femoral osteotomies for hip dislocations and spinal rod placement for 
scoliosis. At age 15 he was inconsistently visually interactive and has no expressive 
language; he was unable to sit or roll over.  
 
Family G 
This family was reported in 1994 (Guazzi et al., 1994). This pedigree was quite 
complicated with four different phenotypes occurring concurrently: amelogenesis 
imperfecta only, delayed psychomotor development, ataxia and abnormal EEG, 
neurological disorder or seizures and amelogenesis imperfecta. This family was 
atypical for KTS, as the teeth with amelogenesis imperfecta were not truly yellow 
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and degenerated and the later age at onset. Moreover inheritance looks dominant 
but affected individuals from the last generation are born from first-degree cousins 
parents. It is possible that more than just one disorder is responsible for the 
complex phenotypes in this pedigree as there were individuals suffering only from 
amelogenesis imperfecta. 
 
Family H 
This family was previously reported by Donnai (Donnai et al., 2005), comprising two 
affected siblings from healthy unrelated parents. Both siblings developed seizures 
at age of five weeks (male) or 11 weeks (female), delayed psychomotor 
development starting at the age of one year and yellow teeth with hypoplastic and 
hypomineralized enamel. They also had feeding problems with multiple food 
intolerances. The affected female was also clinically and genetically diagnosed with 
neurofibromatosis type 1. 
 
Family I 
This family hasn’t been previously reported. The patient is the second of two 
children born to healthy unrelated parents. He had a delayed motor and cognitive 
development. Both primary and secondary dentition showed absent enamel of 
several but not all teeth. A brain MRI showed mild atrophy of the cranial part of the 
vermis and a small pons, but otherwise was normal. He had periods of unusual 
quiet behavior and sleepiness, thereafter true convulsions were not recognized. 
EEG studies showed multiple epileptiformic activities, mainly frontal and fronto-
temporal. He also had some unusual morphological signs: deeply set eyes, 
horizontal eyebrows, short nose, concave nasal ridge, anteverted nares, irregularly 
placed teeth, many of them without missing enamel, small ears, and mild 
hypermobility of the small joints. He had multiple warts.  
 
Family J 
This patient showed a mildly delayed global development after normal pregnancy 
and delivery. She had several episodes suggestive of epilepsy from the age of 18 
months and a definitive diagnosis of epilepsy was made at age 6 years. She had 
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diverse seizures, including atypical absences and myoclonic seizures. EEG showed 
continuous spike waves during sleep. Epilepsy was resistant to therapy. Her teeth 
were first white, but discoloured some time after eruption, and the diagnosis of 
amelogenesis imperfecta was made by a paediatric dentist. Currently she has mild 
to mental retardation. Neurological examination shows no abnormalities besides 
mild clumsiness.  
  
 97 
Figure 11. KTS pedigrees 
 
 
 
 
 
 
Red circles indicate samples that underwent WES. AI= Amelogenesis imperfecta; 
KTS = Kohlschutter-Tonz syndrome. 
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3.3.2 Genetic investigations  
3.3.2.1 Linkage analysis and homozygosity mapping 
DNA array SNP analysis was run in two affected siblings from family A and one 
affected from family C (using Illumina Human HapMap 300), one affected from 
family I and one affected from family H (using Illumina HumanOmniExpress-
12v1_H). Autozygosity mapping was performed using the plug-in software 
Homozygosity Detector within the BeadStudio suite. Regions of shared 
homozygosity that segregated with disease were visually inspected using the 
Illumina Genome Viewer within the BeadStudio suite.  
As part of a project on mental retardation run by our collaborator Dr. Raoul 
Hennekam, array comparative genomic hybridization (aCGH) analysis with a 
Nimblegen 2.1M oligo array was also carried out in the affected individual from 
family I. 
3.3.2.2 Whole exome sequencing 
WES was carried out on a total of five affected samples from four different families 
(A, C, D and I) (Figure 11). All samples were enriched using the Illumina TruSeq 
exome capture system and run on an Illumina HiSeq 2000 for sequencing by AROS 
Applied Biotechnology, except from one affected from C, which was run using the 
Nimblegen SeqCap EZ enrichment kit and sequenced on one flowcell on the 
Illumina Genome Analyzer IIx at NIH (Bethesda, US). All sequencing reads were 
aligned to the hg19 build of the human reference genome using Novoalign. SNP and 
indel calling were performed using Samtools version 0.18 and were annotated using 
the software ANNOVAR (Wang et al., 2010). Candidate variants were filtered on the 
basis of function (as predicted by ANNOVAR), and the 1,000 genomes 
(www.1000genomes.org) and NHLBI exome sequencing project 
(http://evs.gs.washington.edu/EVS/) frequencies.  
3.3.2.3 Sanger sequencing 
All exons and exon-intron boundaries of the ROGDI gene (NM_024589.2) were 
sequenced by Sanger sequencing in all affected and unaffected family members for 
whom a sufficient amount of DNA sample was available (primer sequences in table 
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S2). The results were analyzed with the Sequencher 4.1.4 software. We also 
sequenced one additional exon based on UCSC (uc010uxu.2, exon 2) to get s 
comprehensive analysis of all annotated coding exons in public databases. 
Mutations were named based on the sequences with accession numbers 
NM_024589.2 and NP_078865.1. 
3.3.2.4 Fragment analysis 
We performed fragment analysis of ROGDI intron 1-2 using FAM labeled forward 
primer (table S2). A touchdown PCR cycling protocol was used where the initial 
annealing temperature was lowered from 58 °C to 52 °C in 0.3 °C decrements each 
time for each cycle (table S2). Fragment length analysis was performed on an ABI 
3730XL genetic analyzer (Applied Biosystems, Inc., Foster City, CA, USA), after 
incubation at 95°C for 5 minutes of 1μl of PCR product with 10μl of formamide and 
0.5μl of LIZ, and analysed using ABI GeneScan v 3.7 (Applied Biosystems, Inc., Foster 
City, CA, USA). 
3.3.2.5 Transcript analysis 
cDNA was obtained by standard procedures from cultivated peripheral blood 
mononuclear cells (PBMC) of the affected child and both parents from family E and 
family J. Relative expression of ROGDI was quantified by real time PCR with specific 
primers spanning exons 3–5 and the comparative DDCt method using HPRT1 
(RefSeq accession number NM_000194.2) as a reference gene, as previously 
described (Schossig et al., 2012a). Direct cDNA sequencing was performed in family 
E and family J by RT-PCR amplification of the entire ROGDI coding region with a 
forward primer in exon 1, a reverse primer in exon 11 and subsequent sequence 
analysis using internal primers. In family E, the forward primer in exon 1 was used 
in combination with a wildtype-specific reverse primer at the position of mutation 
c.366dupA in exon 6 (the affected child of family E had inherited this mutation from 
his father) to preferentially amplify transcripts from the maternal allele in the 
affected child. Subsequent sequence analysis was performed with the wildtype-
specific reverse primer. 
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3.4 RESULTS 
The linkage analysis previously carried out on five small families including family A, 
C, D, H and G (Lo, C.-N., 2009, Introduction) suggested significant linkage of a 
disease locus on the short arm of chromosome 16 (16p13) under a recessive model. 
To seek further evidence to support this result, we ran microarray analysis for SNP 
detection on affected individuals from family A and C. The three affected 
individuals shared a region of homozygosity on chromosome 16 (telomeric arm 
from 1 to 6,098,295 bp).  
Given the large number of genes in the linked region (279 genes, bases on NCBI 
MapView: http://www.ncbi.nlm.nih.gov/projects/mapview/), we decided to 
perform WES. Five KTS samples in total underwent WES. We initially sequenced one 
proband from family C. Shortly after that we were offered by Aros -an independent 
company that provides services to universities- a trial run and we decided to 
perform WES on two additional samples: one affected sibling from family A and one 
from family D. The run was successful but due to an excess number of duplicate 
reads the coverage was low. Therefore Aros offered a free additional run, and we 
ran the other affected sample from family C and from family I (Figure 11, Table 12). 
Using a frequency cut off of 1% (based on both the 1,000 Genomes project and the 
NHLBI exome variant server), we found the affected individual from family A had a  
single variant in the linked region on chromosome 16. This variant is homozygous, 
located in the ROGDI gene (1bp frameshift truncating deletion c.507delC, 
p.Glu170Argfs*72) and was not found in any database available to us. This variant 
was confirmed through Sanger sequencing and was shown to segregate within the 
family (Figure 13). The remaining exome data did not identify additional rare 
variants in ROGDI.  An in depth analysis of exome data from other affected samples 
showed that, owing to limited sequencing depth, some of the ROGDI exons were 
not well covered in our exome sequence data (mainly exons 1 and 2) (Figure 12).  
We therefore decided to pursue ROGDI gene and Sanger sequence the two exons 
not covered. 
At this time ROGDI mutations were independently identified in Innsbruck in three 
KTS families (Schossig et al., 2012). Subsequently, Sanger sequencing of all coding 
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exons, exon-intron boundaries and the short introns 1, 3, 8, 9 and 10 of ROGDI was 
carried out in all samples from 7 families available in our laboratory (22 samples, of 
which 13 affected and 9 unaffected individuals) and in all affected members of 4 
families collected in Innsbruck. Family D was investigated independently both in 
London and Innsbruck. Together, we identified ROGDI mutations in five families 
(families A, B, C, D and E) (Table 13). The affected individual from family B had the 
same mutation present in family A (c.507delC, p.Glu170Argfs*72). Affected 
individuals in families C and D carried different homozygous deletions in intron 1 
that segregated with disease: c.46-37_46-30del and c.45+9_45+20del respectively. 
The mutations were heterozygous in the parents (Figure 13). The presence of these 
deletions was also confirmed through fragment analysis (Figure 14). The affected 
individual from family E was compound heterozygous for a 1 bp frameshift 
truncating duplication (c.366dupA, p.Ala123Serfs*19) and the same intron 1 
deletion c.45+9_45+20del which was found in family D. The father was 
heterozygous for c.366dupA and the mother was heterozygous for 
c.45+9_45+20del. The intron deletion c.45+9_45+20del was assumed to alter mRNA 
splicing albeit this was not indicated by the splice prediction programs available 
through ALAMUT or Spliceview. Therefore, to further investigate the effects of 
c.45+9_45+20del we studied the mRNA transcripts in the cells from patients from 
family E. Quantitative RT-PCR showed a reduction of transcripts to about 55% and 
60% in both the mother (heterozygous carrier) and the affected child (compound 
heterozygous) respectively when compared to controls (data not shown), while it 
did not show any reduction in the father. These findings indicate that the intron 
deletion c.45+9_45+20 is associated with markedly reduced mRNA production or 
stability while c.366dupA does not lead to nonsense mediated decay (NMD). 
 102 
 
 
Table 12. WES summary metrics for KTS samples 
 
 Sample I Sample II Sample III Sample IV Sample V 
 
Family  
 
A 
 
C 
 
C 
 
D 
 
I 
 
Target capture kit  
 
Illumina Truseq 
 
Nimblegen SeqCap 
EZ  
 
Illumina Truseq 
 
Illumina Truseq 
 
Illumina Truseq 
       
Total number unique reads 
 
7,870,652 171,506,673 35,822,484 10,002,954 28,014,742 
% duplicated reads 
 
86% 8% 39% 76% 36% 
Reads aligned to target  
 
59% 53% 24% 60% 41% 
Mean target coverage  
 
7,6 130,7 22,4 9,9 18,1 
Tot number of variants  15959 16085 16231 15875 15359 
  
 
   
 Target enrichment = method used to selectively capture the coding regions of the genome; total number of unique reads = number of reads that are not marked as 
duplicates after alignment; mean target coverage = mean coverage of targets that received at least coverage depth = 2 at one base 
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Figure 12. WES data at the ROGDI locus.  
 
ROGDI gene structure in blue, (exons=rectangles, introns = line). Each gray line is a whole exome 
sequencing read. There are no reads covering exon 1 and exon 2. 
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Figure 13. ROGDI gene structure and mutations identified 
 
 
 
 
Upper panel: gene structure and mutations reported in the Schossig and Mory papers. Red: 
novel mutations reported in the present study.  
Lower panel: chromatograms showing the mutations identified in this study. Curly brackets 
indicate deleted nucleotides in affected members 
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Figure 14. Fragment analysis in families C and D  
 
 
Numbers indicate fragment length. 
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To investigate the effect of c.45+9_45+20del on pre-mRNA processing we designed 
an RT-PCR primer pair that specifically amplifies transcripts of the maternal allele in 
the affected child. We obtained and RT-PCR aberrant band approximately 60 base 
pairs longer than the normal amplicon. This band was not seen in the father or the 
control (Figure 15). Sequencing of the RT-PCR amplicon in the child showed that the 
aberrant transcript contains intron 1 with the 12 bp deletion (Figure 15), confirming 
that c.45+9_45+20 does not allow correct splicing of intron 1. This data suggest that 
the deletion c.45+9_45+20del prevents recognition of intron 1 by the splicing 
machinery and leads to frameshift and creation of a premature stop codon 
(p.Glu16Valfs*57) in exon 3.  
We failed to identify ROGDI mutations in families F, G, H, I and J. To exclude the 
presence of large indels we ran SNP arrays on affected samples from family H and I.  
Over the ROGDI locus they were not homozygous nor showed any large indel 
(Figure 17).   
Interestingly the proband from family I was found to have a 2.75Mb de novo 
duplication on chromosome 7 (hg18 coordinates chr7: 5,100,000-7,855,000), which 
was confirmed by aCGH array (Figure 16).  
ROGDI expression levels were investigated in the affected from family J and his 
parents and were comparable to those in normal controls. Direct cDNA sequencing 
did not uncover a ROGDI mutation. 
  
 107 
Figure 15. RNA analysis  
 
 
(A) Wildtype-specific rtPCR amplification in family E. The mother (M) shows a strong 400 
bp wildtype amplicon and an aberrant approx. 460 bp band. The wildtype band is also 
found in the father (F) and the control (C). The affected child (P) shows predominantly the 
aberrant 460 bp band. All samples have an additional band of approx. 340 bp which 
represents skipping of exon 4 in a small fraction of transcripts as shown by rtPCR 
sequencing (data not shown). L = Size standard. (B) rtPCR sequence analysis in the affected 
child of family E. The mutation c.45+9_20del causes inclusion of intron 1 between 
unaltered exons 1 and 2 in the ROGDI transcript. 
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Figure 16. Duplicated region on chr.7 from family I  
 
 
 
Oligo array CGH results for the affected child from Family I shown in UCSC genome browser 
(chr7:5,500,000-8,000,000, NCBI Build 36, hg17). Deviations of probe log2 ratios from zero 
are depicted by vertical grey/black lines, with those exceeding a threshold of 1.5 standard 
deviations from the mean probe ratio colored green and red to represent relative gains 
(duplications) and losses (deletions), respectively. Genes are depicted in blue below the 
CGH data 
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Table 13. Summary of analyses and results for each KTS family 
Core features = epilepsy, developmental delay and amelogenesis imperfecta 
Family ID Phenotype WES 
Linkage and 
homozygosity 
mapping 
ROGDI Sanger 
sequencing 
Fragment and 
cDNA analysis 
ROGDI mutations 
Family A Core Features One affected 
proband 
Linkage  Yes N/A Homozygous c.507delC 
Family B Core Features N/A N/A Yes q RT-PCR Homozygous c.507delC  
Family C Core Features Both affected 
siblings 
Linkage and 
homozygosity mapping  
Yes  Fragment 
segregation 
Homozygous  
c.46-37_46-30del 
Family D Core Features One affected 
proband  
Linkage  Yes cDNA and 
Fragment 
segregation 
Homozygous  c.45+9_45+20del 
Family E Core Features N/A N/A Yes q RT-PCR, cDNA 
amplification, and 
sequence analysis 
Compound heterozygous 
c.366dupA/c.45+9_45+20del  
Family F Core Features + 
Spasticity 
N/A N/A Yes N/A None 
Family G Atypical KTS N/A Linkage  Yes  N/A  None  
Family H Core Features+ 
feeding problems 
+neurofibromatosis 
1 
N/A Linkage   Yes N/A None  
Family I Core Features+ 
dysmorphic signs+ 
multiple warts 
Single affected 
member 
N/A Yes N/A None 
Family J Core Features N/A N/A Yes q RT-PCR, cDNA 
amplification, and 
sequence analysis 
None 
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3.5 DISCUSSION 
In this study, WES failed to identify the causal mutation in three samples from two 
families because the mutation is intronic. WES has been shown to detect SNVs in 
the introns, especially for Trusequ capture kit (this is because the bait often extends 
farther outside the exon target) (Clark et al., 2011). In this study WES did not 
sequence the intron (albeit very small, 73bp) and the flanking exons. This is 
probably due to the high GC content of the region.  
The initial identification of a ROGDI mutation in family A did point to a causal role of 
this gene in KTS, but the concurrent absence of other ROGDI mutations in the 
remaining families initially slowed down our analysis. In this case, the absence of 
mutations was due to the lack of sequencing reads in some ROGDI exons. Only an 
in-depth inspection of WES data over the ROGDI gene allowed us to identify regions 
that had not been sequenced. This result highlights the importance of a detailed 
analysis of WES data over a candidate region.  
Traditional Sanger sequencing of the regions not covered by WES, allowed us to 
identify the intronic deletions in families C, D and E. RNA analysis further confirmed 
their splicing- altering role and the consequent premature truncation of the ROGDI 
protein in the patients cells. Of note, splice site prediction programs (like ALAMUT 
and Spliceview) did not predict the intronic deletion to alter mRNA splicing. 
The location of the two intronic deletions in positions distant to the exon-intron 
boundaries could indicate that they affect splicing through interfering with the 
stem-loop formation (Stallings and Moore, 1997).  
 
The identification of homozygous mutations in the ROGDI gene in five families 
(family A, B, C, D and E), all segregating with disease, supports the fact that 
mutations in the ROGDI gene cause KTS and confirm the results of Schossig et al 
and Mory et al 2012. The families carrying the mutation had typical KTS, and three 
of them had previously been linked to chromosome 16 within which the ROGDI 
gene lies and have likely loss of function ROGDI mutations. 
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Conversely, in five KTS families (families F, G, H, I and J) no mutations were found in 
the ROGDI gene. Clinically these families had atypical KTS phenotype as they had 
additional features. Family F had spasticity. Family G presented late, had a likely 
dominant pattern of inheritance and teeth that were amelogenic but not truly 
yellow. Family H had all the features of KTS but were unusual, in that they also had 
feeding difficulties and Family I had additional dysmorphic features. These clinical 
differences reflect that so far ROGDI mutations have been identified only in typical 
KTS and even though the phenotype is complex there seems to be a relatively tight 
pattern of clinical signs associated with this gene. 
ROGDI mutations were excluded by exome and Sanger sequencing, where all exons 
of the gene were amplified and sequenced in all samples. No heterozygous or 
homozygous changes were seen throughout the ROGDI gene making this gene 
unlikely to cause atypical forms for the disease, although we cannot rule out 
difficult to detect deep intronic mutations or compound heterozygous exonic copy 
number deletions. Nevertheless, this is improbable as haplotype analysis on 
chromosome 16p13.3 failed to show a shared haplotype on chromosome 16p13.3-
13.2 in family G and H (Figure 18). Moreover, in family J additional rtPCR 
sequencing performed in the affected individual with primers spanning exon 1-11 
and quantitative rtPCR showed no reduction of mRNA in the family members. Of 
note, none of the ROGDI negative families showed consanguinity, making the 
gene(s) causing atypical forms of KTS only possibly recessive. With this in mind, de 
novo mutations in other genes could be causing atypical phenotypes of KTS. Indeed, 
the proband from family I has been extensively investigated at a genetic level (WES 
and CHG array) and was found to have a de novo 2.75Mb duplication on 
chromosome 7, comprising about 60 genes (NCBI mapviewer). It is likely that a 
dosage effect of one of the genes in this region is causing a ROGDI like phenotype 
although this was not seen in any of the other families. WES in this sample showed 
no defects in this region. 
 
In summary, this work confirms the role of ROGDI mutations in typical KTS. This 
work also exemplify the importance of sequencing non-coding regulatory regions, 
at least to within 20 bp of the exon for the analysis of Mendelian disorders.  
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A number of families with atypical KTS phenotype were identified, who were 
negative for ROGDI mutations and failed to show homozygosity in the ROGDI region, 
suggesting genetic heterogeneity of atypical forms of disease. 
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Figure 17. Chromosome 16 linked region (1-10Mb)  
 
 
Genome Viewer tool, showing individuals from family H (sample C1) and I (sample D1) are 
heterozygous, individual from family A (sample E1) block of homozygosity  (1bp to 6Mb). 
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Figure 18. Haplotype analysis of families G and H 
 
This is part of a PhD thesis by Lo CN (Lo, C.-N., 2009) and shoes that the affected individuals 
from families G and H do not share that same haplotype on the chr 16 region, suggesting 
genetic heterogeneity of the disease. 
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4 C12orf65 MUTATIONS CAUSE 
AXONAL NEUROPATHY WITH OPTIC 
ATROPHY     
 
 
4.1 STATEMENT OF CONTRIBUTION TO THIS RESEARCH 
I performed autozygosity mapping and WES data analysis of a family presenting 
with axonal neuropathy and optic atrophy and I was involved in the laboratory 
based DNA sequencing and RNA analysis experiments. I made contacts with people 
working on mitochondrial biology, asked them to run experiments to further 
confirm our results and coordinated different people working on different aspects 
of mitochondrial function. I collected the cohort of patients to screen for the gene 
we found mutations in. I wrote the original manuscript that has been submitted to 
the Journal of Medical Genetics journal. 
 
4.2 BACKGROUND 
CMT type 6 is characterized by axonal neuropathy and optic atrophy and is 
genetically heterogeneous. Mutations in Mitofusin 2 have been found to cause 
dominant forms of CMT6, whilst until now, the genetic cause of the recessive form 
has remained unknown. 
We describe a family with CMT6, beginning in late childhood and with a slow 
progression. By performing homozygosity mapping followed by WES of two 
affected cousins, we identify a homozygous protein-truncating mutation in the 
C12orf65 gene.  C12orf65 encodes for a 166 amino acid protein, involved in 
mitochondrial translation. We show mitochondrial impairment in the patients 
lymphoblast cell lines by multiple lines of evidence: decrease of complex V activity 
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and a defect in stability pattern, decrease mitochondrial respiration rate as well as 
reduction of mitochondrial membrane potential. 
This work describes for the first time the genetic defect in a recessive form of CMT6 
and confirms the role of mitochondrial dysfunction in this complex axonal 
neuropathy.  
 
4.3 METHODS 
4.3.1 Samples 
DNA samples from an Indian family with CMT6 and from 93 additional patients 
affected by complex neuropathy (neuropathy plus one of the following: optic 
atrophy, retinitis pigmentosa, psychomotor retardation, cerebellar ataxia, or 
pyramidal signs) were collected by Prof. Henry Houlden at the National Hospital for 
Neurology and Neurosurgery (NHNN), London.  All patients had been previously 
screened for known mutations in the following genes PMP22, GJB1, MFN2, MPZ, 
GDAP1, BSCL2, TRPV4, NEFL, HSPB1, HSPB8, or GARS.  
We also agreed to collect 90 additional samples to screen for C12orf65 mutations 
from the Neurometabolic Unit (NMU) at the NHNN, a designated supra-regional 
centre in the UK for the investigation of neurometabolic disorders, with special 
interest in mitochondrial disease. Samples were chosen from their database, based 
on the following criteria: presence of a decreased complex V activity or combined 
oxidative phosphorylation enzymes deficiency in the blue native gel and/or clinical 
presentation with neuropathy/optic atrophy/ataxia or a Leigh-like phenotype.  
Genomic DNA was purified from peripheral blood cells using standard procedures. 
4.3.2 Nerve biopsy 
The nerve biopsy soon after the surgical removal were immersed in a fixative for 
overnight containing 3% buffered glutaraldehyde and 0.2M sodium cacodylate 
buffer. Then specimens were cut with razor in 1-2 mm thick pieces and osmicated 
in secondary fixative - osmium tetroxide. After fixation the specimens were 
impregnated into epoxy resin from which semi-thin (~1µ) sections or ultra-thin 
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(~70nm) sections were cut and put on glass slides or grids, respectively. Semi-thin 
sections were stained either with Methylene blue - Azure A and basic fuchsin or 
Toluidine blue and examined by light microscopy on various magnifications. Ultra-
thin (~70nm) sections were stained with Uranyl Acetate/Lead Citrate and examined 
by electron microscopy at various magnifications.  
The paraffin blocks of the sural nerve biopsy from case 1, performed when he was 
investigated at the time of his deterioration, were kindly made available and 
examined by Prof. Sebastian Brandner. He also compared Case 1 biopsy to a MFN2 
mutation positive and a patient not carrying known mutations. 
4.3.3 SNP genotyping and autozygosity mapping 
Genome-wide SNP genotyping was performed in two affected family members of 
the family (case 1 and case 3) at NIH (Bethesda, US). Each individual was assayed on 
an Illumina chip (HumanHap300 BeadChip), yielding approximately 317,000 SNPs. 
Samples were processed, hybridized, and scanned following the instructions of the 
manufacturer. Clustering, normalization, and genotype calls were performed using 
the GenomeStudio 2010.3 Genotyping Module (Illumina). Autozygosity mapping 
was performed using the Homozygosity Detector plug-in software within the 
BeadStudio suite. Regions of shared homozygosity that segregated with disease 
were visually identified using the Illumina Genome Viewer tool within the 
BeadStudio suite. 
WES was carried out on case 1 and case 3 at NIH (Bethesda, US). Nimblegen SeqCap 
EZ Exome (in solution capture) kit for was used for the exome capture. Shotgun 
sequencing libraries were generated from three µg of DNA from each individual. 
Sequencing was performed on a Genome Analyzer IIx, according to the 
manufacturer's instruction.  
Raw sequencing reads were aligned to the hg18 build of the reference genome 
using the software Novoalign. Calling was performed using Samtools 0.18 and the 
resulting calls were annotated using ANNOVAR (as discussed in Chapter 2). 
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4.3.4 Mutation validation and screening in the additional cohorts 
Primers for PCR amplification were designed by Generunner 
(http://www.generunner.net/).  Primer sequences and the PCR thermocycling are 
listed in the supplementary table S3. The PCR reaction mix consisted of 30ng 
genomic DNA, 5nM forward primer, 5nM reverse primer and 12μl of FastStart PCR 
Master (www.rocheapplied-science.com). Unincorporated dNTPs, primers, salts 
and polymerase were removed using Multiscreen PCR Cleanup Filter Plates 
(Millipore, MA, USA) as per the manufacturer’s instruction. After PCR amplification, 
coding regions and exon-intron junctions of C12orf65 gene were sequenced by 
Sanger’s sequencing, using the Big Dye Terminator cycle sequencing kit v3 (Applied 
Biosystems, Foster City, California, USA), and analyzed by a 3130 Genetic Analyser 
sequencing machine (Applied Biosystems). Sequences were examined in silico for 
mutations by Sequencher software 4.9 (Gene Codes Corporation, Ann Arbor, MI, 
USA). 
4.3.5 Lymphoblast cells cultures  
Lymphoblasts cells were obtained from case 1 and two unaffected relative carriers. 
Lymphoblastoid cell lines were established by Epstein–Barr virus transformation of 
lymphocytes isolated from peripheral blood. Cell lines were stored at the European 
Collection of Cell Cultures (ECACC). Informed consent was obtained from the 
patient and his relatives. Patient and control lymphoblasts were thawed and 
maintained in culture in modified RPMI-1640 medium containing 300mg/L L-
Glutamine and HEPES (Invitrogen) supplemented with 10% heat inactivated FBS 
(Invitrogen) at 37°C, 5% CO2. Fresh medium was added every 3 days and cultures 
were expanded accordingly.  
4.3.6 Transcript analyses 
Purification of total RNA from patients’ lymphoblasts was performed using the 
Qiagen miRNeasy Mini Kit, Hilden, Germany (catalogue #217004). Cell pellets were 
prepared by centrifuging 3–4 x 106 cells for 5 min at 300xg; all supernatant was 
removed by aspiration. Then, to disrupt cells bodies, 700μl of QIAzol Lysis Reagent 
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was added to the tube, mixed to the cell pellet, and incubated at room temperature 
for 5 minutes. 140μl chloroform were added to the tube containing the 
homogenate and mixed thoroughly by shaking the tube for 15s. The tube was 
incubated at room temperature for 5 minutes. Then the tube was centrifuged for 
15 min at 12,000 x g at 4°C. After centrifugation, the sample separated into 3 
phases, with the upper phase containing RNA. The upper aqueous phase (about 
350μl) was transferred to a new collection tube and 525μl of 100% ethanol were 
added to the tube and mixed thoroughly. 700μl of the sample were pipetted into an 
RNeasy Mini spin column in a 2 ml collection tube and centrifuged at 10,000 rpm 
for 15 s at room temperature; the flow-through was discarded. Then 500μl Buffer 
RPE were added into the RNeasy Mini spin column; the tube was and centrifuged 
for 15 s at 10,000 rpm to wash the column and the flow-through was discarded. 
Another 500μl Buffer RPE were added to the spin column and centrifuged for 2 min 
10,000 rpm to dry the column membrane. Then the spin column was transferred to 
a new 1.5 ml collection tube. 30μl RNase-free water were added directly onto spin 
column membrane and centrifuged for 1 min at 10,000 rpm to elute the RNA; this 
step was repeated two times. RNA concentration was then measured with 
spectrophotometer (all samples had a concentration of approximately 1000ng/μl) 
and quality was assessed evaluating 260/280 nm and 260/230 nm ratio. cDNA 
synthesis was performed using Qiagen Omniscript RT Kit, Hilden, Germany 
(catalogue #205110). Briefly, for each reaction, a fresh master mix was prepared 
containing: 10x Buffer RT 2μl, dNTP mix 2μl, Random primers 1μl, RNAse inhibitor 
1μl, Ominscript RT 1μl and RNAse-free water 11,5μl. 1,5μl of template RNA and was 
added to the mix and then incubated for 60 min at 37°C. 
Multiplex quantitative real-time PCR assays for the levels of C12orf65 and RPL13A 
were performed using SYBR Green PCR Master Mix kit (Applied Biosystems) with a 
Corbett Rotor-Gene real-time quantitative thermal cycler (Corbett 
Research/Qiagen). Thermal cycling consisted of 10 minutes at 94°C for initial 
denaturation and DNA polymerase activation, followed by 40 cycles of denaturation 
at 94°C for 15 s and annealing/extension at 60°C for 1 min. Each assay contained 
template negative controls and a quantitative standard curve dilution run in 
duplicate. All reactions were performed in triplicate in a final volume of 10 μl. 
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Gene-specific primers are listed in table S3. Dissociation curves were run to detect 
nonspecific amplification, and single amplified product was confirmed in each 
reaction. Standard curves showed that all duplexed assays had equal efficiencies 
(99.9%), satisfying criteria for the comparative Ct method of quantification.  The 
quantities of each tested gene and internal controls were then determined from 
the standard curve using the Rotor-Gene 6000 series software 1.7 (Corbett 
Research/Quiagen). Relative quantity of each C12orf65 level normalized by the 
RPL13A level was then calculated. The results were expressed as percentage of 
control.  
4.3.7 Blue native in-gel complex V assay 
Blue native gel (BN gel) electrophoresis was used to examine mitochondrial 
respiratory chain protein levels, and complex V (ATP synthase: EC 3.6.3.14) activity.  
Briefly, a mitochondrial fraction was obtained from the lymphoblastoid cell pellets 
(7.5 × 105 cells) using two low speed centrifugation steps (600 g × 10 min) at 4 °C, 
separated by a homogenisation step (30 strokes). The supernatant from each spin 
was combined and a higher spin (14,000 g × 10 min) was performed in order to 
eliminate nuclei and other subcellular membranes. Then the mitochondrial 
membranes were solubilised with a 750 mM amino hexanoic acid/50 mM Bis Tris 
buffer + 4 % n-dodecyl β-D maltoside detergent. Samples were left on ice for 30 
minutes and a further high spin (14,000 g × 10 min) was used to pellet insoluble 
material. 
An equal quantity of mitochondrial protein (30 μg) was loaded from each sample 
(case 1, two unaffected carriers and two controls). The BN gel was run as previously 
described with slight modifications (Wittig et al., 2006), using a 3-12 % Bis-Tris gel 
(Invitrogen) to ensure discrete separation of complex V. The complex V  activity was 
measured in a reverse direction, where ATP is hydrolyzed into ADP and Pi (inorganic 
phosphate). The lead ions in the buffer combine with Pi, which results in the 
accumulation of Lead phosphate, a grey precipitate where the complex V band is 
present. Complex V assay was performed by incubating the gel overnight in stain 
containing 34mM Tris, 270mM glycine, 14mM magnesium chloride, 6mM Lead (II) 
nitrate and 8mM ATP. 
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4.3.8 Oxygen Consumption  
Oxygen consumption was measured to investigate the mitochondrial respiration 
rate. 
To measure mitochondrial respiration rate in intact cells, approximately 1x107 cells 
were suspended in respiration medium (HBSS, with 10 mM D-glucose) in a Clark-
type oxygen electrode thermostatically maintained at 37ºC. The oxygen electrode 
was calibrated with air-saturated water, assuming 406 nmol O2 atoms/ml at 37ºC. 
Oxygen consumption was measured over 10 minutes with addition of oligomycin 
(final concentration 2μg/ml) and FCCP (0.5 μM). All data were obtained using an 
Oxygraph Plus system (Hansatech Instruments, UK) with chart recording software. 
For measurements of mitochondrial membrane potential (Δψm), cells were loaded 
with 25 nM tetramethylrhodamine methylester (TMRM) for 30 min at room 
temperature in HBSS (156 mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM KH2PO4, 2 
mM CaCl2, 10 mM glucose, and 10 mM HEPES, pH adjusted to 7.35), and the dye 
was present during the experiment. TMRM is used in the redistribution mode and 
therefore a reduction in TMRM fluorescence represents Δψm depolarization. Z-
stack images were obtained for accurate analysis. The values for WT were set to 
100% and the other genotypes were expressed relative to WT (Yao et al., 2011; J 
Cell Science).  
Confocal images were obtained using a Zeiss 710 LSM with a 40x oil immersion 
objective. TMRM was excited using the 560 nm laser and fluorescence measured 
above 580-nm. 
 
4.4 RESULTS 
4.4.1 Clinical details 
Three members of a large consanguineous Indian family (Figure 19), affected by 
axonal neuropathy and optic atrophy, were identified at the National Hospital for 
Neurology and Neurosurgery. Briefly, they all presented with a similar syndrome 
characterized by a very slowly progressing axonal neuropathy (onset in childhood), 
bilateral optic atrophy and pyramidal signs. Case 3 was first seen at the age of 35 
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years old and then again at the age of 51 years. She is the first cousin of cases I and 
2 and presented as a child with delayed milestones, later at the age of 9 years old 
she had lower limb and at 11 years upper limb weakness along with static cognitive 
problems and visual difficulties. The examination at the age of 35 and 51 years were 
remarkably similar with only mild deterioration of her clinical features. She had no 
dysmorphic features, but severe bilateral optic atrophy and static, but significant 
cognitive problems. She had a brisk jaw jerk and a pout reflex. Marked distal 
symmetrical weakness and wasting affecting the limbs. In contrast to her cousins, 
tone in her upper and lower limbs was reduced with severe distal weakness in 
upper and lower limbs. Upper limb reflexes were normal. Knee and adductor 
reflexes were abnormally brisk. Ankle and plantar reflexes were absent. She had a 
moderately severe thoracic scoliosis. Sensation was impossible to assess reliably 
due to cognition but was likely to be abnormal. As a crude estimate of visual acuity, 
they were able to watch television and recognise faces across the room and she 
could do needlework.  
Case 1 noted distal wasting and weakness at the age of 8, which slowly spread 
proximally. When he was examined (at the age of 34) he had severe muscle wasting 
of lower and upper limbs, bilateral optic atrophy and macular colloid bodies. 
Pyramidal signs were present in the upper limbs. Case 3 presented with a similar 
syndrome characterized by a very slowly progressing axonal neuropathy (onset in 
childhood), bilateral optic atrophy and pyramidal signs. This CMT6 family were 
originally reported as a case report in 1987 when the family members were in their 
middle 30s (MacDermot and Walker, 1987). 
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Figure 19. Pedigree of the family  
 
A square represents a male person, a circle represents a female. A double 
horizontal line indicates parental consanguinity. Black symbols indicate affected 
members with CMT2 and optic atrophy in whom a neurological exam was 
performed; blank symbols show unaffected family members. A diagonal line marks 
deceased individuals. This pedigree has been reported elsewhere (MacDermot and 
Walker, 1987). 
  
 124 
Nerve Biopsy  
The light microscopy of the sural nerve biopsy from case 1 showed a marked 
reduction of large myelinated fibres. The fascicles were populated by numerous 
small myelinated fibres majority of which were associated with regeneration 
clusters. Ultrastructural assessment on electron microscopy confirmed the absence 
of both active and chronic demyelination and showed no evidence of ongoing 
axonal degeneration. The remaining myelinated fibres revealed normal 
configuration of the myelin. Although the assessment of loss of unmyelinated fibres 
was confounded by frequent unmyelinated axonal sprouts associated with 
regeneration, the evidence of decreased numbers of unmyelinated fibres was 
indirectly confirmed by increased amounts of endoneural collagen with formation 
of collagen pockets amongst flattened Schwann cell profiles. The depicted 
mitochondria on the transverse sections of nerve fascicles showed no obvious 
ultrastructural abnormality (Figure 20). 
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Figure 20. Sural nerve biopsies 
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Sural nerve biopsies (light and electron microscopy). Case 1. Semi-thin resin section stained 
with toluidine blue (A and B) show markedly reduced numbers of large myelinated fibres 
accompanied by numerous small myelinated fibres mainly associated with regeneration 
clusters (arrow in B). Ultrastructural assessment (C and D) further highlights frequent 
regeneration clusters (arrow in C). The evidence of decreased numbers of unmyelinated 
fibres is confirmed by increased amounts of endoneural collagen and the formation of 
collagen pockets (read arrowhead in D) amongst flattened Schwann cell profiles (blue 
arrowhead in D). Scale bar: 60μm (A), 30μm (B), 2μm (C and D).  Patient with MFN2 
mutation. Semi-thin resin section stained with toluidine blue (A and B) show markedly 
reduced numbers of large myelinated fibres accompanied by occasional regeneration 
clusters and occasional fibres surrounded by concentric Schwann cell profiles forming 
onion bulb-like structures (arrows in B). Ultrastructural assessment (C and D) confirms that 
myelinated fibres are markedly reduced in numbers and shows no evidence of active or 
chronic demyelination; instead it reveals pseudo-onion bulbs indicative of regeneration 
(arrow in C). The depicted mitochondria on the transverse sections of the nerve fascicles 
show no obvious ultrastructural abnormality; although some intra-axonal clusters of 
mitochondria are occasionally observed (arrowhead in C). Scale bar: 80μm (A), 40μm (B), 
5μm (C and D). Patient with no known mutation. Semi-thin resin section stained with 
methylene blue azure – basic fuchsin (MBA-BF) (A) shows markedly reduced numbers of 
large myelinated fibres with no apparent evidence of regeneration and no evidence of 
active macrophage-associated demyelination or chronic demyelinating/re-myelinating 
process. Electron microscopy (B, C and D) confirms the markedly reduced numbers of large 
and small myelinated fibres (arrows in B and C). The unmyelinated fibres in contrast are 
better preserved (arrowhead in D). Scale bar: 40μm (A), 5μm (B, C and D). 
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4.4.2 Genetic analyses  
Autozygosity mapping was carried out on two affected cousins (case 1 and case 3) 
with the aim to fine map homozygous by descent (HBD) regions potentially 
containing the recessive disease gene. SNP analysis identified five HBD 
chromosomal segments of significant length (>1Mb), which were concordant in 
both cousins (Table 14, Figure 17) encompassing 15.8Mb and containing 226 genes 
(NCBI build 37.2, map viewer). Given the large number of candidate genes, we used 
WES to perform a comprehensive search for pathogenic mutations in both affected 
cases. Alignment metrics on WES data showed good coverage for all samples (Table 
15).  
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Table 14. Homozygous regions >1Mb concordant in case 1 and case 3 
Chr Start End size (bp) 
        
Chr12 rs2433345 rs12369591 6,251,757 
Coord 119575350 125764947  
        
Chr1 rs2764654 rs11576605 4,262,234 
coord  77074588 81336822   
        
        
Chr10 rs224731 rs1480524 2,287,163 
coord  34226309 36513472   
        
        
Chr20 rs6087487 rs6058150 1,541,781 
coord  32015038 33556817   
        
Chr5 rs7726515 rs2240525 1,469,711 
Coord 129736249 131343783   
        
 
 
 
       
 
 
Table 15. Summary metrics of WES 
 case 1 case 3 
    
Total number of reads  
 
75403508 72122880 
Non-duplicated reads 
 
35% 41% 
Reads aligned to target  
 
47% 44% 
Mean target coverage  
 
26,2 27,6 
Tot number of variants  12965 13144 
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To identify potential causal variants we selected all coding variants in the 
homozygous regions present in both samples. Then we filtered them by discarding 
(i) variants documented in the Single Nucleotide Polymorphism Database and the 
1000-Genomes Project and (ii) synonymous substitutions. Five variants passed 
these filters: two were missense, one was a non-frameshift deletion and one was 
nonsense mutation. The latter is a 1 bp deletion in C12orf65 gene, resulting in a 
premature stop codon (NM_001143905:c.346delG: p.V116X). As this was the most 
protein-damaging variant, and as mutations in C12orf65 had been described to 
cause a severe encephalomyopathy (Antonicka et al., 2010), we thought it was the 
best candidate to follow up. The presence of this variant and its segregation with 
disease in this family was confirmed with Sanger sequencing: the deletion was 
homozygous in the affected cases, and either absent or heterozygous in the 
unaffected relatives (Figure 17). To further investigate the presence of the mutation 
in patients with complex CMT, we sequenced the coding exons of C12orf65 in an 
additional cohort of 93 patients.  None of the patients harbored potentially 
pathogenic variants. 
To determine whether the truncating mutation affected mRNA stability and 
induced mRNA nonsense mediated decay (NMD), we tested the level of expression 
by qPCR. This showed that level of the C12orf65 mRNA was not reduced in the 
lymphoblasts from affected individuals versus controls (Figure 23) as predicited by 
the ’55 nucleotides rule’, an hallmark of mammalian NMD that predicates that stop 
codons located at least 55 nucleotides upstream of the last exon junction will be 
interpreted as 'premature' and trigger NMD (Nagy and Maquat, 1998). 
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Figure 21. Homozygous region on chromosome 12 shared by case 1 and case 3 
 
 Upper panel, Log R ratio and B allele frequency metrics for Case 1. Lower panel, Log R 
ration and B allele frequency metrics for Case 3.  Bounded in pink is the primary candidate 
interval identical by descent between both affected samples. Stretches of homozygosity 
are denoted by a contiguous stretch of genotypes where B allele frequency is either 0 or 1.  
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Figure 22. The C12orf65 p.V116X mutation 
  
 
A) Left panel: WES data for the p.V116X mutation in C12orf65. The aligned reads viewed 
through the IGV viewer (http://www.broadinstitute.org/igv/). Reads are depicted as arrows 
(grey bands). A coverage histogram per base is shown above the reads. RefSeq gene (over 
the C12orf65 gene) is represented in the lower part both as aminoacid sequence (blue) and 
as reference sequence: green, A; orange, G; red, T; blue, C. Dashes represent the deleted 
base. Note the drop of coverage (black arrow) over the dashed base, representing the G 
base deleted in both samples. Right panel: Chromatorgrams show the p.V116X mutation in 
C12orf65 and segregation in the family. From the top to the bottom panel: mutant 
homozygote (Case 3), wild type sequence (V:4), heterozygous p.V116X mutation (V:5), wild 
type sequence (VI:9) and heterozygous p.V116X mutation (VI:8).  
B) Schematic diagram of the C12orf65 gene and protein. The position of the mutation in 
the patient DNA and the position of the resulting premature stop codon are indicated in 
red; blue indicates the mutation and the position of the resulting stop codon described in 
patients with Leigh syndrome, optic atrophy and ophthalmoplegia. 
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Figure 23. The expression level of C12orf65 
 
 
 C12orf65 mRNA expression levels in the lymphoblasts were measured by quantitative real-
time PCR (qRT-PCR). The bar graph represents relative C12orf65 levels normalized to 
RPL13A. Levels are shown as the percentage of the average of control. There is no 
difference between expression levels in case and controls. 
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4.4.3 Mitochondrial impairment 
C12orf65 is a nuclear gene that encodes a mitochondrial matrix protein that 
appears to contribute to mitochondrial translation. Nonsense mutations in this 
have been found in patients with a mitochondrial disease associated with combined 
oxidative phosphorylation enzymes (OXPHOS) deficiency (Antonicka et al., 2010). 
Hence, lymphoblasts obtained from patients were analyzed by BNPAGE analysis to 
study mitochondrial respiratory chain protein complexes. This analysis showed a 
decreased activity of complex V as well as a defect in assembly or stability of 
complex V in the patient sample compared to controls (Figure 24).  
4.4.4 Oxygen consumption 
In order to investigate the effect of mutations on mitochondrial respiration we 
measured the rate of oxygen consumption in lymphocytes. The basal oxygen 
consumption in Case 3 cells was significantly reduced compare to control cells 
(0.42±0.02 nmol/O2/min/106 cells; n=4 experiments; compared to 0.85±0.03 nmol 
O2/min/106; n=5 experiments; p<0.001; Fig. 6A). Oligomycin (Inhibitor of complex 
V; 2μg/ml) inhibited the respiration coupled to oxidative phosphorylation in control 
lymphocytes but to a significantly lesser extent in kn0193 cells (p<0.001; Figure 
24b). It suggest profound mitochondrial uncoupling and confirm decreased activity 
of the complex V in Case 3 cells. Addition of 1μM of the uncoupler FCCP accelerated 
respiration to maximal levels in control lymphocytes but in significant less degree in 
Case 3 cells, suggesting that activity respiratory chain in these cells is limited. 
Mitochondrial membrane potential (Δψm) is a major indicator of mitochondrial 
function and health.  Δψm in Case3 and control lymphoblasts was assessed by the 
fluorescent indicator tetramethylrhodamine methyl ester, TMRM. Case 3 cells were 
associated with a significant reduction in the TMRM signal (and hence in Δψm) to 
77.5±3.9 of controls (n=29 cells; n=34 contr, p<0.001; Figure 24). There are no 
difference between cell groups in mitochondrial morphology. 
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Figure 24. Mitoc ondria impairment in t e patient’s lymp oblasts 
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A) BN-PAGE (in gel activity): shows decrease in complex V (F1-Fo) activity and presence of 
intense F1 band.  
B) Oxygen consumption in Case 3 and controls. Oxygen consumption was measured in 
immortalised lymphocytes using a Clark oxygen electrode. Respiration was inhibited by 
blocking ATP production using oligomycin (2 μg/ml), and maximised by adding the 
uncoupler FCCP (1μM). Data is represented as mean ± SEM. In all cases, * indicates p<0.05 
and ** indicates p<0.01 compared to WT values. The basal oxygen consumption in Case 3 
cells was significantly reduced compared to control cells (0.42±0.02 nmol/O2/min/106 
cells; n=4 experiments; compared to 0.85±0.03 nmol O2/min/106; n=5 experiments; 
p<0.001. Oligomycin (Inhibitor of complex V; 2μg/ml) inhibited the respiration coupled to 
oxidative phosphorylation in control lymphocytes but to a significantly lesser extent in Case 
3 cells (p<0.001). Addition of 1μM of the uncoupler FCCP, accelerated respiration to 
maximal levels in control lymphocytes but to a significant less degree in the patient cells, 
suggesting that respiratory chain activity in these cells is limited. 
C) Mitochondrial membrane potential. Mitochondrial membrane potential in control, 
carrier and Case3 lymphoblasts determined by TMRM fluorescence.  Control was taken as 
100%. 
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4.5 DISCUSSION 
The present study describes a recessive mutation in C12orf65 associated with CMT6. 
Mutations in C12orf65 have been previously described in patients with 
enchephalomyopathy and combined OXPHOS deficiency (Antonicka et al., 2010). 
We investigated mitochondrial function in the patients’ lymphoblasts and showed 
that it is impaired at multiple levels. Mitochondrial membrane potential and 
mitochondrial respiration rate were reduced; at the protein level we showed a 
decrease in complex V activity as well as a defect in the assembly of the complex.  
When I was drafting the article, a paper was published describing a mutation in 
C12orf65 in a Japanese family with complex spastic paraplegia, optic atrophy and 
neuropathy (Shimazaki et al., 2012).  
These results highlight the importance of mitochondrial function in peripheral  
neuropathies and in optic atrophy. Indeed mitofusin 2, the major cause of 
dominant CMT2, is a mitochondrial membrane protein involved in mitochondrial 
fusion (Santel and Fuller, 2001) and in the regulation of mitochondrial membrane 
potential and the OXPHOS system (Pich et al., 2005).  Similarly the two most 
common inherited optic neuropathies, Leber hereditary optic neuropathy (LHON, 
OMIM #535000) and autosomal dominant optic atrophy (DOA), are the result of 
mitochondrial dysfunction. LHON is caused by primary mitochondrial DNA (mtDNA) 
mutations affecting the respiratory chain complexes (Mackey et al., 1996), while 
the majority of DOA families have mutations in the OPA1 gene, which encodes for 
an inner mitochondrial membrane protein important for mtDNA maintenance and 
oxidative phosphorylation (Alexander et al., 2000), (Zanna et al., 2008).  
C12orf65 encodes for a 166 amino acid protein which contains one RF-1 domain, 
involved in protein translation termination and is found in peptide chain release 
factors. Patients carrying mutations in C12orf65 that interrupt the RF-1 domain 
present with a severe infanthood encephalomyopathy (Leigh syndrome, optic 
atrophy and ophthalmoplegia) (Antonicka et al., 2010). The different location of the 
truncating mutation in our patients and the consequent sparing of the RF-1 domain 
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may account for the milder phenotype and a more selective deficiency of ATPase 
activity (Shimazaki et al., 2012) (Table 16).   
Of note similarly, mutations in the mtDNA encoding MTATP6 and leading to 
impaired ATPase activity (Nijtmans et al., 2001), are known to cause a clinical 
syndrome that manifests as neuropathy, ataxia, retinitis pigmentosa (NARP) or the 
more severe maternally inherited Leigh’s syndrome (MILS). 
This study also highlights the suitability of WES in providing an accurate genetic 
diagnosis in heterogeneous disorders such as CMT. Given that most known CMT2 
genes each account for a small proportion of CMT2 families, WES is likely to lead to 
the discovery of further genes for CMT
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Table 16. Clinical features of patients carrying different C12orf65 mutations 
 
 
 
(Antonicka et al., 2010) (Shimazaki et al., 2012) This study 
Patients Patient 1 Patient 2 Patient 1 Patient 2 Case 1 Case 3 
C12orf65 mutation c.248delT p.L84X c.210delA p.L84X c.394C>t 
p.R132X 
c.394C>t 
p.R132X 
c.346delG 
p.V116X 
c.346delG p.V116 
 
Psychomotor 
milestones 
Severe retardation 
(1 yo) 
Retardation (3 yo) Normal Normal Delayed (3yo) Delayed (8yo) 
 
Neuropathy NA Severe, motor + sensory 
(8 years) 
Motor + sensory 
(10 yo) 
Motor + sensory 
(10 yo) 
Motor ++ 
Sensory NA (8yo) 
Motor ++ (age 9), 
sensory NA 
Optic atrophy Decreased vision (3 
yo) 
Decreased vision (20 yo) Reduced visual 
acuity (7 yo) 
Reduced acuity 
(7 yo) 
Decreased visual 
acuity (? yo) 
Decreased visual 
acuity ( ? yo) 
Pyramidal involvement NA NA Bilateral leg 
spasticity (30 yo) 
Bilateral leg 
spasticity  
Bilateral upper 
limb spasticity 
Brisk reflexes 
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5 A GENOME-WIDE ASSOCIATION 
STUDY FOLLOW UP: THE PARK16 
LOCUS 
 
5.1 STATEMENT OF CONTRIBUTION TO THIS RESEARCH 
I was involved in the experimental design of this project. I performed the laboratory 
based sequencing experiments for the NUCKS1 and SLC41A1 genes and the 
statistical analysis. 
I drafted parts of the original publication that has been published in European 
Journal of Human Genetics and reviewed the manuscript. 
 
5.2 BACKGROUND 
GWAS carried on PD patients conducted in a Japanese and a Caucasian population 
(Satake et al., 2009) (Simón-Sánchez et al., 2009), identified a novel risk locus for PD 
on chromosome 1q32, known as PARK 16 (OMIM #613164).  This locus comprises 
169.6kb and contains four different genes (NUCKS1, RAB7L1, SLC41A1 and 
PM20D1). We investigated this new locus by performing sequencing analysis in a 
cohort of 180 pathologically proven PD cases and 480 controls. For each 
polymorphism identified, we performed an association test. For each novel coding 
variant identified in the PD cohort we further screened 350 PD (including 82 familial 
PD). We failed to identify any coding polymorphism associated to PD. We identified 
association between a novel intronic RAB7L1 variant (c.379-12insT) and disease (P 
value = 0.0325). We found two novel mutations in two PD patients (one in RAB7L1 
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and one in SLC41A1 gene, in one patient each). I will discuss these findings in the 
light of the most recent literature. 
5.3 MATERIALS AND METHODS 
5.3.1 Samples 
A total of 453 PD samples were selected from brain tissues at the Queen Square 
Brain Bank for Neurological Disorders in the UK. All samples were clinically and 
pathologically diagnosed according to the PD Brain Bank criteria by an experienced 
neuropathologist and based on accepted morphological criteria (S. Wharton, 2008). 
The mean age at onset was 59 years (range 35-86) and the average of death was 78 
years (range 51-94). The male-to-female ratio was 3.5: 1. 82 additional familial PD 
DNA samples were also employed; were considered familial those cases reporting 
one or more first-degree relatives with PD. Patients gave informed consent for 
scientific research. The control cohort (n=483) here analyzed was the “1958 British 
birth cohort” (http://www.b58cgene.sgul.ac.uk/) which is also used in all disease-
related studies carried out by the Wellcome Trust Case Control Consortium 
(WTCCC).  
5.3.2 PCR and sequencing analyses 
We first performed PCR and sequencing analyses of all open reading frames (ORFs) 
of NUCKS1 (NM_022731), RAB7L1 (NM_003929) and SLC41A1 (NM_173854.4) 
genes in 182 PD cases. Then, for each coding variant identified in the PD cohort 
(n=9) we also analyzed 351 neurologically normal individuals. SNPs showing 
association with the disease (RAB7L1 c.379-12insT) and novel coding variants 
absent in controls (p.K157R in RAB7L1 and p.A350V in SLC41A1) were further 
analyzed in larger cohort comprising a total of 453 PD cases and 483 controls. 
Additionally, the novel coding variants were tested in 82 familial PD cases.  
All PCR analyses were performed using primers designed by ExonPrimer 
(http://ihg.gsf.de/ihg/ExonPrimer.html). We amplified all exons and exon-intron 
boundaries using the following PCR reaction mix: 20ng of genomic SNA, 5nM 
forward primer, 5nM reverse primer and 12μl of FastStart PCR Master 
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(www.rocheapplied-science.com). To amplify exon 1 of NUCKS1 we added 1 μl of 
5% dimethyl sulfoxide (DMSO; Sigma). Primer sequences and PCR thermo-cycling 
conditions are listed in table S4. Following PCR cleanup using MultiScreen PCR Filter 
Plates (Millipore), sequencing was performed with both forward and revers primers 
under the following protocol: 5μl of cleaned PCR products, 0.5μl of BigDye 
terminator v.3.1 (Applied Biosystems), 0.75μl of 5nM primer, 2μl of 5X Sequencing 
Buffer (Applied Biosystems) and 5,5μl of deionized molecular grade water. The 
resulting reactions were then purified with MultiScreen PCR  Filter Plates (Millipore) 
and sequences resolved on ABI3730XL genetic analyzer (Applied Biosystems). 
Electropherograms were visualized in Sequencer software (4.9 Gene Codes 
Corporation). 
5.3.3 Statistical analyses  
For each variant identified in the PD cohort we calculated the allele frequencies in 
cases and controls, tested for departures from HWE and performed χ2-test and test 
on allelic association. All computations (test of association and permutation 
analyses) were performed using the Haploview 4.1 software 
(http://www.broad.mit.edu/haploview/). 
To compare PARK16-associated allele frequencies between diverse populations, 
HapMap data corresponding to the PARK16 locus from Yoruba (YRI), Japan (JPT), 
Han Chinese (CHB) and Northern and Western European (CEUUtah residents) 
populations were also analyzed through haploview software (www.hapmap.org). 
5.3.4 Bioinformatic Analysis 
To determine the level of sequence conservation of newly identified variants we 
performed multiple sequence analysis and alignments with paralogues and 
orthologues using the National Center for Biotechnology Information domain 
associated homoloGene database using the MUSCLE program (Edgar, 2004). 
We also used the program Alamut, a mutation interpretation software, to look for 
amino acid properties and for predictions of the functional and structural effects of 
novel coding mutations (http://www.interactive-biosoftware.com/alamut). 
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5.3.5 Variants definition 
Any difference from the reference sequences (NM_022731, NM_003929 and 
NM_173854.4) was called variant. Variants with MAF >1% in controls samples (or 
dbSNP) were classified as polymorphism. Variants for which the following criteria 
applied: absent in controls or dbSNP, and stop or frameshift or missense mutations 
were defined as mutations. 
 
5.4 RESULTS 
To identify coding variants underlying risk for PD in a British case-control cohort, we 
investigated the genomic area harboring the PARK16 locus through sequencing 
analysis. The PARK16 genomic area identified by both the Caucasian and the 
Japanese study is flanked by the SNPs rs823128 and rs11240572 and contains four 
genes (NUCKS1, RAB7L1, SLC41A1 and PM20D1) (Table 17). However, NUCKS1, 
RAB7L1, SLC41A1 genes were located on the same haplotype block as the most 
significantly associated SNPs in the Caucasian GWAS (Figure 25). In addition, the 
minor allele frequency of rs11240572, located in intron 10 of PM20D1, is 0.02 in the 
European ancestry population (Table 19), which is too low to reach significance in 
the Caucasian GWAS (Figure 2) and was therefore excluded. Hence only the coding 
regions of NUCKS1, RAB7L1 and SLC41A1 were analyzed. 
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Table 17. PD associated SNPs within the PARK16 locus 
 
SNP Chr Position 
Chromosomal  
Localization 
Alleles 
(min/maj) 
Caucasian  
P-values * 
Japanese 
 P-values** 
       rs16856139 1 203905087 SLC45A3 (intronic) T/C NA 1.02 x 10
-7
 
rs823128 1 203980001  NUCKS1 (intronic) G/A 7.29 x 10
-8
 4.88 x 10
-9
 
rs823122 1 203991651 Genomic region C/T  NA 5.22 x 10
-9
 
rs947211 1 204019288 Genomic region A/G NA 1.52 x 10
-12
 
rs823156  1 204031263 SLC41A1 (intronic) G/A 7.60 x 10
-4
 3.60 x 10
-9
 
rs708730 1 204044403 SLC41A1 (intronic) G/A NA 2.43 x 10
-8
 
rs11240572 1 204074636 PM20D (intronic) A/C 6.11 x 10
-7
 1.08 x 10
-7
 
              
              
Nucleotide positions refer to NCBI build 36.  
RAB7L1 chromosomal localization: 204,003,738–204,011,233 bp. 
* Combined p values obtained from combining stage I + stage II 
** p values obtained from GWAS+replication 1+2 
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Figure 25. LD Plot of the PARK16 locus 
 
LD structure and association signals across the PARK16 locus in the Caucasian population 
from the GWAS locus. NUCKS1, RAB7L1 and SLC41A1 genes are in the same haplotype 
block. This picture has been published elsewhere (Simón-Sánchez et al., 2009). 
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We identified seven variants in the genes RAB7L1 (n=4) and SLC41A1 (n=3); of these, 
none was a coding change. A single-marker χ2-test of association was then 
performed. This analysis revealed a significant association between a novel, intronic 
variant in the RAB7L1 gene (c.379-12insT, intron 3) and PD (p value=0.0325), which 
remained significant after one million iterations of permutation testing to adjust for 
multiple comparisons (permuted P-value=0.0399) (Table 18). No other significant 
association was detected. 
In the course of sequencing we also identified two novel coding mutations in 
RAB7L1 (p.Lys157Arg) and SLC41A1 (p.Ala350Val) present in one PD patient each 
and absent in 480 controls (Figure 26). To inspect whether these novel coding 
mutations were disease-causing mutations, both were screened in a larger sample 
size of additional pathologically proven PD cases (n=272, n(total)=454) and 82 
familial cases clinically diagnosed with PD. The investigation failed to detect any 
other mutation carrier. 
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Table 18. Association tests for variants identified in the PARK16 locus 
 
Gene Mutation Associated allele Chi square P value Case/ctrl ratio 
      
 
RAB7L1  
rs708725  
(5’-UTR) 
 
 
A  0.609 0.4351 0.443, 0.418  
RAB7L1  
c.197-49InsG 
(intronic) 
A  0.949 0.3301 0.072, 0.057  
RAB7L1  
rs41302139 
(p.Gln104Glu) 
C  0.075 0.7844 0.019, 0.017   
RAB7L1  
c.379-12InsT 
(inronic)  
Ins T  4.573 
0.0325 
(0.0399)  
0.013, 0.004  
SLC41A1  
rs708727 
(p.Asn252Asn) 
T  0.776 0.3783 0.438, 0.409  
SLC41A1  
rs41264905 
(intronic) 
T  1.402 0.2364 0.009, 0.003  
SLC41A1  
rs11240569 
(p.Thr113Thr) 
T  0.971 0.3243 0.301, 0.270  
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Figure 26. RAB7L1 p.Lys157Arg and the SLC41A1 p.Ala350Val mutations 
 
    
Upper panel: Chromatograms of the sequences showing both novel mutations 
identified in RAB7L1 and SCL41A1 genes. Lower panel: Tables showing conservation 
of both lysine and alanine amino-acids among different species. RAB7L1 (Hs: 
NP_001129134.1, Pt: XP_001162428.1, Clf: XP_536104.2, Bt: NP_001092564.1, 
Mm: NP_659124.1, Gg: XP_417967.2); SLC41A1 (Hs: NP_776253.3, Clf: XP_536105, 
Bt: XP_613469.2, Mm: NP_776290.1, Gg: XP_417968.2, Dr: XP_001922471.1). 
  
  
 148 
 
5.5 DISCUSSION 
The rationale of GWAS is to test for association of ‘tag SNPs’ (representing common 
variation of an haplotype block) in large case-control cohorts to investigate the role 
of common genetic variation in diseases. This association can be explained by 
variants (such as a common coding change, or by a SNP influencing gene expression 
or splicing), lying in the same haplotype block as the tag SNPs showing association 
in that locus (Altshuler et al., 2008). To identify changes underlying association in a 
novel locus (PARK16) identified by two GWAS (a Japanese and a Caucasian study), 
we investigated all coding regions of genes located in the same haplotype block as 
the most significantly associated SNPs in the GWAS in a Caucasian case-control 
cohort. We failed to identify any coding variants significantly associated to the 
disease. We identified two novel coding mutations in one PD patients each, and 
although they are conserved among species (Figure 26), the lack of occurrence of 
both mutations in a large sample of ethnicity-matched control individuals (n=483) 
and the lack of segregation data does not fully disclose their pathogenicity.  
 
We found one intronic variant in RAB7L1 gene (12 bp upstream of exon 3) 
associated to PD (p val = 0.03). This variant is not predicted to alter a splice site by 
current prediction programs. Based on our data this is a rare allele (allele frequency 
0.013 in cases, 0.004 in controls), therefore unlikely to underpin by itself a strong 
association signal at a GWAS level. This variant has been identified by the most 
recent release of the 1000 Genomes Project, and catalogued in dbSNP 137 as 
rs34402174. The absence of frequency data for this variants confirms its rarity; only 
very large association studies will clarify its role in PD. 
The results of this study do not explain the PARK16 association in PD in our UK 
cohort. Of note, the PARK16 locus was originally identified in the Asian study (with 
p value ranging from 10-7 to 10-12) while it did not reach a significant level in the 
Caucasian GWAS or its replication, but it did after combining samples from stage I 
and II (Simón-Sánchez et al., 2009) (Table 17). This difference can be explained by 
marked differences in the minor allele frequencies of the PARK16 associated SNP 
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between populations (Table 19). The low allele frequencies of the SNPs in the 
PARK16 locus in the Caucasian population have limited the statistical power to 
address whether variants are associated with Parkinson's disease in this locus.  
Conversely, subsequent replication studies in the Asian populations have confirmed 
the association at the PARK16 locus even in smaller case-control cohorts (Tan et al., 
2010), (Vilariño-Güell et al., 2010), (Chang et al., 2011). 
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Table 19. PARK16 core SNPs frequencies in diverse populations 
CEU Name Position ObsHET PredHET Hwpval MAF Alleles (Maj:Min) 
 
rs16856139 203905087 0.094 0.09 1 0.047 C:T 
 
 
rs823128 203980001 0.034 0.034 1 0.017 A:G 
 
 
rs823122 203991651 0.077 0.09 0.4364 0.047 T:C 
 
 
rs947211 204019288 0.376 0.364 0.9746 0.239 G:A 
 
 
rs823156 204031263 0.308 0.295 0.938 0.179 A:G 
 
 
rs708730 204044403 0.222 0.248 0.3983 0.145 A:G 
 
 
rs11240572 204074636 0.043 0.042 1 0.021 C:A 
 
         
       
    
CHI+JPT                 
 
rs16856139 203905087 0.224 0.217 1 0.124 C:T 
 
 
rs823128 203980001 0.253 0.247 1 0.144 A:G 
 
 
rs823122 203991651 0.253 0.247 1 0.144 T:C 
 
 
rs947211 204019288 0.494 0.494 1 0.447 A:G 
 
 
rs823156 204031263 0.365 0.347 0.7025 0.224 A:G 
 
 
rs708730 204044403 0.371 0.35 0.6318 0.226 A:G 
 
 
rs11240572 204074636 0.324 0.294 0.3199 0.179 C:A 
 
         
                  
YRI                 
 
rs16856139 203905087 0.087 0.159 5.00E-04 0.087 C:T 
 
 
rs823128 203980001 0.522 0.472 0.381 0.383 A:G 
 
 
rs823122 203991651 0.478 0.499 0.7532 0.483 C:T 
 
 
rs947211 204019288 0.487 0.476 1 0.391 A:G 
 
 
rs823156 204031263 0.426 0.427 1 0.309 G:A 
 
 
rs708730 204044403 0.217 0.258 0.1759 0.152 G:A 
 
 
rs11240572 204074636 0 0 1 0 C:C 
 
         
         
CEU = Caucasian population (Utah residents with Northern and Western European ancestry 
from the CEPH collection); CHB+JPT = Han Chinese in Beijing, China + Japanese in Tokyo, 
Japan; YRI = Yoruba in Ibadan, Nigeria. ObsHET is the marker's observed heterozygosity; 
PredHET is the marker's predicted heterozygosity (i.e. 2*MAF*(1-MAF)); HWpval is the 
Hardy-Weinberg equilibrium p value, which is the probability that its deviation from H-W 
equilibrium could be explained by chance. This data was available on the HapMap project 
(http://hapmap.ncbi.nlm.nih.gov/). The table was created with Haploview software. 
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Only recently, large case-controls studies have addressed the role of PARK16 in the 
Caucasian population. Large studies capture genetic variants that are not very 
common and whose genetic effects could be to be small (Ioannidis et al., 2006); 
moreover power is improved by combining genome-wide datasets with meta-
analytic techniques. The most recent phase of GWA studies involved the 
combination of existing and new datasets in more extensive meta-analyses; these 
have provided more persuasive results that have been substantiated through 
replication. In 2011, two large association studies have been carried out: one, by 
the International Parkinson’s Disease Genomics Consortium, comprising ~12000 
cases and ~21000 controls, and the other by the genetic testing company 23andMe 
comprising ~3,426 cases and 29,624 controls (International Parkinson’s Disease 
Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 
(WTCCC2), 2011), (Do et al., 2011). These groups replicated each other’s signals and 
provided stronger evidence of association of the PARK16 locus (rs708723, p value = 
8.82 x 10-15; rs823156, p value = 1.27 .x 10 -7) 
A further meta-analysis of the PD GWAS data from the PDGene database 
(www.pdgene.org/) was also recently carried out combining different datasets from 
up to 16,452 PD cases and 48,810 controls. This study also confirmed the 
association of PARK16 to PD (rs947211, p value = 8 x 10 -10).  
These results collectively provide convincing evidence of association at the PARK16 
locus. However, the variants underlying associations have not been yet identified. 
There are two ongoing studies from the IPDGC that address this issue: i) deep 
sequencing of ~3000 PD cases and ~1000 controls of all the GWAS hits (including 
PARK16), ii) WES of ~4000 PD cases and 2000 controls. The first study will use a 
technology available, targeted sequencing, to sequence all coding and noncoding 
regions of all the loci significantly associated to PD published to date. This will 
ultimately identify variants associated to PD likely to underpin the association. The 
second study will lead to the identification of all coding variants potentially 
associated to PD.  
In summary, this study provided limited evidence of association of PARK16 locus to 
PD in a UK cohort, mainly due to low statistical power to detect a significant result. 
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The PARK16 variants are rare in the Caucasian population and only large studies 
have confirmed the association of variants in the PARK16 locus. Deep-sequencing 
studies in large case control cohorts will ultimately identify the variants 
underpinning the association.  
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6 STUDY OF VARIABILITY OF A 
PARKINSON’S DISEASE GENE: EIF4G1 
 
6.1 STATEMENT OF CONTRIBUTION TO THIS RESEARCH 
I was involved in the conceptualization and experimental design of this project. I 
performed the laboratory based sequencing experiments and the statistical analysis. 
I wrote the original manuscript that has been published in the journal Neuroscience 
Letters. 
6.2 BACKGROUND  
Recently variants in the 4 eukaryotic translation initiation factor 4G1 gene (EIF4G1) 
were identified in familial PD, and sporadic PD cases, with a frequency of <0.2% in 
affected cases (Chartier-Harlin et al., 2011). We screened our familial PD cohort, to 
determine whether we could provide further evidence that this gene is a PD-related 
locus. We also investigated genetic variability around these coding positions in a 
cohort of Africans from the Human Diversity series (Cann et al., 2002). Moreover, to 
obtain an exhaustive description of the pattern of variability in the EIF4G1 gene, we 
extracted genotype data from the 1000 Genomes Project and NHLBI exome 
sequencing project (URL: http://evs.gs.washington.edu/EVS/) [January 2011]. We 
failed to identify any mutation in the familial PD cohort. We describe a high number 
of polymorphisms in the exons where the two PD variants have been previously 
reported. We also identify a variant previously associated with PD in Caucasians.  
6.3 METHODS 
6.3.1 Samples 
The study included our UK cohort of familial PD samples (n=150). All patients 
fulfilled criteria for clinical diagnosis of PD at the time of the study with at least 2 of 
3 cardinal signs of tremor, rigidity, and bradykinesia, and a positive response to 
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levodopa therapy. Familial cases were defined as those reporting 1 or more first 
degree relatives with PD with a pedigree consistent with autosomal dominant 
pattern of inheritance. Patients carrying known mutations in SNCA and LRRK2 
pathogenic mutation were excluded.  
The African cohort consisted of 114 samples from different Subsaharian African 
regions obtained from Centre d'Etude du Polymorphisme Humain, Human Genome 
Diversity Project (Table 20) (Cann et al., 2002). 
The National Heart, Lung, and Blood Institute (NHLBI) exome sequencing project 
(ESP, (Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA 
(URL: http://evs.gs.washington.edu/EVS/) [January 2011] includes exome data for 
3,500 American individuals of European descent and 1,850 African American.  
 
 
 
Table 20. African samples studied per population and geographic regions 
 
Number  of 
samples Population Geographic origin 
35 Biaka Pygmy Central African Republic 
15 Mbuti_Pygmy Democratic Republic of Congo 
12 Bantu_N.E. Kenya 
7 San Namibia 
26 Yoruba Nigeria 
24 Mandenka Senegal 
8 Bantu_S.E._Pedi South Africa 
 
6.3.2 PCR and sequencing 
Primers for exon 8 and exon 22 in EIF4G1 were designed in Gene Runner (v.3.0.5, 
Hastings Software Inc., Hastings, NY, USA) using the GenBank reference sequence 
NM_182917.3 (primers listed in table S5). All exons and exon‐intron boundaries 
were amplified using the following PCR reaction mix: 20ng of genomic DNA, 10nM 
forward primer, 10nM reverse primer and 12μl of FastStart PCR Master (Roche, IN, 
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USA). Following PCR cleanup using MultiScreen PCR  Filter Plates (Millipore), 
bidirectional sequencing of exons and exon‐intron boundaries was performed 
under the following protocol: 5μl of cleaned PCR product, 0.5μl of BigDye (v.3.2), 
1μl of 10nM primer, 2μl 5X Sequencing Buffer (Applied Biosystems), and 5μl 
distilled and deionised molecular grade water. After cleanup of the sequencing 
products with MultiScreen PCR  Filter Plates (Millipore), sequences were analyzed 
on a 3730xl DNA Analyzer (Applied Biosystems, CA, USA) and electropherograms 
were visualised in Sequencher software. 
6.3.3 Variants frequency and annotation  
Vcf files were downloaded from NHLBI and the 1000 Genomes Project websites: 
http://evs.gs.washington.edu/EVS/, 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release 
Frequencies in the 1000 Genome Project and the NHLBI were computed using 
VCFtools (Danecek et al., 2011), with the following command: 
  
vcftools --vcf file1.vcf --chr --from-bp 184032283  --
to-bp 184053146 --freq 
 
ANNOVAR was then used to annotate the function of the variants: 
 
annovar/convert2annovar.pl -format vcf4 
output_Var.vcf_filtered -outfile 
output_annovar/annovar_${code} 
annovar/summarize_annovar.pl –buildver hg19 
output_annovar/annovar_${code} annovar/humandb_hg19/ 
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Figure 27. The Recent African Origin’ model of modern  umans 
 
 
 
 
The ‘Recent African Origin’ model of modern humans and population substructure in Africa 
(Campbell and Tishkoff, 2008). Humans originated in Africa ~200,000 years ago and then 
migrated to the rest of the world in the past ~100,000 years. Thus humans have existed 
continuously in Africa longer than in any other geographic region and have maintained 
relatively large effective population sizes, resulting in high levels of within-population 
genetic diversity. For these reasons African populations should be studied when 
investigating human genetic variation. This picture has been published elsewhere 
(Campbell, 2010). In this figure, decreasing intensity of color represents the concomitant 
loss of genetic diversity as populations migrated in an eastward direction from Africa. Solid 
horizontal lines indicate gene  flow between ancestral human populations and the dashed 
horizontal line indicates recent gene-flow between Asian and Australian/Melanesian 
populations. 
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6.4 RESULTS 
We failed to identify any previously reported variant in the PD familial samples. We 
identified one coding change (P486S) in one PD individual. This variant was initially 
identified by Farrer et al (personal communication) in 5 PD cases and 2 
neurologically normal controls (in a cohort of 3225 cases and 2273 controls).  
However, this variants was subsequently reported in dbSNP 35 (rs112545306), in 
African-Americans (http://snp.gs.washington.edu/EVS), with a frequency of 0.15%.  
We identified six non-synonymous changes in the African cohort from the Human 
Genome Diversity Project. Of these, one is a novel change (P382L), the others are 
variants recently reported in dbSNP and found mainly in African populations 
(http://snp.gs.washington.edu/EVS). To predict the impact on protein function of 
these non-synonymous variants, we performed an in silico analysis using the 
software PolyPhen and SIFT (Kumar et al., 2009) and all were predicted to be 
benign (Table 21). 
Analysis of the NHLBI samples allowed us to detect the A502V variant in the 
European-American individuals, with frequency of 0.02%. We identified a total of 
95 nonsynonymous SNP over 32 exons in total. Of note, about a third of all coding 
variants (36) are found in exon 8 and exon 22 (table S7), making these exons 
extremely polymorphic.  
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Table 21. EIF4G1 coding variants identified in the African cohort 
 
Nucleotide 
change 
Protein 
change 
SNP accession 
number 
Frequ
ency 
Population 
Effect 
(SIFT) 
      
c.870G>A M290I rs144947145 0.01 San, Bantu SE 
tolerate
d 
c.913C>T  R305C rs116508885 0.01 Youruba 
tolerate
d 
c.932A>G  Y311C  rs16858632 0.03 
Bantu SW, Bantu NE, 
Yoruba, Mandenka 
tolerate
d 
c.1145C>T  P382L NA 0.004 San 
tolerate
d 
c.1429G>A E477K rs145228718  0.004 Mandenka 
tolerate
d 
c.3918G>A R1216H rs34086109 0.004 Biaka Pygmy 
Tolerat
ed 
 
6.5 DISCUSSION 
 
We took three approaches to assess whether mutations in EIF4G1 cause PD: first, 
we screened a cohort of PD familial cases; then, we investigated genetic variation in 
the African samples from Human Genome Diversity Panel (HGDP); and last, we 
described variability in the whole gene occurring in the 1000 Genomes Project and 
the NHLBI. 
We screened our UK PD familial cohort in which we have previously identified 
LRRK2, VPS35 and SNCA mutations (Sheerin et al., 2011), (Khan et al., 2005). If we 
had found a mutation in another family we would have provided further evidence 
that EIF4G1 is a gene involved in PD. We failed to find any mutation, suggesting that 
mutations in the EIF4G1 gene are very rare in PD. Further sequencing studies will 
clarify if the original mutation occurred privately in the original French family, 
making it difficult to assess its role in PD. 
We then assessed the exons containing the mutations originally described in PD in 
the African samples from HGDP, as they have the greatest diversity (Campbell and 
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Tishkoff, 2008) and offer a rapid route to the identification of benign 
polymorphisms (Guerreiro et al., 2010). We found six nonsynsonymous changes 
(five in exon 8 and one on exon 22) in a small number of samples, suggesting that 
they are benign.  
The in-depth analysis of variability occurring in the EIF4G1 gene in the 1000 
Genomes Project and NHLBI revealed the presence of a variant originally described 
as pathogenic (A502V) in two samples of European ancestry, making it likely to be a 
rare benign polymorphism.  The high number of coding polymorphisms in the exons 
where the two PD variants have been previously reported suggests that the protein 
can tolerate some extent of variability particularly at this point of the protein. 
The study here presented was the first negative report of EIF4G1 mutations in PD.  
Subsequent studies in larger case-control cohort have confirmed our findings in 
Caucasians and Asian populations (Lesage et al., 2012), (unpublished results, in 
press in Neurobiology of Aging journal). Of note, recently the original variant found 
in the French family (R1205H) was found in Caucasian controls samples and not in 
PD (Schulte et al., 2012). Overall these results do not support the pathogenicity of 
EIF4G1 mutations in PD. 
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7 CONCLUSIONS AND FUTURE 
DIRECTIONS 
 
My PhD research focused on the use of WES to dissect the genetic aetiologies of 
neurodegenerative diseases. WES was first available in 2009 and I was the first in 
our department to use it. Therefore I had the opportunity to fully appreciate WES 
strengths, pitfalls and challenges (Chapter 2) and to start applying this technology 
where it was most promising: rare Mendelian disorders (Chapters 3 and 4). The in-
depth understanding of the technology also provided me with the appreciation of 
its potential utility in sporadic diseases. The work on the PARK16 locus (Chapter 5) 
and the study of variability of the EIF4G1 gene (Chapter 6), that had ben carried out 
before WES was available in our lab, clearly show that WES and related 
technologies will help us elucidating the genetic architecture of sporadic diseases 
and will provide us with a better knowledge of coding variations as more samples 
will be sequenced. 
I will briefly discuss the major findings and limitations of the projects presented in 
this thesis. 
 
WHOLE EXOME SEQUENCING PILOT PROJECT (Chapter 2) 
This pilot project was conducted to test and validate the technology by preparing 
DNA libraries and sequencing from small number of DNA samples. We generated 
the first sequencing data in the department, and set up an analysis pipeline which 
would be used for all following WES projects. The importance and usefulness of this 
project were in understanding both technical and analytical obstacles to overcome. 
 
KOHLSCHÜTTER-TÖNZ SYNDROME: ROGDI MUTATIONS AND GENETIC 
HETEROGENEITY PROJECT (Chapter 3) 
WES had been shown to be very suitable for gene identification in recessive, 
clinically well-defined conditions, especially when coupled with linkage data. We 
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had collected 10 families with the clinical presentation of Kohlschütter-Tönz 
syndrome, a very rare recessive Mendelian disorder. WES was performed on a 
number of patients that had homogeneous clinical features and shared a disease 
candidate region based on linkage analysis. However, WES failed to identify a 
mutation in our patients, as it was intronic. This study shows one of WES limitation, 
that is the absence of data in intronic regions.  
Overall we identify mutations in the ROGDI gene by a combination of WES and 
traditional Sanger sequencing in five patients that had typical Kohlschütter-Tönz 
syndrome. We failed to identify ROGDI mutations in five patients, who had 
additional atypical features.  We anticipate that those patient carry mutations in 
other genes and that an accurate description of endophenotypes could help 
defining the genetic defect.     
 
C12orf65 MUTATIONS CAUSE AXONAL NEUROPATHY WITH OPTIC ATROPHY 
(Chapter 4) 
Charcot-Marie Tooth disease (CMT) forms a clinically and genetically 
heterogeneous group of inherited peripheral nerve disorders.  
This study shows for the first time the genetic defect individuals affected by 
recessive CMT type 6. Homozygosity mapping coupled with WES quickly identified a 
nonsense mutation in C12orf65 gene as a strong candidate for this disease. 
C12orf65 encodes for a mitochondrial protein and C12orf65 mutations had been 
previously described in patients with Leigh-like syndrome and a mitochondrial 
translation defect. In his study we report mitochondrial dysfunction in the patient’s 
lymphoblasts at different levels (decreased complex V stability, decreased 
mitochondrial respiration rate and reduction of mitochondrial membrane potential). 
In this project WES proved its utility in different ways: it provided a genetic 
diagnosis in a heterogeneous disorders such as CMT; it expanded the phenotype 
associated to C12orf65 mutations. Moreover, the identification of this novel gene 
brought new biological insight to the pathogenesis of CMT type 6 and the role of 
mitochondria impairment in this disease. 
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A GENOME-WIDE ASSOCIATION STUDY FOLLOW-UP: THE PARK16 LOCUS (Chapter 
5) 
In this project we investigated a novel locus for PD (PARK16), previously identified 
in two GWAS, in an attempt to pinpoint the variant(s) underlying the GWAS signal. 
We used traditional Sanger sequencing to sequence the genes in the locus in a 
cohort of UK PD patients and controls. We identified one rare intronic variant 
(rs34402174; MAF 0.013 in cases, 0.004 in controls) weakly associated to PD (p 
value = 0.03). We also identified two mutations in one PD patient each and absent 
in controls. The rarity of the variants here identified makes them unlikely to 
underpin the GWAS signal.  
A complete catalogue of all variations in the locus is required in the search for 
causal variants; this can be achieved nowadays by using targeted resequencing, an 
application of next generation sequencing technology. This technology allows to 
capture all variation of a genomic region in a cost-effective (especially compared to 
Sanger sequencing) and efficient manner in multiple DNA samples. Targeted 
resequencing projects in PD are currently ongoing (in large case controls cohort) 
and they will likely reveal the full allelic spectrum of causal variants underpinning 
GWAS signals. 
 
STUDY OF VARIABILITY OF A PARKINSON’S DISEASE GENE: EIF4G1 (Chapter 6) 
We performed a study of variants in the EIF4G1 gene previously reported in PD in 
our UK PD cases, in a cohort of African samples and by searching all public 
databases. Here, the rarity of the variants and the absence of segregation data 
made it very difficult to assess their pathogenicity. The study of variability of EIF4G1  
in a WES database (Exome Variant Server) was pivotal, as it revealed the presence 
of one of the variant previously associated to PD in the normal Caucasian 
population.  This was the first study published questioning the role of EIF4G1 
variants in PD; subsequent studies in other populations have confirmed the 
presence of variants previously associated to PD in controls.  
Here WES has allowed a full appreciation of benign variability across populations 
and we envisage that as more samples will be sequence, we will further define 
normal coding variability in this gene. 
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Future directions 
Most of the successes of WES have been in studies on rare Mendelian disorders, 
caused by variants of high penetrance segregating in families, such as the C12orf65 
mutation in complex CMT (chapter 4).  In the immediate future, the power of WES 
should enable the identification of genes underlying a large fraction of Mendelian 
disorders that are currently unsolved.  
The main challenge of WES remains to interpret the data in a way that is clinically 
useful to the individual, as the number of genetic variants predicted to disrupt 
protein-coding genes in each individual is much more than what was previously 
suspected (Tennessen et al., 2012), (MacArthur et al., 2012). Determining which of 
many potentially damaging variants in an individual play a role in more complex 
diseases is an open issue.  There is a significant shortfall in our current ability to 
systematically interpret genetic variants detected in human exomes outside the 
context of Mendelian diseases, and this represents the biggest obstacle for the 
translation of WES to a clinical setting. As more and more complete exomes/ 
genomes will be sequenced for a wide variety of human populations, our 
understanding of normal pattern of coding variation will expand. Comprehensive 
catalogues of the location, frequency and properties of the full spectrum of human 
variation will provide an important resource for the investigation of clinically - 
relevant variants. 
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Table S1. Primers sequences used for NimbleGen Sequence Capture control locus assays. 
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qPCR 
assay  
Primer sequences (5’ -3’) Tm 
(°C) 
Product 
length 
qPCR 
efficiency 
NSC-0237 F: CGCATTCCTCATCCCAGTATG 
R: AAAGGACTTGGTGCAGAGTTCAG 
81.15 80bp 1.84 
NSC-0247 F: CCCACCGCCTTCGACAT 
R: CCTGCTTACTGTGGGCTCTTG 
81.03 74bp 1.80 
NSC-0268 F: 
CTCGCTTAACCAGACTCATCTACTGT 
R: ACTTGGCTCAGCTGTATGAAGGT 
78.99 75bp 1.78 
NSC-0272 F: CAGCCCCAGCTCAGGTACAG 
R: ATGATGCGAGTGCTGATGATG 
82.23 71bp 1.93 
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Table S2. PCR and sequencing primers for ROGDI 
Exon(s) Product 
length (bp) 
Forward primer Reverse primer 
Exon 1-2 326 GAGGACCGAGGACAGAAAGA GAGCCAGGGAAATGAGGAG 
Exon 3-4 589 CAGCTGAACCCAGGTGAG TTCCAAAGGAGAAAACTGAG 
Exon 5 352 GAGACCCTCTGCCCTATAC GCTGTTAGGAAACACCCTC 
Exon 6  305 GAGAGTGGAATGACGTGG GTGCTTACAGGTTGCACAG 
Exon 7  308 ACAGTAGCCACTGGGCTG CCACCTATAATCTGGGAGTG 
Exon 8-9  467 CATTGATGAGAAGAGCATC AGTGAGAGGGTC CCTGAG 
Exon 8-10 735 GATGAGAAGAGCATCTCTGG GACAATATGTCAGGACAGGG 
Exon 10-11  586 CATGTTGTAAGTAGGCAGG GAGATAAATAGCAGCCTGG 
Exon 11 241 GCCCTGTCCTGACATATTG GGAGATAAATAGCAGCCTGG 
 
FAM labeled primers: 
Exon 1-2 483 CAGTCTGGTTCCAGGGCTC 5'-FAM-
GAGCCAGGGAAATGAGGAG 
 
cDNA analysis (RT PCR) 
Exon 1-11  CCATGGCCACCGTGATG TTCCTGGAGACAAGCTCCTG 
Exon 1-6 
(wild-type 
specific) 
 CCATGGCCACCGTGATG GGTAAGCAGGTAAATGGCTTC 
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Table S3. PCR, qPCR and sequencing primers for C12orf65 
Exon(s) Product 
length (bp) 
Forward primer Reverse primer 
C12orf65 DNA   
Exon 2 584 GGTAACATGGCAGACAGTG CACACTTGGGAGAAATCTC 
Exon 3 490 ATCACTTGGACCCAGGAG ACTCGCCACCATTATTCC 
C12orf65 cDNAi   
Exon 2-3 336 CTACCCTGCACTGCTTTC TCCCACAGTTCTTTAAGTAGC 
C12orf65 cDNAii    
Exon 2  164 GCACTGCTTTCCTTGGATGA CTGTTCTGATCAACTGATCTTG 
Exon 3  135 GCTGAAGCACATCCCCTCA TGAACAGGACTGTTTTCACC 
 
i)
primers used
 
to confirm the mutation at the cDNA level; 
ii)
primers used for qPCR. 
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Table S4. PCR primers for genes in the PARK16 locus 
Exon(s) Product 
length 
(bp) 
Forward primer Reverse primer 
NUCKS1   
Exon 2 285 TTATGAAAGAGAAATGTGTG TTGCTTTGGTTGACACAGATC 
Exon 3 262 TCCAACAATTTAGAGATCAG TTATGTCAGTAAATATAGTGGTG 
Exon 4 262 AAACGTCTTTGTAATCCC CTTCTCAAGTCAGAAATCAG 
Exon 5  322 GCCAAAGTAACCAAGGTC CAGTCAGTTATGTTTTCAGTC 
Exon 6 597 AATGAGGAATTTCTGTATTG CCTCTAGTCATTCTTAGCAC 
SLC41A1   
Exon 1 597 AAAGATGAAGCAGTCAATC GATTGTTGTATTTTGTAGCTG 
Exon 2 458 CATCTGAAGAGCAGGGAG GAATTTGGTTGAGCTCTTCTAC 
Exon 3 274 GTGGAGAAGGGCTCGTAG TCAGACTACCTGTTGAACCTC 
Exon 4 544 TGAGAGGAAGAGAGGCGACTG GCACCACCAAGAACTGAGAAC 
Exon 5-6 597 ACACAGAAGAAACTCTTGCAC CCAGATGCTTATGACCTCAG 
Exon 7 346 TGAACACATTTCTAGGGTCTG ATCTGTTGGGACATTTTCAG 
Exon 8 392 CTTGTTCTGGAGTCACTGTGC GCTGGAACCCTGACTGATAC 
Exon 9 311 AGGAGAACCTGTGGATCTG AGTGAGAAGATCATTTTGTTCC 
Exon 10 310 CCTGCTCCTGCCACTTTGTAC AGACCACAGGATGCAGAAGTAG 
Exon 11 563 GACAAAACTCCCCTGCTC GAATGGGTCTGATCATGTG 
 
 
 
Table S5. PCR and sequencing primers for EIF4G1 gene  
Exon(s) Product 
length 
(bp) 
Forward primer Reverse primer 
Exon 8a 605 TGGAGTGACTTGAACTGGGTAC GCTCATGAATTTCCACTGTGTG 
Exon 8b 662 TCTCGCCGAACCCATACTG CAGGGACCCAGAAACATGTC 
Exon 22 403 TGCTAAGAACAAGGCCCAACAG CTAGTCCCAAGGCAGCCAATG 
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Table S6. 60 Touchdown 50 PCR cycling program 
 1 
cycle 
8 cycles 20 cycles 16 cycles 1 
cycle 
Phase den den ann ext den ann ext den ann Ext ext 
Temp. 
°C 
94 94 60 72 94 60 72 94 50 72 72 
Temp. 
gra 
0 0 0 0 0 -0.5 0 0 0 0 0 
Duration 5min 30sec 30sec 30sec 30sec 30sec 30sec 30sec 20sec 30sec 5min 
den = denaturation; ann = annealing; ext = extension; temp = temperature; gra = gradient. 
 
 
Table S7. 57 touchdown 52 PCR cycling program 
 1 
cycle 
15 cycles 16 cycles 14 cycles 1 
cycle 
Phase den den ann ext den ann ext den ann ext ext 
Temp. 
°C 
94 94 57 72 94 57 72 94 52 72 72 
Temp. 
gra 
0 0 0 0 0 -0.5 0 0 0 0 0 
Duration 1min 30sec 30sec 30sec 30sec 30sec 30sec 30sec 30sec 30sec 5min 
den = denaturation; ann = annealing; ext = extension; temp = temperature; gra = gradient. 
 
 
  
 181 
 
Table S6. PSP 5 novel and damaging variants (i.e. nonsense, splicing, frameshift)  
Gene AAChange Exonic
Func 
Depth
hpth 
Q
AL 
Seg
Dup 
omimID esp540
0_ea 
Chr;pos 
ISG15 NA splice 12 14
4 
NA 147571 NA 1;94884
7 
H6PD H6PD:uc001apt.2:wholegene, frame
shift 
deleti
on 
31 21
7 
NA 138090;604931 NA 1;93049
87 
PRAM
EF1 
uc001auj.1:c.T314A:p.L105X stopai
n SNV 
28 10
4 
0.96 NA 0.17 1;12854
090 
CASP9 uc001awm.1:c.1234_1235ins
G:p.G412fs 
frame
shift 
inserti
on 
20 81
.5 
NA 602234 NA 1;15820
311 
NBPF1 NA spliceg 10 14
0 
0.99 NA NA 1;14461
9346 
KDM4
A 
NA spliceg 52 78
.5 
NA 609764 NA 1;44125
967 
NBPF1
0 
uc010oyd.1:c.G790T:p.E264X stopai
n SNV 
19 22 0.98 NA 0.02 1;14482
8764 
GPATC
H4 
uc001fpl.2:c.1068_1069insTG:
p.T356fs 
frame
shift 
inserti
on 
51 21
4 
NA NA NA 1;15656
5050 
FCRL5 uc001fqv.1:c.1731_1732insC:
p.L577fs 
frame
shift 
inserti
on 
26 14
8 
0.91 605877 NA 1;15750
4354 
CD34 uc001hgv.1:c.71_72insT:p.V2
4fs 
frame
shift 
inserti
on 
7 43
.5 
NA 142230 NA 1;20806
3112 
ANGEL
2 
uc001hkb.2:c.659_660insT:p.L
220fs 
frame
shift 
inserti
on 
35 25
.5 
NA NA NA 1;21318
0458 
OR2T2
9 
uc001ieo.1:c.C52T:p.Q18X stopai
n SNV 
11 51
.1 
0.99 NA 0.00 1;24872
2723 
OR2T3
5 
uc001ies.1:c.604_610del:p.20
2_204del 
frame
shift 
deleti
on 
65 21
7 
0.98 NA NA 1;24880
1950 
SLC3A
1 
uc002rty.2:c.1139delT:p.L380
X 
stopai
n SNV 
52 19
5 
NA 220100;606407;104614 NA 2;44528
269 
CD207 uc002shg.2:c.73_74insG:p.E2
5fs 
frame
shift 
inserti
on 
2 33
.2 
NA 604862 NA 2;71062
834 
CRELD
1 
uc003buh.2:c.959delA:p.Q320
fs 
frame
shift 
deleti
on 
41 21
4 
NA 600309;607170;606217 NA 3;99851
10 
ZNF16
7 
uc011azx.1:c.1472_1473del:p.
491_491del 
frame
shift 
deleti
on 
8 20
2 
NA NA NA 3;44540
796 
OR5K3 uc011bgw.1:c.904_905insA:p.
I302fs 
frame
shift 
inserti
on 
15 16
3 
NA NA NA 3;98110
413 
ATG3 uc003dzc.2:c.911_912insT:p.I
304fs 
frame
shift 
inserti
on 
41 20
9 
NA 609606 NA 3;11225
3068 
HSPBA
P1 
uc003efu.1:c.763_764insTG:p.
W255fs 
frame
shift 
inserti
on 
25 20
7 
NA 144700;608263 NA 3;12247
1500 
SLC41
A3 
uc003eik.2:c.1388_1391del:p.
463_464del 
frame
shift 
deleti
on 
26 18
4 
NA 610803 NA 3;12572
5275 
ALDH1
L1 
uc010hsf.1:c.1610delG:p.R53
7fs 
frame
shift 
deleti
on 
15 22
.5 
NA 600249 NA 3;12585
4318 
ALG1L
2 
uc011bld.1:c.469delC:p.L157f
s 
frame
shift 
deleti
on 
28 21
4 
0.96 NA NA 3;12981
4936 
CEP70 uc011bmm.1:c.1338_1522del:
p.446_446del 
frame
shift 
deleti
on 
29 21
7 
NA NA NA 3;13821
3853 
ZNF59
5 
uc011but.1:c.12_13insC:p.S4f
s 
frame
shift 
inserti
on 
3 54
.4 
NA NA NA 4;86102 
CXCL6 uc003hhf.2:c.239_240insT:p.V
80fs 
frame
shift 
inserti
on 
16 18
0 
NA 138965 NA 4;74702
810 
NHED
C1 
uc011cev.1:c.C232T:p.R78X stopai
n SNV 
17 48 0.96 611527 0.07 4;10383
2611 
ALPK1 uc010imo.2:c.103_104insT:p.
S35fs 
frame
shift 
inserti
on 
36 74
.5 
NA 607347 NA 4;11334
7619 
ZNF47
4 
uc003ksv.2:c.953delT:p.L318X stopai
n SNV 
42 18
0 
NA NA NA 5;12148
8638 
ACSL6 uc010jdn.1:c.615_616insCA:p.
S205fs 
frame
shift 
inserti
on 
3 77
.2 
NA 604443 NA 5;13132
4256 
TIGD6 uc003lri.2:c.1031delA:p.Q344f
s 
frame
shift 
deleti
on 
57 21
4 
NA NA NA 5;14937
4881 
CYFIP2 uc003lwq.2:c.280_281insC:p.
Q94fs 
frame
shift 
inserti
on 
3 35
.2 
NA 606323 NA 5;15672
1866 
NOP1
6 
uc003med.2:c.576_577insAC:
p.L192fs 
frame
shift 
inserti
on 
2 74
.2 
NA NA NA 5;17581
1102 
DSP uc003mxp.1:c.1_2insA:p.M1fs frame
shift 
inserti
on 
6 19
.5 
NA 125647;605676;607655;
607450;609638 
NA 6;75421
49 
TPMT uc010jpm.1:c.594_595insTT:p
.G198fs 
frame
shift 
inserti
on 
20 25
.5 
NA 187680 NA 6;18134
021 
ZNF18
7 
NA spliceg 9 93
.7 
NA NA NA 6;28239
933 
HLA-A uc011dmd.1:c.673delG:p.V22
5fs 
frame
shift 
deleti
on 
31 50
.5 
0.91 142800 NA 6;29912
417 
CDSN uc003nsm.1:c.1589_1617del:
p.530_530del 
frame
shift 
deleti
on 
44 21
4 
NA 602593 NA 6;31083
801 
PSORS
1C2 
uc003nso.3:c.280delC:p.P94fs frame
shift 
deleti
on 
14 66
.5 
NA NA NA 6;31105
859 
HLA-
DRB5 
uc003obj.2:c.C97T:p.R33X stopai
n SNV 
56 11
6 
0.89 604776;142857 NA 6;32497
905 
HLA-
DQA1 
uc003obt.1:c.745_746insTT:p.
X249delinsF 
stoplo
ss SNV 
6 12
9 
NA 146880 NA 6;32610
162 
HLA-
DQA1 
uc003obt.1:c.684delC:p.S228f
s 
frame
shift 
deleti
on 
21 25
.5 
NA 146880 NA 6;32610
101 
MANE
A 
uc003pon.2:c.567_568insATG
T:p.Y189fs 
frame
shift 
inserti
on 
11 10
2 
NA 612327 NA 6;96034
882 
PBOV1 uc003qhv.2:c.347_348insC:p.
T116fs 
frame
shift 
inserti
on 
46 17
1 
NA 605669 NA 6;13853
9186 
AOAH uc010kxf.2:c.1913_1914insA:
p.Q638fs 
frame
shift 
inserti
on 
19 21
3 
NA 102593 NA 7;36552
792 
AOAH uc010kxf.2:c.1973_1974insA:
p.Q658fs 
frame
shift 
inserti
on 
18 15
2 
NA 102593 NA 7;36552
732 
PKD1L
1 
NA spliceg 35 12
1 
NA 609721 NA 7;47869
201 
WNT1
6 
uc003vjv.2:c.1_2insCCCA:p.M
1fs 
frame
shift 
inserti
on 
45 21
7 
NA NA NA 7;12096
5470 
MLL3 uc003wla.2:c.2447_2448insA:
p.Y816_I817delinsX 
stopai
n SNV 
98 21
7 
0.97 606833 NA 7;15194
5072 
EIF3E uc010mcj.1:c.489_492del:p.1
63_164del 
frame
shift 
deleti
on 
22 21
.5 
NA 602210 NA 8;10924
7206 
PYCRL uc003yyy.2:c.743delC:p.T248f
s 
frame
shift 
deleti
on 
35 10
2 
NA NA NA 8;14468
7988 
CBWD
3 
uc004agl.3:c.189_190insA:p.K
63fs 
frame
shift 
inserti
on 
4 60 0.99 611080 NA 9;70900
917 
OR1B1 uc011lyz.1:c.38_39insT:p.V13f
s 
frame
shift 
inserti
on 
20 21
4 
NA NA NA 9;12539
1777 
GPSM
1 
uc004chc.2:c.1242delC:p.P41
4fs 
frame
shift 
deleti
on 
3 22
.5 
NA 609491 NA 9;13923
5485 
ITIH5 uc001ijp.2:c.2154delG:p.M71
8fs 
frame
shift 
deleti
on 
46 21
4 
NA 609783 NA 10;7605
079 
PTCHD
3 
uc001itu.2:c.918_919insG:p.L
306fs 
frame
shift 
inserti
on 
23 46
.5 
0.9 611791 NA 10;2770
2262 
CCAR1 NA spliceg 29 21
7 
NA 612569 NA 10;7054
7894 
C10orf
57 
uc009xsn.2:c.123_124insAA:p
.K41fs 
frame
shift 
inserti
on 
10 53
.5 
0.9 NA NA 10;8184
1431 
ATRNL
1 
uc001lcf.2:c.1400_1401insTT:
p.L467fs 
frame
shift 
inserti
on 
16 21
4 
NA 612869 NA 10;1169
31102 
CYP2E
1 
NA spliceg 19 21
4 
NA 124040 NA 10;1353
40867 
C11orf
40 
uc010qyg.1:c.597_598insCT:p.
N199fs 
frame
shift 
inserti
on 
58 21
7 
NA NA NA 11;4592
710 
OR52R
1 
uc010qym.1:c.C637T:p.R213X stopai
n SNV 
46 22
3 
NA NA 0.00 11;4825
211 
OR51I
2 
uc010qzf.1:c.715_716insCA:p.
N239fs 
frame
shift 
inserti
on 
48 21
7 
NA NA NA 11;5475
433 
CYB5R
2 
uc001mfm.2:c.830_831insAA
CA:p.X277delinsX 
frame
shift 
inserti
on 
35 21
4 
NA 608342 NA 11;7686
606 
SPI1 uc009ylp.1:c.579_580insGT:p.
A193fs 
frame
shift 
inserti
on 
9 24
.5 
NA 165170 NA 11;4738
0291 
OR4C3 uc010rhv.1:c.G522A:p.W174X stopai
n SNV 
75 22
3 
NA NA NA 11;4834
7014 
FAM1
11B 
uc010rko.1:c.304delT:p.Y102f
s 
frame
shift 
deleti
on 
32 13
0 
NA NA NA 11;5889
1964 
SNX32 uc009yqt.2:c.206delG:p.G69fs frame
shift 
deleti
on 
19 52
.5 
NA NA NA 11;6561
7118 
ALDH3
B1 
uc001ona.2:c.790_791insC:p.
R264fs 
frame
shift 
inserti
on 
16 16
0 
0.93 600466 NA 11;6778
9294 
GDPD
4 
uc001oyf.2:c.1191_1192insT:
p.N397fs 
frame
shift 
inserti
on 
32 21
7 
NA NA NA 11;7695
4789 
MMP1 uc001phi.2:c.572delT:p.I191fs frame
shift 
deleti
on 
52 21
7 
NA 120353 NA 11;1026
67448 
CASP5 uc010rvb.1:c.19_20insA:p.K7f
s 
frame
shift 
inserti
on 
25 19
.5 
NA 602665 NA 11;1048
78050 
HYOU
1 
uc010ryu.1:c.28_29insG:p.G1
0fs 
frame
shift 
inserti
on 
26 19
5 
NA 601746 NA 11;1189
27016 
TULP3 uc001qlj.2:c.C70T:p.R24X stopai
n SNV 
38 19
9 
NA 604730 0.00 12;3018
723 
CLECL
1 
uc001qwj.2:c.149_150insACT
TA:p.Y50fs 
frame
shift 
inserti
on 
30 21
7 
NA 607467 NA 12;9885
712 
 182 
GUCY2
C 
uc001rcd.2:c.T2943G:p.Y981X stopai
n SNV 
35 19
9 
NA 601330 NA 12;1476
9594 
C12orf
60 
uc001rcj.3:c.550_551del:p.18
4_184del 
frame
shift 
deleti
on 
28 21
7 
NA NA NA 12;1497
6419 
OR10A
D1 
uc001rrl.1:c.200_201insT:p.L6
7fs 
frame
shift 
inserti
on 
62 21
7 
NA NA NA 12;4859
6876 
OR9K2 uc010spe.1:c.38delT:p.L13fs frame
shift 
deleti
on 
48 18
1 
NA NA NA 12;5552
3590 
OR6C1 uc010spi.1:c.24_25insA:p.T8fs frame
shift 
inserti
on 
32 21
4 
NA NA NA 12;5571
4407 
RXFP2 NA spliceg 26 21
7 
NA 606655 NA 13;3236
0701 
OR11
H12 
uc010tkp.1:c.T699G:p.Y233X stopai
n SNV 
41 62 1 NA 0.73 14;1937
8292 
OR11
G2 
uc010tlb.1:c.687_688insA:p.K
229fs 
frame
shift 
inserti
on 
59 21
7 
NA NA NA 14;2066
6181 
FANC
M 
NA spliceg 10 10
2 
NA 609644;227650 NA 14;4562
8296 
FANC
M 
NA spliceg 18 16
2 
NA 609644;227650 NA 14;4565
4415 
NIPA2 uc001yva.2:c.1025_1381del:p
.342_342del 
frame
shift 
deleti
on 
17 21
7 
NA 608146 NA 15;2300
6219 
TPSD1 uc002clb.1:c.127delG:p.E43fs frame
shift 
deleti
on 
11 99
.5 
0.97 609272 NA 16;1306
561 
PHKG2 NA spliceg 4 11
1 
NA 172471 NA 16;3076
8503 
MNT NA spliceg 35 14
9 
NA 603039 NA 17;2297
598 
P2RX5 uc002fwh.1:c.329delC:p.T110f
s 
frame
shift 
deleti
on 
25 15
0 
NA 602836 NA 17;3594
281 
VMO1 NA spliceg 25 71
.5 
NA NA NA 17;4689
196 
MAP2
K3 
uc002gys.2:c.C304T:p.Q102X stopai
n SNV 
68 20
4 
NA 602315 NA 17;2120
4210 
POLDI
P2 
NA spliceg 2 32
.2 
NA 611519 NA 17;2668
4395 
SARM
1 
NA spliceg 3 71
.4 
NA 607732 NA 17;2669
9368 
SLC46
A1 
uc002hbg.1:c.1142delT:p.I381
fs 
frame
shift 
deleti
on 
2 22
.2 
NA 611672;229050;607732 NA 17;2672
7723 
MMP2
8 
uc002hjy.1:c.436_437insG:p.P
146fs 
frame
shift 
inserti
on 
7 12
7 
NA 608417 NA 17;3410
0350 
DHRS1
1 
NA spliceg 50 21
7 
NA NA NA 17;3495
6588 
DSC3 uc002kwi.3:c.1540delC:p.P51
4fs 
frame
shift 
deleti
on 
23 11
8 
NA 600271 NA 18;2858
8105 
KIAA1
468 
uc002lik.1:c.3008_3009insT:p.
L1003fs 
frame
shift 
inserti
on 
29 81
.5 
NA NA NA 18;5994
2759 
SERPI
NB3 
uc010dqb.2:c.354_355insA:p.
V118fs 
frame
shift 
inserti
on 
42 21
4 
0.93 600518;600517 NA 18;6132
6630 
ZNF56
2 
uc010xkx.1:c.420_424del:p.14
0_142del 
frame
shift 
deleti
on 
12 21
0 
0.91 NA NA 19;9801
443 
HKR1 uc002ofz.2:c.512_513del:p.17
1_171del 
frame
shift 
deleti
on 
2 71
.2 
NA 165250 NA 19;3785
0583 
CYP2F
1 
uc002opu.1:c.15_16insC:p.S5f
s 
frame
shift 
inserti
on 
49 21
7 
NA 124070 NA 19;4162
2108 
BCKD
HA 
uc010xvz.1:c.972_973insC:p.P
324fs 
frame
shift 
inserti
on 
26 21
4 
NA 248600;608348 NA 19;4192
8870 
CEACA
M20 
uc010ejp.1:c.1169delA:p.E390
fs 
frame
shift 
deleti
on 
2 27
.2 
NA NA NA 19;4501
6992 
HAS1 NA spliceg 48 19
.5 
NA 601463 NA 19;5222
7177 
ZNF48
0 
uc010ydl.1:c.9_10del:p.3_4de
l 
frame
shift 
deleti
on 
48 21
4 
NA NA NA 19;5280
3674 
ZNF76
1 
uc010eqp.2:c.139delC:p.L47fs frame
shift 
deleti
on 
10 94
.5 
0.91 NA NA 19;5395
2889 
AURKC NA spliceg 6 74
.1 
NA 243060;603495 0.76 19;5774
2489 
ZNF27
4 
uc002qrs.1:c.214_215insG:p.A
72fs 
frame
shift 
inserti
on 
7 10
6 
NA 605467 NA 19;5871
8361 
DEFB1
26 
uc002wcx.2:c.317_318del:p.1
06_106del 
frame
shift 
deleti
on 
31 15
0 
NA NA NA 20;1263
14 
TTLL9 NA spliceg 2 23
.8 
NA NA NA 20;3052
7070 
CPNE1 uc002xdc.2:c.187_188insT:p.F
63fs 
frame
shift 
inserti
on 
32 20
2 
NA 604205 NA 20;3421
5237 
BIRC7 uc010gkc.1:c.672_673insG:p.
G224fs 
frame
shift 
inserti
on 
13 16
0 
NA 605737 NA 20;6187
0608 
DNAJC
28 
uc002yrv.2:c.940_944del:p.31
4_315del 
frame
shift 
deleti
on 
40 21
7 
NA NA NA 21;3486
0757 
CLTCL
1 
NA spliceg 2 34
.2 
NA 601273 NA 22;1918
9004 
PI4KA uc002zuv.3:c.1624_1627del:p
.542_543del 
frame
shift 
deleti
on 
7 55
.7 
0.99 NA NA 22;2182
9516 
APOL4 uc003aox.2:c.330_331insAG:p
.K110fs 
frame
shift 
inserti
on 
3 12
9 
NA 607254 NA 22;3658
7847 
C22orf
33 
uc003aqe.2:c.G498A:p.W166X stopai
n SNV 
34 20
8 
NA NA NA 22;3738
7310 
SSTR3 uc003ara.2:c.1257_1258insG:
p.X419delinsX 
frame
shift 
inserti
on 
27 21
4 
NA 182453 NA 22;3760
2586 
RRP7A NA spliceg 17 20
.5 
0.97 607979 NA 22;4291
0686 
PHKA1 uc010nll.2:c.89_90insA:p.Q30
fs 
frame
shift 
inserti
on 
8 27
.5 
NA 300559;311870 NA X;71813
204 
TCEAL
6 
uc004eiq.2:c.521_522insC:p.A
174fs 
frame
shift 
inserti
on 
8 13
6 
0.92 NA NA X;10139
5783 
FAM5
8A 
uc010nug.2:c.50_51insG:p.R1
7fs 
frame
shift 
inserti
on 
3 30
.2 
NA 300707;300708 NA X;15286
4480 
Nbla1
0314 
NA spliceg 2 81
.2 
NA 605477 NA 13;1119
34542 
BCR 
varian
t 
protei
n 
uc002zwy.1:c.577_578insC:p.
R193fs 
frame
shift 
inserti
on 
35 91
.5 
NA 608232;151410 NA 22;2363
1820 
AX746
964 
uc003lhy.1:c.523delG:p.G175f
s 
frame
shift 
deleti
on 
12 70
.5 
NA NA NA 5;14024
2453 
PCDH
B9 
uc003liw.1:c.1141_1142insA:
p.I381fs 
frame
shift 
inserti
on 
13 12
1 
NA 606335 NA 5;14056
8035 
MSTP
9 
uc010ock.1:c.117_121del:p.3
9_41del 
frame
shift 
deleti
on 
60 12
2 
0.99 NA NA 1;17087
544 
AL359
605 
uc003vwg.1:c.G35A:p.W12X stopai
n SNV 
2 20
.8 
NA NA NA 7;14117
6756 
KIAA1
019 
uc002ysf.1:c.1320_1321insA:
p.G440fs 
frame
shift 
inserti
on 
33 15
8 
0.96 182465 NA 21;3494
8685 
pp144
50 
uc003yyi.2:c.442_443insAGG
GC:p.P148fs 
frame
shift 
inserti
on 
10 49
.5 
NA NA NA 8;14464
2171 
AK126
429 
uc002jku.2:c.170delG:p.G57fs frame
shift 
deleti
on 
14 79
.5 
NA 605949 NA 17;7243
9810 
FRG1B uc010ztk.1:c.260_261insA:p.K
87fs 
frame
shift 
inserti
on 
28 11
2 
0.96 NA NA 20;2963
2679  
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Table S7: EIF4G1 coding variants present in NHLBI Exome Sequencing Project. 
EA= European American population; AA=African American population  
Nucleotide change Protein change SNP accession number Frequency (EA) Frequency (AA) Exon 
c.C71T P24L 
 
0.000142 0 2 
c.C167G A56G 
 
0.000142 0 3 
c.C211T P71S rs113810947 0.000285 0 3 
c.282C>G I94M 
 
0 0.000268 3 
c.451C>G V151L 
 
0.000143 0 5 
c.481A>G A161T rs13319149 0.996722 0.999465 5 
C.602G>A R201H rs34838305 0.000427 0 6 
C.608C>T A203V 
 
0.000142 0 6 
C.704G>A R235Q rs144543953 0.000142 0.000268 8 
C.731G>A R244Q rs147855566 0.000142 0 8 
C.779C>T S260L 
 
0.000142 0 8 
c.821C>T P274L rs139626338 0 0.000268 8 
c.870G>A M290I rs144947145 0 0.001338 8 
c.913C>T R305C rs116508885 0 0.00321 8 
c.914G>A R205H rs151151194 0.000142 0.000268 8 
c.926A>G E309G 
 
0.000142 0 8 
c.932A>G Y311C rs16858632 0.000427 0.059658 8 
c.1001A>C P334Q 
 
0.000285 0 8 
c.1013C>T S338F rs139021806 0 0.000268 8 
c.1036C>A Q346K 
 
0 0.000268 8 
c.1054G>T A352S 
 
0.000142 0 8 
c.1063A>G T355A 
 
0 0.000268 8 
c.1064C>T T355I 
 
0 0.000268 8 
c.1142C>G A381G rs142095694 0.000142 0 8 
c.1256G>T S419I rs138207269 0 0.000535 8 
c.1294A>G M432V rs2178403 0.759544 0.943553 8 
c.1298C>T A433V rs145998921 0.000142 0 8 
c.1309A>G I437V rs144222028 0 0.000268 8 
c.1316C>A S439Y rs148709174 0.000142 0 8 
c.1331C>T T444M rs143014570 0 0.000268 8 
c.1352C>A P451Q rs147419996 0.000142 0 8 
c.1429G>A E477K rs145228718 0 0.000268 8 
c.1456C>T P486S rs112545306 0.00057 0.000803 8 
c.1505C>T A502V rs111290936 0.000285 0 8 
c.1610C>T A537V 
 
0 0.000268 10 
c.1648G>C A550P rs111924994 0.001994 0.000535 10 
c.1679G>A G560D rs149685875 0.000142 0 10 
c.1696C>T R566C rs145521479 0.000142 0.000268 10 
c.1700C>A P567H rs140212150 0 0.000268 10 
c.1754A>C E585A 
 
0 0.000268 10 
c.1801T>C W601R rs145247318 0 0.000268 11 
c.1831C>T R611C 
 
0 0.000268 11 
c.1980A>G I660M 
 
0.000142 0 12 
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c.1982A>G N661S rs145780534 0.000142 0 12 
c.2096G>C G699A 
 
0.000142 0 13 
c.2114C>G S705C rs141054452 0.000142 0 13 
c.2152G>C A718P rs111396765 0.001567 0.000268 13 
c.2225C>T T742M rs147678593 0 0.004013 13 
c.2276A>G Q759R 
 
0.000142 0 14 
c.2278G>C D760H rs142947014 0.000142 0 14 
c.2386A>G K796E 
 
0 0.000268 14 
c.2419A>G I807V rs62287499 0.000427 0 14 
c.2488A>T T830S rs111500185 0.000285 0 15 
c.2612A>C E871A 
 
0.000142 0 15 
c.2671A>G I891V 
 
0 0.000268 16 
c.2882A>G N961S rs191888688 0 0.000268 17 
c.3187C>T R1063C 
 
0.000142 0 19 
c.3221C>T T1074I rs146433145 0.000142 0 19 
c.3343C>T R1115C rs150054202 0 0.000268 21 
c.3428A>G Q1143R rs145414660 0 0.000268 21 
c.3482G>A R1161H rs139135683 0.000427 0 22 
c.3511C>T R1171C rs141684202 0 0.000268 22 
c.3529C>T R1177C 
 
0 0.000268 22 
c.3580C>T R1194W 
 
0.000142 0 22 
c.3584G>A S1195N 
 
0.000142 0 22 
c.3592C>T R1198W rs113388242 0 0.000268 22 
c.3617G>A R1206H rs112176450 0.000285 0 22 
c.3649C>T R1207C 
 
0.000143 0 22 
c.3650G>A R1217H rs34086109 0 0.010433 22 
c.3652G>A G1217R rs138270117 0 0.000268 22 
c.3686C>T P1299L 
 
0 0.000268 23 
c.3688C>G P1230A rs35629949 0.005842 0.001606 23 
c.3701T>C L1234P rs2230570 0.021937 0.080257 23 
c.3743A>G K1248R 
 
0.000142 0 23 
c.3773A>G N1258S rs73053766 0 0.001873 23 
c.3935C>T S1312F 
 
0 0.000268 24 
c.3937A>G T1313A rs144570332 0.000142 0.000803 24 
c.3988A>G M1330V rs112809828 0.000285 0 25 
c.4067T>C M1356T rs144059151 0.000855 0 25 
c.4068G>C M1356I rs145975905 0.000285 0 25 
c.4081A>G R1361G rs139793721 0 0.000268 25 
c.4106C>T P1369L rs142064428 0 0.000803 26 
c.4184C>T T1395M rs112441721 0 0.000268 27 
c.4201G>A G1401R rs149821418 0.000142 0.000803 27 
c.4229A>C E1410A rs141776790 0 0.000268 27 
c.4259A>G E1420G 
 
0 0.000268 27 
c.4292C>T S1431L 
 
0.000142 0.000268 28 
c.4300C>T P1434S rs147696097 0.000142 0 28 
c.4379G>A R1460Q 
 
0.000142 0 28 
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c.4399G>A A1467T rs148270724 0.000142 0 29 
c.4433C>T T1478M rs141379472 0.000142 0 29 
c.4454C>T T1485M 
 
0.000142 0 29 
c.4486A>T T1496S 
 
0 0.000268 29 
c.4712C>T A1571V rs144462594 0.000142 0 31 
c.4772G>A R1591H 
 
0.000142 0 31 
 
 
 
 
 
 
 
 
 
 
